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Diclofenac is a commonly used anti-inflammatory drug in the treatment of arthritis and
pain.

Although mechanisms of injury following diclofenac administration have been

characterized, the roles that transporters have as modulators of exposure and toxicity
remain unclear.

To that end, in vivo transporter models were used to assess the

toxicokinetics of diclofenac and its major metabolites. Whole body transporter knockout
mice were administered diclofenac, and the dispositions of parent and metabolites were
determined in bile, plasma, and liver. Diclofenac and its reactive acyl glucuronide were
shown to be substrates for the efflux transporter Bcrp. Biliary excretion of diclofenac
and its acyl glucuronide decreased in Bcrp knockout mice while only the plasma levels
of the glucuronide increased compared to wild-type mice. Diclofenac acyl glucuronide
was likewise determined to be a substrate for the basolateral efflux transporter Mrp3
evidenced by reduced plasma concentrations in Mrp3 knockout mice with no changes in
biliary excretion. Toxic challenge by diclofenac resulted in increased intestinal injury in
Mrp3 knockout mice compared to wild-types.

In vitro assays revealed that human

MRP3 also can transport diclofenac acyl glucuronide with apparent high affinity
compared to human MRP2. The uptake of diclofenac acyl glucuronide was shown to be
mediated by human OATPs in an in vitro system, specifically OATP2B1 exhibited
concentration-dependent active uptake kinetics. As OATP2B1 and mouse Oatp2b1 are

expressed along the intestinal tract, the active uptake of the glucuronide metabolite may
be contributory to the intestinal toxicity observed in animal models and human patients.
Mechanistic studies indicated that diclofenac acyl glucuronide was able to induce
oxidative stress through creation of reactive oxygen species and inhibition of superoxide
dismutase. Furthermore, diclofenac acyl glucuronide was shown to be an inhibitor of
both COX-1 and COX-2, which may also have contributed to intestinal injury. Lastly it
was demonstrated that diclofenac acyl glucuronide can inhibit human MRP4 that is
upregulated during oxidative stress.

In summary, the data presented herein

demonstrate the multifactorial pathways by which diclofenac acyl glucuronide is
transported and contributes to tissue injury.
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Chapter 1 REVIEW OF LITERATURE
1.1 Liver Overview
1.1.1 Structure and Function
The liver is the largest gland in the body and is responsible for a variety of important
physiological functions. A depiction of the liver is shown in Figure 1.1. The human liver
is divided into a right and left lobe, each of which is further organized into hepatic
lobules with a hexagonal appearance. At the core of every lobule is a central vein. The
corners of the lobule contain portal triads that are composed of a bile duct, hepatic
artery, and a portal vein. About 60 to 70% of the blood supply to the liver originates
from the portal vein while the remainder is provided by the hepatic artery (Richardson
and Withrington, 1982). Blood coming from the portal veins can enter the sinusoids,
which is an area that bathes the resident hepatic cells. Arterial blood is mixed with the
partially deoxygenated portal blood in the sinusoidal space to provide oxygen.
Sinusoidal blood traverses from the portal triad through the lobule and eventually
collects into the central vein where it then gathers into the hepatic vein that ultimately
drains into the inferior vena cava.
The lobule is divided into subregions referred to as centrilobular, midzonal, and
periportal. In terms of functional units, the lobular regions are referred to as an acinus
consisting of three zones wherein zone 1 is proximal to the portal triad, zone 2 is
centrally located, and zone 3 is the area closest to the hepatic central vein.

The

periportal region (zone 1), being much closer to where oxygenated blood enters the
sinusoids, is exposed to relatively high oxygen content.

Oxygen levels continually

decline through the midzonal (zone 2) and centrilobular (zone 3) regions. As a result,
1

the centrilobular zone is prone to hypoxia and injury due to low blood supply (TreinenMoslen, 2001).
There are several cell types that can be found in the liver. Among the cells residing in
the sinusoidal space are liver sinusoidal endothelial cells (LSEC) and Kupffer cells (KC).
LSECs line the sinusoidal lumen and represent about 20% of the total liver cells (Maslak
et al., 2015). They possess pores to permit the passing of material from the sinusoids
into the space of Disse. KCs are the resident macrophages, making up over 80% of the
total macrophages in the body. KCs play an integral role in the overall health of the liver
as they are an important first line of defense against bacteria (Bilzer et al., 2006).
Owing to their function as sentinels to hepatic well-being, the majority of KCs are found
in the periportal region, which is the likely site of entry of microbes from portal blood
circulation (Bouwens et al., 1986). KCs can be activated via microorganisms or hepatic
injury with subsequent release of cytokines. Within the space of Disse are Ito cells (also
known as stellate cells) that synthesize collagen and act as storage sites for vitamin A
and fat (Stanciu et al., 2002).
The vast majority of hepatic cells are hepatocytes, which are the cells that carry out
much of the metabolism in the liver. Hepatocytes take up about 80% of the total liver
volume and constitute approximately 60% of all the liver cells (Malarkey et al., 2005).
The liver is one of the primary sites for glycogen storage, which is converted to glucose
during states of hypoglycemia.

Hepatocytes carry out gluconeogenesis and are

responsible for the synthesis of albumin, bile, and lipoproteins (Kutchai, 2004b). There
is an estimated 139 million cells per gram of human liver yielding an approximate total

2

number of 217 billion hepatocytes in an adult liver (Sohlenius-Sternbeck, 2006; Molina
and DiMaio, 2012).
1.1.2 Metabolic Enzymes and Transporters
Hepatocytes are metabolically active and possess the full array of enzymes that
participate in Phase I (hydrolysis, reduction, and oxidation) as well as Phase II
biotransformation (acylation, amino acid conjugation, glucuronidation, glutathione
conjugation, methylation, and sulfation).

Phase I metabolism occurs predominantly

through cytochrome (CYP) P450 enzymes of which the main subtypes are CYP1A2,
CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5.
In general the CYPs preferentially act upon the following substrates: 1) CYP1A2 –
planar hydrophobic compounds with high logP that may be basic or neutral (e.g.,
phenacetin and theophylline), 2) CYP2C9 – acidic compounds or neutrals with high
level of hydrogen bonding that have both hydrophobic and lipophilic regions (e.g.,
diclofenac and warfarin), 3) CYP2D6 – basic amines that are lipophilic and possess a
nitrogen

that

is

protonated

at

physiological

pH

(e.g.,

atomoxetine

and

dextromethorphan), 4) CYP2E1 – lipophilic compounds that are small with low logP
(e.g., aniline and chlorzoxazone), and 5) CYP3A4 – basic or neutral compounds that
are lipophilic (e.g., filodipine and midazolam) (Smith et al., 1998b; Lewis, 1999; Smith,
2003; Zhou et al., 2009; FDA, 2014).
Of the Phase II enzymes, uridine 5ʹ-diphospho-glucuronosyltransferases (UGTs) have a
significant role as an elimination mechanism for non-steroidal anti-inflammatory drugs
(NSAIDs).

There are three subfamilies, UGT1, UGT2A, and UGT2B with each

subfamily consisting of multiple enzymes many of which are expressed in the liver
3

(Ohno and Nakajin, 2009; Harbourt et al., 2012). UGTs catalyze the transfer of uridine
5ʹ-diphosphoglucuronic acid to a nucleophilic region of substrate thereby facilitating the
biliary or urinary excretion of the conjugated metabolite (Coughtrie and Fisher, 2003). A
review by Williams et al. (2004) indicated that of the top 200 marketed drugs that
undergo glucuronidation, approximately 35% of the conjugation is mediated by UGT2B7
while UGT1A4 and UGT1A1 accounted for 20% and 15%, respectively (Williams et al.,
2004).

Glucuronidation does not always result in permanence of conjugation as

glucuronides can be degraded back to an aglycone parent and glucuronate by the
actions of β-glucuronidase (Sperker et al., 1997). UGTs can form an acyl glucuronide
(R-COO-), ether glucuronide (R-O-), or nitrogen glucuronide (R-N-).
Returning to the structural layout of the hepatic lobule, work by Jungermann and Katz
(1989) demonstrated that the periportal region (zone 1) was higher in glutathione (GSH)
and lower in CYP abundance while the centrilobular region (zone 3) exhibited higher
CYP levels along with lower intracellular glutathione. As glutathione has a critical role to
sequester reactive intermediates, the reduced glutathione supply makes the
centrilobular region more prone to certain types of injury. The gradient distribution of
CYPs and GSH throughout the lobule renders a phenotypic pattern for which the
periportal region is susceptible to injury from allyl alcohol and cocaine, from different
mechanisms that involve generation of reactive metabolites (also higher oxygen levels
may be contributory for oxygen-dependent reactions), while the centrilobular zone is
sensitive to damage from carbon tetrachloride and acetaminophen as a result of
depletion of GSH (Harisch and Meyer, 1985; Badr et al., 1986; Powell et al., 1994; Lim
et al., 1995).
4

Of the aforementioned CYPs, CYP3A4 accounts for roughly 30% of total hepatic CYP
content, yet CYP3A4 is responsible for nearly 50% of the overall metabolism that occurs
in the liver (Shimada et al., 1994; Rodrigues, 1999; Williams et al., 2002). One of the
reasons for the wide-ranging activity of CYP3A4 is due in part by a large binding pocket
that can accommodate substrates of different sizes (Beaumont et al., 2010). Phase I
metabolism by CYPs is dependent on β-Nicotinamide adenine dinucleotide 2ʹphosphate (NADPH) to provide a source of electrons while Phase II reactions rely on
cofactors that must be continually replenished. Generally, biotransformation is thought
of as a detoxifying process that converts xenobiotics into more water-soluble forms that
can subsequently excreted via biliary efflux or elimination in urine, however this is not
always the case. Hepatocytes in the centrilobular region are responsible for metabolism
of acetaminophen, making this region more susceptible to injury due to the generation
of reactive intermediates such as NAPQI that are partially sequestered by GSH
(Parkinson, 2001; Hinson et al., 2010).
The hepatocyte, which is essentially cuboidal in nature, is a polarized cell that is
specifically oriented with respect to functionally active surfaces. The surface exposed to
sinusoidal blood and the space of Disse is the basolateral membrane while the
opposing side is the apical membrane.

It is via the apical membrane that the

hepatocyte excretes substances in the bile canaliculi which coalesce into bile ducts.
The flow of bile in the lobule runs counter to that of sinusoidal blood flow, going from the
centrilobular region toward the portal triad. The bile ducts merge into the common bile
duct that terminates into the duodenal region of the small intestine. The basolateral
membrane of hepatocytes has a number of transporters that facilitate the uptake of
5

substrates from sinusoidal space into the cell.

Among the uptake transporters are

equilibrative nucleoside transporters (ENTs, SLC29s), organic anion transporters (OATs,
SLC22As), organic anion transporting polypeptides (OATPs, SLCOs), organic cation
transporters (OCTs, SLC22As), and sodium-taurocholate co-transporting polypeptide
(NTCP, SLC10A1) (Giacomini et al., 2010).
Also on the basolateral membrane are multidrug resistance-associated proteins (MRPs)
that are efflux transporters from the ATP-binding cassette family C (ABCCs). A listing of
the major uptake and efflux transporters along with their corresponding intra-family
protein homologies is shown in Table 1.1. The bile canalicular membranes likewise
host a number of efflux transporters belonging to several different transporter gene
families (ABCBs, ABCCs, ABCGs, SLC29s, and SLC47As).

Many of the

aforementioned uptake and efflux transporters are involved in the hepatobiliary
disposition of endogenous substances as well as xenobiotics and their metabolites
emphasizing the importance of understanding their roles in modulating the systemic
exposure

and

elimination

of

compounds

(Zamek-Gliszczynski

et

al.,

2012).

Physiologically, the interplay of uptake and efflux transporters is responsible for the
recirculation of bile as 20% of the total bile pool is eliminated from the body on a daily
basis (Heaton, 1969). The recirculation is primarily dependent upon NTCP (basolateral
uptake) and BSEP (canalicular efflux) along with secondary uptake by the OATPs and
basolateral as well as canalicular efflux by MRPs (Kullak-Ublick et al., 2000).
1.1.3 Gene Regulation
The expression of CYPs, UGTs, and transporters can be modulated via several
mechanisms. CYP1A2 for instance is inducible via activation of the aryl hydrocarbon
6

receptor (AhR) (Nebert et al., 2004). Cigarette smoke has been shown to increase
CYP1A2 expression via AhR, a result that may be causally linked to the increased
tumorigenesis due to metabolism of procarcinogens present in cigarette smoke
(Dertinger et al., 2001). Activation of the pregnane X receptor (PXR) leads to induction
multiple genes such as CYP2C9, CYP3A4, and the efflux transporters MDR1 (ABCB1)
as well as MRP2 (ABCC2). PXR belongs to a class of orphan nuclear receptors for
which the endogenous substrate has yet to be identified. PXR has a ligand binding
domain as well as a DNA-binding domain, enabling it to both recognize circulating
substrates and bind to regulatory regions in target genes (Kliewer et al., 1998). After a
ligand binds to PXR, the PXR-ligand complex enters the nucleus and forms a
heterodimer with retinoid X receptor (RXR). The heterodimer is stabilized by additional
cofactors allowing the complex to bind to response elements in the target genes and
promote transcriptional upregulation. Shukla et al. (2011) reported that out of 2,816
clinically relevant compounds, 310 (11% of the total) were found to be activators of PXR.
UGTs are regulated by a wide array of transcriptions factors such as AhR, constitutive
androstane receptor (CAR), farnesoid X receptor (FXR), nuclear factor erythroid-related
factor 2 (Nrf2), peroxisome proliferator-activated receptors (PPAR α & γ), PXR, and
RXR (Hu et al., 2014).
Activation of PXR has physiological ramifications. For instance, elevation in bile salts
stimulates PXR to modulate both CYP activity as well as transporter expression
resulting in a reduction of toxic bile salts, which if left unchecked could induce
cholestasis and ultimately lead to hepatic injury (Staudinger et al., 2001; He et al., 2011).
Induction of the efflux transporter MRP3 (ABCC3) has been demonstrated to occur via
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pathways involving CAR and PXR while MRP4 (ABCC4) is upregulated by activation of
CAR (Cherrington et al., 2002; Teng et al., 2003; Zollner et al., 2006). The induction of
MRP3 and MRP4 as a compensatory defense mechanism during cholestasis is
indicative of the important role that basolateral efflux transporters have in attenuating
cell injury (Claudel et al., 2011). Aleksunes et al. (2008b) reported induction of Mrp3
and Mrp4 in mice following toxic challenge by acetaminophen, and the induction was
mediated through Nrf2. Further material on transporters will be detailed in subsequent
sections.
1.2 Small Intestine Overview
1.2.1 Structure and Function
The small intestine is a contiguous structure, with an average length of 6.5 meters in
adults (Hounnou et al., 2002). A representation of the small intestine structure is shown
in Figure 1.2. The small intestine is functionally separated into three areas: duodenum,
jejunum, and ileum. The duodenum represents the first part of the small intestine and is
physically joined to the pyloric region of the stomach. The duodenum is the shortest
region of the small intestine with a length of approximately 25 cm. The next portion of
the small intestine is the jejunum, which is about 2.5 meters in length in adults. The
ileum is the last section of the small intestine and accounts for the remaining length
before the gastrointestinal tract transitions into the large intestine.
It is in the duodenum where gastric chyme is mixed with secretions from the liver, gall
bladder, pancreas, and small intestine. Bile, which elmusifies lipids to permit absorption
of fats, is released into the small intestine though the action of cholecystokinin, a
hormone that stimulates the gall bladder to release bile through the common bile duct.
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The duodenum neutralizes the acidic contents emanating from the stomach by
secreting bicarbonate (Campbell, 1993). The jejunum also secretes digestive enzymes
and moves luminal contents via peristaltic contractions to the ileum. The ileum is the
segment where nutritional absorption is greatest. Bile acids are reabsorbed via active
uptake in the ileum (Kutchai, 2004a). There is a pH gradient along the small intestine
with a duodenal pH range of 6 to 6.6 while the terminal ileum pH is approximately 7.4
(Evans et al., 1988; Fallingborg, 1999).
The structure of the small intestine can be regarded as an elongated tube, and the
cavity within the small intestine is referred to as the lumen. Taken as a whole, the small
intestine has an absorptive surface area of 32 square meters (Helander and Fandriks,
2014).

The effective surface area exceeds that of a standard cylinder due to the

presence of plicae circulares, which are folds along the entirety of the small intestine.
The plicae circulares are comprised of projections called villi, and each villus has a layer
of enterocytes that are the absorptive cells of the intestinal tract. The enterocytes have
microvilli that further increase surface area of the cells. Goblet cells are also present in
the villi, though to a far less degree than enterocytes. The function of goblet cells is to
secrete mucus. Within the villus is a network of blood capillaries and lymph vessels
known as the lacteal. The capillaries take up amino acids and sugars while lipids are
absorbed into the lacteal. The flow of nutrients into the intestinal capillaries is directed
to the hepatic portal vein that eventually goes to the liver (Campbell, 1993). In addition
to nutrients, the small intestine has a role in the absorption of critical electrolytes and
buffers such as sodium, potassium, chloride, and bicarbonate.
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1.2.2 Metabolic Enzymes and Transporters
Similar to the liver, the small intestine possesses both Phase I and Phase II metabolic
enzymes (Prueksaritanont et al., 1996).

In contrast to the liver for which CYP3A4

constitutes 30% of the total CYP content, the allotment of CYP3A4 makes up nearly
82% of all the CYPs expressed in the intestine with CYP2C9 accounting for 14% (Paine
et al., 2006). Despite the relatively high expression of intestinal CYP3A, the absolute
amount of CYP3A4 present in the small intestine is only 1% of the CYP3A amount in
the liver (Yang et al., 2004). Nonetheless, the metabolic enzymes in the small intestine
are able to modulate the overall bioavailability of substances. In pharmacokinetic terms,
the extent of bioavailability after oral dosing is determined using the relationship:
Equation 1.1

where F is the oral bioavailability, Fa is the fraction of dose absorbed from the intestinal
lumen, Fg is the fraction of dose escaping the intestine (gut), and Fh is the fraction of
dose escaping the liver. The sedative agent midazolam is a compound that has high
passive uptake and can easily enter enterocytes yielding an apparent Fa value of 1.
Metabolism in the enterocytes diminishes the amount of midazolam presented to the
intestinal capillaries due to activity of CYP3A4 (Paine et al., 1996) resulting in a Fg of
0.54. Furthermore, the loss of midazolam from intestinal metabolism was found to be
comparable to the liver Fh value of 0.56 (Thummel et al., 1996).

Thus the oral

bioavailability of midazolam is about 30% given that F = 1 × 0.54 × 0.56 = 0.30, and this
value was also observed by other researchers (Akabane et al., 2009). In addition to
CYP3A4, other major CYPs found along the small intestine are CYP1A1, CYP2C9,
CYP2C19, and CYP2D6. The distribution of CYPs is not uniform as expression is
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relatively high in the duodenum and reaches maximal expression in the proximal
jejunum followed by sustained decreases through the medial and distal jejunal regions
with low or non-existent CYP protein in the ileum (Paine and Thummel, 2003).
Regarding Phase II enzymes, the small intestine has expression of UGTs throughout
each of the respective intestinal regions (Ritter, 2007). It was recently shown that of the
major UGTs, UGT1A1 was present in the jejunum and ileum at levels comparable to
CYP3A4 (Busch et al., 2015). Additionally, UGT1A3 and UGT2B7 were detected at
protein levels greater than or equal to other major Phase I enzymes such as CYP2C9,
CYP2C19, and CYP2D6. For the UGTs quantified, protein amounts were highest in the
jejunum. Intestinal UGTs can be regulated by the same transcription factors previously
mentioned as well as caudal-related homeodomain protein 2 (Cdx2), which is specific to
the intestine and modulates several UGTs (Gregory et al., 2004; Gregory et al., 2006).
Just as the hepatocyte is polarized, enterocytes too possess a polarized orientation.
The apical membranes of enterocytes face the intestinal lumen and express a number
of uptake and efflux transporters. Recently, proteomic work by Groer et al. (2013) and
Drozdzik et al. (2014) demonstrated that transporter expression in the small intestine is
dominated by PEPT1 (SLC15A1), which is involved in the transport of peptides (Adibi,
2003). PEPT1 accounted for approximately half of the quantified transporters in a small
pool of healthy subjects. Also detected were the sodium dependent bile transporter
ASBT (SLC10A2), organic cation transporters, OATP2B1 (SLCO2B1), MDR1, MRP2,
MRP3, and breast cancer resistance protein (BCRP, ABCG2). MDR1 and CYP3A4 are
in close proximity to each at the apical membrane, creating a synergistic mechanism by
which substrates that elude CYP-mediated metabolism are excreted back into the
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lumen after which reuptake into the cell may eventually result in substrate
biotransformation (Christians, 2004). Though the large intestine lies beyond the scope
of this thesis, a significant finding from Drozdzik’s work was the relatively high MRP3
expression in the colon, accounting for 36% of the total quantified transporter proteins.
The extent of MRP3 expression along the intestinal tract, and its role as a protective
mechanism, is an important concept as it relates to the research detailed in subsequent
chapters.
Metabolic enzymes and transporters in the small intestine are regulated via similar
mechanisms as those present in the liver. Additionally, Phase I and II enzymes as well
as transporters are also subjected to modulation by components that are in food. For
instance, grapefruit juice has been shown to inhibit the activities of both CYPs and
transporters (Kantola et al., 1998; Kivisto et al., 1999; Fukazawa et al., 2004; Glaeser et
al., 2007; Scialis et al., 2011).

It is well known that bergamottin, a component of

grapefruit juice, incapacitates CYP by a mechanism colloquially referred to as suicide
inactivation (Eagling et al., 1999; Goosen et al., 2004). The impact of grapefruit juice on
small intestine function is multivariate ranging from reduced bioavailability of
fexofenadine due to inhibition of intestinal OATPs that mediate uptake into enterocytes
or alternatively increased plasma concentrations of cholesterol lowering 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors (henceforth referred to as statins) due
to blockade of CYP metabolism.
Analysis of the constituents in grapefruit juice revealed that the contributors of the
observed inhibition (e.g., bergmamottin, naringin, and quercetin) were present in µM to
mM concentrations depending on whether the juice or pulp were assayed (Ross et al.,
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2000; De Castro et al., 2006). Intestinal transporter inhibition was reported to also
occur with other fruit juices such as apple, grape, and orange (Dresser et al., 2002).
Owing to the inhibition potential grapefruit juice possesses, clinicians need to be mindful
of potential drug interactions that may result in toxicity as demonstrated in a patient
taking verapamil while consuming grapefruit juice (Pillai et al., 2009). In that case, the
intake of grapefruit juice along with the recommended dosage of verapamil led to a
marked increase in plasma verapamil concentrations. The cause for the increased
exposure was two-fold: 1) the constituents in grapefruit juice inhibited CYP3A4 that is
the primary enzyme involved in verapamil metabolism, and 2) the transporter-mediated
elimination of verapamil via MDR1 was likewise inhibited by grapefruit juice.
1.3 Transporters
1.3.1 Structure and Function
The movement of materials into and out of cells may occur through passive diffusion or
carrier-mediated transport. In a carrier-mediated process, transporter proteins function
to translocate substrates, and this process may or not involve an energy input
component. Some gene families are responsible for excretion of substrates from the
cell to extracellular space while other gene families function as uptake transporters. Of
the entirety of transporters in the genome, several families of transporter genes are
responsible for the disposition of therapeutic agents and/or their metabolites, and three
of the major subtypes that are relevant to the work presented herein are listed in Table
1.1 along with their respective intra-family protein sequence homologies.
The first major class of transporters belongs to the ATP-binding cassette (ABC) family
which is further divided into seven subfamilies (ABCCA to ABBCG). Most of the focus
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of this review will be on members of the ABC subfamily C. As suggested by their name,
the ABC transporters use ATP to energize transport activity.

Although the overall

structure of ABC transporters can vary, there are several conserved features. ABCC
proteins, of which there are thirteen identified genes, have the following general
arrangement: 1) extracellular N-terminus linked to a membrane spanning domain
(MSD0) with five transmembrane helices followed by a cytoplasmic loop 2) MSD1 with
six transmembrane helices, 3) cytosolic nucleotide binding domain (NBD1), 4) MSD2
with six transmembrane helices, and 5) cytosolic NBD2 with C-terminus. The above
indicated structure is reflective of the longer ABCCs 1, 2, 3, 6, 8, 9, and 10 whereas the
shorter ABCCs 4, 5, 7, 11, and 12 have a cytosolic N-terminus-MSD1-NBD1-MSD2NBD2 arrangement (Gottesman et al., 2002). MSD0 is important for trafficking of the
proteins to their respective locations and for retention of the protein to the plasma
membrane (Westlake et al., 2005; Bandler et al., 2008). The NBD regions carry out the
binding of ATP and subsequent hydrolysis to ADP. The two MSDs with their twelve
helices form a channel that closes on the cytoplasmic side upon presentation of
substrate and ATP. The substrate is then released into the extracellular space, and
ATP is hydrolyzed to ADP re-initializing the transporter to accept substrate from the
cytoplasm (Linton, 2007).

Each transport cycle requires two ATP molecules.

The

presence of glutathione has been shown to promote the activity of ABCCs in vitro (Qian
et al., 2001).
Most of the ABCC proteins are expressed at the basolateral membrane while ABBC2
(alias MRP2) is unique in that it is exclusively expressed on the apical membrane.
There is broad overlap of substrates for the various ABCCs. Common substrates of the
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longer ABCC proteins are organic anions, glucuronide conjugates, glutathione as well
as glutathione conjugates, and sulfated compounds (Deeley et al., 2006). The shorter
ABCCs transport glucuronide conjugates as well as bile salts, nucleosides,
prostaglandins, and sulfates. ABCC7 (alias cystic fibrosis transmembrane conductance
regulator [CFTR]) is an atypical ABCC in that it functions as a chloride ion channel and
was identified as being the protein that is defective in cystic fibrosis (Rommens et al.,
1989). ABCCs 8 and 9 serve as sulfonylurea receptors (alias SURs) and have a role in
modulating insulin (Thomas et al., 1995; Aguilar-Bryan et al., 1998). ABCCs 11 and 12
are thought to be duplicates with closest homology to ABCC5 (Tammur et al., 2001).
ABCC11 can efflux anions, glucuronides, nucleotides, and is a determinant for ear wax
type (wet vs. dry) while ABCC12 is expressed in breast cancer (Bera et al., 2002; Chen
et al., 2005; Yoshiura et al., 2006). The consequence of the wet ear wax phenotype is
an increased risk of breast cancer in Japanese but not Caucasian women (Ota et al.,
2010; Lang et al., 2011). ABCC13 does not appear to be a functional protein as it
contains only one fully formed NBD, hence it cannot properly bind ATP (Annilo and
Dean, 2004).
The members of the ABCG subfamily of transporters are much smaller and consist of a
cytosolic N-terminus coupled to a NBD and a single MSD with six helices and cytosolic
C-terminus. The proteins are considered half-transporters in that they dimerize to form
a functional unit (Ozvegy et al., 2001). ABCG1 is the human homologue to a protein in
Drosophila that produces a white eye color due to the efflux of brown and red pigments
(Chen et al., 1996). ABCG1 and ABCG4 are thought to modulate the efflux of sterols
and have high expression the brain (Wang et al., 2008). ABCG2 (alias BCRP) has a
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major role in the disposition of xenobiotics and can mediate the efflux of anti-cancer
drugs, statins, and Phase II conjugates (Robey et al., 2007). BCRP is responsible for
the basolateral efflux of substrates from the central nervous system and is also located
along the canalicular domains in the hepatocyte and the apical domain of the intestines
(Berge et al., 2000). ABCG5 and ABCG8 form a heterodimer and are located at the
apical membrane in hepatocytes where they excrete cholesterol and other sterols into
the bile (Lu et al., 2001).
The last major transporter family that will be covered is the solute-carrier (SLC) that is
comprised of more than fifty subfamilies. As it pertains to the research in the thesis,
focus will be on the SLCO subfamily. There are thirteen distinct transporter proteins
encoded by the SLCO genes, and the SLCOs are referred to as organic anion
transporters or more colloquially as organic anion transporting polypeptides (OATPs).
The SCLOs have a typical structure of cytosolic N-terminus, a MSD with eight to nine
helices, an extracellular loop, a second MSD with three helices, and finally a cytosolic
C-terminus. In contrast to the ABC transporters, SLCOs are not energized by ATP and
may use bidirectional transport as a driving mechanism.

The exact mechanism of

SLCO transport has not been clearly defined, though it is generally thought that the 2
MSDs form a pore having an internal positive charge with multiple substrate binding
sites (Han et al., 2010; Niemi et al., 2011). SLCO2B1 activity can be modulated by
extracellular pH in that acidic conditions increase the inward transport of substrates,
however other SLCOs do not necessarily share this trait (Tirona and Kim, 2007).
The SLCOs are distributed throughout the body and with diverse orientation, i.e. apical
vs. basolateral localization (Roth et al., 2012). Among those expressed in the brain are
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SLCO1A2, SLCO2B1, SLCO1C1, and SCLO3A1.

The liver has SLCO1B1 and

SLCO1B3, which are hepatoselective, as well as SLCO1A2 and SLCO2B1. Intestinal
expression of SLCOs consists of SLCO1A2 and SLCO2B1 that are both facing the
intestinal lumen.

The kidneys possess SLCO1A2 and SLCO4C1 on opposing

membranes. Finally, SLCO2B1 is expressed constitutively in skeletal muscle. Muscle
tissue is sensitive to a type of injury called rhabdomyolysis, which is a syndrome
characterized by muscle pain and myopathy. During rhabdomyolysis, muscle tissue is
destroyed, and the degradants are released into the blood potentially leading to renal
failure as the kidneys become inundated with the muscle protein myoglobin that cannot
be cleared properly (Sauret et al., 2002; Polderman, 2004).

A causative factor for

rhabdomyolysis is the accumulation of statins via uptake by SLCO2B1 into muscle
tissue. As the intracellular statin concentrations increase beyond the muscle’s ability to
metabolize the substances, toxicity begins to occur resulting in myopathy of muscle
(Knauer et al., 2010).

Inhibition of SLCO-mediated statin uptake by the clinically

relevant antibiotic rifampicin was shown to attenuate statin-induced cytotoxicity using an
in vitro model (Zhang et al., 2013). Among the other SLCOs substrates are antibiotics
(β-lactams), bile salts, glucuronide conjugates, peptides, prostaglandins, sulfated
compounds, and thyroid hormones (Tirona and Kim, 2007; Roth et al., 2012).
1.3.2 Pharmacogenomics
As is the case for many genes, transporters can have a variety of polymorphisms that
can affect protein functionality with clinical ramifications.

For instance, a SNP for

ABCC2 in which the amino acid at position 412 changes from an arginine to a glycine
(R412G) resulted in a loss of methotrexate efflux, as measured in an in vitro system,
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compared to wild type ABCC2 (Hulot et al., 2005). The arginine at 412 is conserved in
the Abcc2 sequence of other animals and is thought to be involved in substrate
recognition.

Clinically, the R412G mutation was linked to a 3-fold increase in the

elimination half-life of methotrexate resulting in an overdose that may have contributed
to nephrotoxicity. Another SNP for ABCC2, this time in the promoter region hence
having a no impact on the protein sequence, was correlated with a statistically
significant 25% increase in the plasma concentrations of mycophenolic acid acyl
glucuronide (AcMPAG) in healthy subjects compared to homozygous wild-type carriers
(Levesque et al., 2008). AcMPAG has immunosuppressive pharmacology similar to its
parent compound, thus a rise in plasma concentration of the pharmacologically active
metabolite in carriers of mutant ABCC2 may result in pharmacodynamic effects (Schutz
et al., 1999; Shipkova et al., 2002).
Mutations in ABCC2 are associated with pathogenesis of Dubin-Johnson Syndrome
(DJS) as a result of impaired expression and functionality. The phenotype of affected
subjects is characterized by hyperbilirubinemia, jaundice, and darkened livers (Dubin
and Johnson, 1954; Shani et al., 1970). The mutations in the ABCC2 gene are a
combination of alternate deletion, splicing, or substitution (Chen and Tiwari, 2011).
Several SNPs were shown to have reduced activity suggested to be the result of
misfolded protein structure (Mor-Cohen et al., 2001). Other explanations for loss of
activity were attributed to SNPs in the NBDs that might limit the binding of ATP to
energize transport (Tsujii et al., 1999).

In addition to functional loss, trafficking of

ABCC2 was shown to be impaired with localization of protein directed to the
endoplasmic reticulum rather than the plasma membrane (Arlanov et al., 2012). The
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Eisai hyperbilirubinuria rats, which lack Mrp2 as a result of a stop codon insertion, are
used as a rodent model of DJS (Ito et al., 1997; Johnson et al., 2006).
To date, there has been little focus on the clinical significance of ABCC3 polymorphisms.
Nonetheless, research from multiple groups demonstrated that polymorphisms of
ABCC3 are numerous. Saito et al. (2002) initially reported 30 ABCC3 SNPs, however
the functional significances were not investigated.

Work by Lang et al. (2004)

indentified 51 mutations, and a SNP in the promoter region was correlated with a
reduction in both hepatic mRNA and protein though only the mRNA reduction was
statistically significant. A comprehensive analysis of ABCC3 SNPs was performed by
Kobayashi et al. (2008) who characterized eleven SNPs with all polymorphisms
occurring in the protein coding regions. Eight of the polymorphisms that were found in
MSD0, NBD1, and NBD2 were determined to have normal function as well as
expression and had proper localization to the plasma membrane. A SNP in NBD2, in
which arginine was changed to serine at position 1381 (R1381S), caused the protein to
accumulate within the cell and remain bound to the endoplasmic reticulum.
The remaining two SNPs in Kobayashi’s research were determined to have reduced
functional activity. The first of these SNPs is located on the extracellular side of MSD1
at position 346 where serine is replaced with a phenylalanine (S346F). The second
SNP is localized near NBD1 at position 607 and consists of an asparagine substitution
in place of serine (S607N). The transport activity was measured using estradiol-17βglucuronide as a probe and compared to the wild-type ABCC3 sequence. Transport
activity for the two SNPs was between 67 to 77% lower compared to the wild-type.
Moreover, the previously mentioned eight SNPs yielded transport activity that was
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greater than or similar to that of wild-type. The S346F mutation is estimated to occur in
2.5% of Caucasians while the S607N SNP has a prevalence of approximately 2.8% in
African-Americans. More recently, a report by Pussegoda et al. (2013) indicated that a
SNP near the N-terminus at position 1503 was significantly correlated with ototoxicity in
children receiving cisplatin during chemotherapy treatment. Considering that cisplatin is
a substrate for ABCC3, the correlation may be due to altered protein function, though
the authors of the study did not investigate ABCC3 protein activity.
Polymorphisms have likewise been discovered for uptake transporters. Nozawa et al.
(2002) reported that 10% of Japanese subjects were homozygous for a SNP at position
392 where isoleucine is changed to threonine (I392T) for SLCO2B1, and that the
prevalence of I392T SNP, known colloquially as the *3 allele, occurred in approximately
31% of the subject pool. Using an in vitro cell-based system, the I392T SNP was found
to have reduced transport kinetics compared to homozygous wild-type (*1 allele) of the
known OATP2B1 substrate estrone-3-sulfate. Substrate affinity, in terms of Km, was the
same between *1 and *3 alleles though the *3 Vmax was reduced by over 50%. Results
from in vivo studies indicate that the reduction in *3 transport capacity has clinical
significance. In a report by Akamine et al. (2010), Japanese subjects with the *3 allele
had a 51% increase in fexofenadine plasma concentrations compared to *1 carriers.
Experiments with in vitro cell-based systems indicated that fexofenadine is an
OATP2B1 substrate (Nozawa et al., 2004; Ming et al., 2011).

However, not all

OATP2B1 SNPs result in loss of activity as substrates aliskiren and glyburide did not
have altered activity compared to the wild-type allele (Ieiri et al., 2012; Tapaninen et al.,
2013).
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Given the importance transporters have in modulating the uptake and efflux of critical
endogenous substances as well as their respective roles in mediating the clearance of
xenobiotics, further investigation into transporter loss of function is warranted.
Transporter knockout models afford a mechanistic means by which dispositional
changes can be uncovered. As it applies to the field of toxicology, transporter knockout
models can serve as surrogates to human polymorphisms whereby the ramifications of
diminished transporter function can be quantified. To this end, a major goal of the
present work is to use animal knockouts to study the disposition of toxicants.
1.4 Cyclooxygenases
1.4.1 Structure and Function
There are two genes that are responsible for the coding of enzymes involved in
arachidonic acid metabolism, prostaglandin-endoperoxide synthase 1 (COX-1, PTGS1)
and 2 (COX-2, PTGS2). Following initial characterization of COX-1 enzyme in sheep
(DeWitt and Smith, 1988), the structure and sequence of human COX-1 was elucidated
by Yokoyama and Tanabe (1989) and found to be 599 amino acids in length. Work by
Funk et al. (1991) showed that mutation of a serine (Ser) to asparagine at position 529
abolished activity of the enzyme. COX-2 was characterized by Hla and Neilson (1992)
and reported to have 604 total amino acids. Kim et al. (2005) discovered that mutation
of a cysteine (Cys) residue at position 555 to a serine eliminated enzyme activity.
Furthermore, mutation of the Cys526 site to a serine prevented the binding of inducible
nitrous oxide synthase (iNOS, NOS2). The binding of iNOS to Cys526 causes it to be
S-nitrosylated resulting in increased enzymatic activity. S-nitrosylation is regarded as
an important post-translational event that can modulate the intrinsic activity of targeted
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proteins (Hess et al., 2005). Of the thirteen cysteine residues on COX-2, only Cys526
can be activated by iNOS.
The two encoded COX proteins share about 65% identity for their native amino acid
sequence (Altschul et al., 1997).

Structurally, the two COX enzymes share similar

features. The COX protein structure has a membrane bound domain at the aminoterminus, a proton acceptor site between residues 190 to 210, a substrate recognition
region is located near position 350, there is a site for cyclooxygenase activity between
amino acids 370-390, a heme binding motif is located three amino acid residues from
the catalytic site, and there is a serine site between positions 510 to 530 near the
carboxyl-terminus that is involved in aspirin pharmacology (Magrane and Consortium,
2011; UniProt, 2015).

COX-1 has ubiquitous expression in most tissues and is

constitutively active thus functioning as a housekeeping gene (Dewitt and Meade, 1993;
Smith and Dewitt, 1996).

COX-2, in contrast, is not detectable under homeostatic

conditions, though its expression can be inducible and sustained for short durations
(Evett et al., 1993). COX proteins are monotopically membrane bound as homodimers
within the endoplasmic reticulum (Mbonye et al., 2006).

Despite the differences in

expression and modulation of activity, the two COX enzymes share similar enzyme
kinetics (Smith et al., 1996).
Both COX proteins perform the same enzymatic reaction of converting arachidonic acid
(AA) to prostaglandin G2, which is subsequently converted to prostaglandin H2 by
hydroperoxidase activity in the COX enzyme. PGH2, being unstable, is then further
metabolized into prostacyclins, prostaglandins, or thromboxanes by a number of
synthases that are tissue specific (Nicolaou et al., 2014).
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The products of these

reactions have varying pharmacologies ranging from induction of inflammation,
inhibition of platelet function, immunosuppression, vasodilation, and inhibition of T-cell
production (Moncada et al., 1976; Sravan Kumar and Das, 1994; Zhou et al., 2007;
Kalinski, 2011).
1.4.2 COX Inhibition
The inhibition of COX enzymes as the pharmacological basis of anti-inflammatory drugs
was first postulated in 1971 (Ferreira et al., 1971; Vane, 1971). Compounds that inhibit
COX are sorted into four structural classes: 1) salicylic acids, 2) anthranilic acids, 3)
acetic acids, and 4) propionic acids. Examples of each structural class are aspirin
(salicylic), mefenamic acid (anthranilic), diclofenac (acetic), and ibuprofen (propionic)
(Kalgutkar and Daniels, 2010). Inhibitors of the COX enzymes fall into one of three
categories: selective 1) COX-1 selective inhibitor, 2) non-selective inhibitor of COX-1/2,
or 3) COX-2 selective inhibitor.
Early therapeutic agents were generally non-selective COX inhibitors. Discovery and
characterization of the COX-2 protein shifted efforts of medicinal chemists to develop
therapeutic agents that had greater COX-2 antagonism so as to minimize the
deleterious effects associated with suppression of COX-1 function (Borne et al., 2013).
Inhibition of COX occurs as a result of competitive inhibition, tight binding of inhibitors,
or covalent modification. Mefenamic acid and ibuprofen are examples of competitive
inhibitors that interfere with the binding of AA to the COX catalytic site (Catella-Lawson
et al., 2001).
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Tight binders are not covalently bound, rather the inhibitor-enzyme complex dissociates
relatively slowly (Rome and Lands, 1975). Formation of the tightly bound complex has
been described as a two step process, initial binding followed by a conformational
change permitting closer association of inhibitor and enzyme wherein the second step is
time dependent (Copeland et al., 1994). Compounds such as indomethacin, a nonselective COX inhibitor in the same structural category as diclofenac, need to bind to
one of the COX-2 homodimer units to block AA metabolism. (Prusakiewicz et al., 2009).
Ibuprofen and mefenamic acid need to occupy the substrate binding sites in both COX2 subunits to inhibit the catalytic conversion of AA into PGH2. The mechanism of action
for COX inhibitors has been linked to interaction with the arginine (Arg) residue at
position 120. Under normal conditions, Arg120 interacts with the carboxylate moiety of
arachidonic acid (Marnett et al., 1999). COX inhibitors occupy the substrate binding site
with an orientation such that the negatively charged carboxylate region of the inhibitor is
ion-paired with Arg120 due to the positively charged arginine. Mutation of Arg120 to
other amino acids diminished the inhibition potency of diclofenac, indomethacin,
ketoprofen, and meclofenamic acid (Mancini et al., 1995).
Selective COX-2 inhibitors do not possess carboxylic acid moieties, rather they contain
sulfonamides or sulfones. The mechanism for selective COX-2 inhibition is such that
the sulfonamide or sulfone of the inhibitor interacts with other regions of the enzyme
rather than orient towards Arg120 as the traditional COX inhibitors do. The changes in
COX-2 amino acids compared to the COX-1 sequence, specifically a valine at positions
434 and 523, create a larger binding pocket allowing the inhibitor to access a secondary
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region in the COX-2 enzyme that is otherwise inaccessible in COX-1 (Zarghi and Arfaei,
2011).
The final category of COX inhibitors is the covalent modifier. Despite the long history of
anti-inflammatory drug research, only one therapeutic agent has been developed and
subsequently identified as a covalent modifier, aspirin. The site of covalent modification
differs for each enzyme with a serine at position 530 and 516 for COX-1 and COX-2,
respectively, that is acetylated by aspirin (Shimokawa and Smith, 1992; Lecomte et al.,
1994). The mechanism of action for aspirin relative to other COX inhibitors is distinct in
that the blockade by competitive inhibitors or tight binders is eventually reversible,
taking more time for the tight binders, while covalent modification is irreversible. COX
enzymes exposed to aspirin must be newly synthesized for cells to regain COX
metabolism of AA. The effect of aspirin on COX-1 in platelets is a loss of ability to
produce thromboxane, a required component in the blood clotting process (Schror,
1997). Though aspirin can acetylate both COX enzymes, its potency for COX-1 is far
greater than that for COX-2 (Awtry and Loscalzo, 2000).
1.4.3 COX Pharmacology
The metabolism of AA by the COX enzymes yields a number of prostaglandin
derivatives.

In the context of the work presented in this thesis, the formation of

prostaglandin E2 (PGE2) is of significance.

Formation of PGE2 occurs through the

metabolism of PGH2 by prostaglandin E synthase (PTGES). PTGES was reported to be
dependent on glutathione and found to be inducible by the proinflammatory cytokine
interleukin 1 beta (IL-1β) (Jakobsson et al., 1999). COX-2 was similarly reported by
Mitchell et al. (1994) to be inducible by cytokines such as IL-1β and tumor necrosis
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factor alpha (TNFα). PGE2 acts as a ligand for several receptors known as EP1, EP2,
EP3, and EP4 (Coleman et al., 1994). The rank order affinity of PGE2 for its receptors
are EP3 > EP4 >> EP2 > EP1 (Abramovitz et al., 2000; Mohan et al., 2012).
Activation of EP1 and EP3 by PGE2 results in an increase of intracellular calcium, or
alternatively, for EP3 activation reduces cyclic adenosine monophosphate (cAMP)
formation.

In contrast, EP2 and EP4 activation stimulates production of cAMP.

Hoshino et al. (2003) reported the involvement of EP2 and EP4 activation as a
mechanism for PGE2-mediated protection of the gastrointestinal tract. Using ethanol as
a model toxicant, PGE2 was able to inhibit apoptosis of cultured gastric mucosal cells
(Hoshino et al., 2002). Use of specific agonists for EP2 and EP4 led to a decrease in
ethanol-induced toxicity.

Furthermore, EP2 and EP4 agonists also suppressed

activation of several caspases.

In consideration that caspases are involved in

mediating apoptosis (McIlwain et al., 2013), suppression of caspase activity via EP2
and EP4 activation promotes cell viability. Neither EP1 nor EP3 agonists maintained
cell viability in gastric cells exposed to ethanol suggesting that EP1 and EP3 do not
have a role with regards to caspase inhibition and suppression of apoptosis.
Nonetheless, EP1 activation by PGE2 is a protective mechanism as it results in an
increase in the release of bicarbonate, a critical buffer for the intestinal tract to
neutralize the acidity of gastric chyme (Takeuchi et al., 1997).
Yokotani et al. (1996) published a report detailing the role that EP3 activation has in
reducing the secretion of gastric acid. Using a gastric epithelial cell line that expressed
EP4, but not EP1 or EP3, the addition of PGE2 to the cells resulted in production of
hexosamine (Hassan et al., 1996).

The formation of hexosamine occurs during
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synthesis of gastric mucous (Gindzienski et al., 2003), hence EP4 activation represents
yet another pathway by which PGE2 maintains the overall health and integrity of the
gastrointestinal tract. Overall, the outcome of PGE2 synthesis and subsequent binding
to its native receptors is an apparent resistance to damage from toxicants through
several distinct but physiologically relevant and complementary pathways.
The role that COX-1 has in maintaining health of the gastrointestinal tract was
demonstrated using mice that were exposed to radiation. Cox-1 but not Cox-2 was
induced in mice exposed to radiation (Cohn et al., 1997). In that same study, mice were
then challenged with indomethacin which has greater potency against COX-1 compared
to COX-2 (Blanco et al., 1999). The administration of indomethacin reduced both PGE2
synthesis as well as the number of surviving intestinal stem cells. Treatment with a
PGE2 analogue was able to counter the indomethacin effect on the stem cells. The
authors conclude that PGE2 generated from Cox-1 had a protective effect in their
mouse model.
The cytoprotective effects of COX-2 are evidenced by its apparent induction in
neoplastic tissue (Eberhart et al., 1994). As an example, PGE2 stimulated colon tumors
in a rat model wherein PGE2 was administered over multiple weeks (Kawamori et al.,
2003). The authors of that study reported transcriptional expression of all EP receptors.
PGE2 administration also decreased the level of apoptosis compared to control. The
authors concluded that PGE2 stimulated cellular proliferation in addition to inhibiting
apoptosis. The potential for PGE2 to induce cellular growth in models of tumor growth
created interest in pursuing COX-2 inhibition as a potential treatment for metastases of
the colon (Ferrandez et al., 2003; Koehne and Dubois, 2004; Fujimura et al., 2007).
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As mentioned previously, COX-2 is inducible, and its expression increases during
inflammation or injury (Mizuno et al., 1997). A rat model was used to demonstrate that
inhibition of COX-2 was associated with a delay in repair of ulcers as well as reduction
of angiogenesis (Ma et al., 2002). A separate study reported that activation of EP4 but
not EP1, EP2, or EP3 accelerated wound healing in a rodent model of intestinal
ulceration (Hatazawa et al., 2007). Ulceration in the animals was induced by application
of heat that led to a marked increase of intestinal PGE2. The involvement of EP4 in
wound repair was confirmed by administration of an EP4 agonist. Administration of a
selective EP4 antagonist caused a delay in healing. Furthermore, rats and mice that
received indomethacin and rofecoxib (a selective COX-2 inhibitor), experienced delays
in ulcer repair in contrast to animals given SC-560 (a selective COX-1 inhibitor).
Furthermore, the latency in healing was observed in Cox-2 knockout mice but not Cox-1
knockout mice.

Thus it can be inferred from the Hatazawa study that COX-2 was

operative in healing of ulcers through generation of PGE2 that acted on EP4 receptors.
Given the importance of COX-1 and COX-2 for protection of the gastrointestinal tract as
well as involvement on cellular regeneration, inhibition of both pathways would be
contributory toward exacerbation of gastrointestinal injury.

One of the critical

components of COX inhibition is the production of PGE2 from AA metabolism. In this
framework, the research presented in subsequent chapters will focus on the role that
DCF and its metabolites have in causing injury to the intestinal tract.
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1.5 Diclofenac
1.5.1 Pharmacokinetics and Metabolism
Diclofenac is an NSAID that was developed by Ciba Geigy and patented in Europe and
the United States in 1965 and 1971, respectively (Sallmann and Pfister, 1971). In the
United States, diclofenac is available only by prescription and is commonly given in 100
mg doses though its therapeutic benefit can be achieved with dosing of 50 to 200 mg
per day (Novartis, 2011; Depomed, 2014). Diclofenac is also prescribed as a gel for
topical applications. Low dose diclofenac was made available as an over-the-counter
(OTC) remedy in a number of countries (Hinz et al., 2005).

As recently as 2015,

diclofenac was removed from OTC status by the Medicines and Healthcare products
Regulatory Agency (MHRA) in the United Kingdom due to concerns of cardiac toxicity
(MHRA, 2015).

Consequently, diclofenac became available as a prescription only

medicine similar to its status in the United States.
The pharmacokinetics of diclofenac has been characterized in animals and man.
Approximately 60% of diclofenac is eliminated in feces in the dog and rat with the
remaining 40% excreted in the urine (Riess et al., 1978). The elimination pathway is
reversed in monkey whereby approximately 80% of the dose is eliminated in urine with
20% excretion in feces. Similar to monkey, 60% of the dose was excreted in the urine
of healthy human subjects with the remainder directed to biliary excretion (Stierlin and
Faigle, 1979). The bioavailability of diclofenac in human subjects given a single 50 mg
dose was reported to be 54% (Willis et al., 1979). In healthy human subjects receiving
an oral dose, the maximum plasma concentration (Cmax) was calculated to be 2.0 µg/mL
(6.75 µM) occurring approximately 2.5 hours after dosing with a terminal half-life of 1.8
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hours. A food effect was observed in humans in that the time to maximum plasma
concentration was increased however the overall exposure of diclofenac, as measured
by integration of plasma-concentration time profiles, was similar between fasting and
non-fasting subjects (Willis et al., 1981).
Diclofenac undergoes extensive metabolism, and less than 1% of the dose is excreted
in the urine as parent compound.

Major Phase I metabolites are 3ʹ-hydroxy-, 4ʹ-

hydroxy-, 5-hydroxy, 3ʹ,4ʹ-dihydroxy-, and 4ʹ,5-dyhyroxy-diclofenac as the result of
catalysis by CYP2C8, CYP2C9 (for 4ʹ-hydroxy), and CYP3A4 (for 5-hydroxy) (Riess et
al., 1978; Stierlin and Faigle, 1979; Bort et al., 1999a). Approximately 30% of the total
diclofenac dose is excreted in urine as the 4ʹ-hydroxy metabolite while biliary excretion
of 4ʹ-hydroxy accounts for up to 20% of the dose (Davies and Anderson, 1997). Phase
II metabolites are taurine and acyl glucuronide conjugates of diclofenac (Pickup et al.,
2012; Sarda et al., 2012). Glucuronide conjugates can subsequently be hydroxylated.
Regarding glucuronide formation, the predominant enzyme is UGT2B7 (UGT2B7). In
addition to UGT2B1, Nakamori et al. (2012) reported that diclofenac can be
glucuronidated by UGT2B15, UGT2B17, and UGT1A9.
Diclofenac has excellent absorption as characterized in the Caco-2 colorectal
adenocarcinoma cell line. Caco-2 cells are often used to test compound permeability
and determine if there is transport by MDR1 as the cells express this efflux transporter
(Marino et al., 2005). Owing to the polarization of Caco-2 cells, test compounds are
assayed in an Apical→Basolateral (A→B) and Basolateral→Apical (B→A) format, and
the flux or movement of compound is reported as a two dimensional parameter with
units of cm/sec. The A→B and B→A values for diclofenac are 20 and 21 × 10-6 cm/sec,
30

respectively (Yazdanian et al., 2004). The B→A/A→B ratio of 1.1 signifies diclofenac is
not a MDR1 substrate as ratios > 2 indicate MDR1 efflux. The cell assay was confirmed
with a parallel artificial membrane permeability assay (PAMPA), which is a non-cell
based assay that uses lipids to mimic a physiologic barrier (Nakamori et al., 2012).
Diclofenac’s permeability classifies it as highly permeable and similar to compounds
such as caffeine, midazolam, and verapamil. Using Equation 1.1, the bioavailability of
diclofenac can be broken down as follows:

The above relationship indicates that: 1) absorption of diclofenac is complete as a
consequence of high permeability, 2) intestinal enzymes significantly contribute to
overall diclofenac metabolism, and 3) hepatic metabolism is less than intestinal
metabolism following an oral dose (Varma et al., 2010).
1.5.2 Reactive Metabolites
The metabolism of diclofenac results in reactive metabolites. Both the 4ʹ- and 5-hydroxy
metabolites (refer to Figure 2.8) can form quinone imines due to the hydroxy groups
being para to nitrogen (Shen et al., 1999). A simplified reaction is shown below:
R
HO

R

N

O

N

H

Exposure to diclofenac has been linked to bone marrow toxicity.

Studies with

neutrophils provided evidence that a quinone imine derivative of diclofenac was
detected in neutrophils (Miyamoto et al., 1997). Neutrophils are white blood cells that
protect the body against microorganisms.
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One the ways in which neutrophils carry out their antimicrobial function is to generate
reactive oxygen species from the release of myeloperoxidase (Monteseirin et al., 2001).
Myeloperoxidase (MPO) generates hypochlorous acid (HOCl) from chloride ions using
hydrogen peroxide, which is reduced to water (Arnhold, 2004). HOCl then reacts with a
number of agents to produce reactive oxygen and nitrogen species.

Regarding

diclofenac-associated bone marrow toxicity, Miyamoto and colleagues demonstrated
that myeloperoxidase, through the synthesis of HOCl, generated diclofenac quinone
imine reactive species. Though the authors admit that quinone imine formation by MPO
is slow, they argue that such a reaction could occur in vivo and be a contributory factor
to the bone marrow toxicity that can occur during treatment with diclofenac (Sell et al.,
1999; Aydogdu et al., 2006).
In addition to diclofenac, a number of marketed agents are metabolized into acyl
glucuronides including clofibric acid, diflunisal, fenoprofen, furosemide, ibuprofen,
ketoprofen, mycophenolic acid, suprofen, tolmetin, valproic acid, and zomepirac (Bailey
and Dickinson, 1996; Bolze et al., 2002). Ferosemide acyl glucuronide has very low
reactivity as a result of its benzoic acid structure providing a stabilizing force through
resonance of the aryl π bonds (Sawamura et al., 2010). Though ibuprofen is converted
to an acyl glucuronide that can covalently bind albumin, it has an excellent safety profile
in that reports of adverse drug reactions (ADRs) were less than or equal to placebo
(Fries et al., 1991; Kellstein et al., 1999).

In the case of ketoprofen, its reactive

glucuronide was shown to covalently bind to the UGT enzyme that generated it (Terrier
et al., 1999). Despite the UGT modification by ketoprofen acyl glucuronide, ketoprofen
usage for pain relief did not result in any ADRs during an 18 month study designed to
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test its overall safety in 402 patients (Kneer et al., 2009). Valproic acid was found to
form covalent adducts, via its acyl glucuronide, in patients taking the drug for epilepsy
treatment. Yet in those patients that tested positive for valproic acid antibodies, the
antibody titer was reportedly low (Williams et al., 1992). Factoring the incidence of
covalent adduct formation and antibody generation in response to the adducts, valproic
acid usage is not likely to result in hypersensitivity reactions. That said, valproic acid
itself has been linked to nonalcoholic fatty liver disease that is characterized by mixed
hepatocellular injury thought to have an immune component (Farinelli et al., 2015). Of
the more reactive acyl glucuronides listed above, the rank order of reactivity is tolmetin
> zomepirac > diclofenac. Zomepirac was withdrawn from marketed status due to fatal
hypersensitivity reactions (FDA, 1998). Interestingly, Cannell et al. (2001) reported that
incubation of colon cancer cells with the acyl glucuronides of diclofenac, diflunisal, and
zomepirac attenuated the cellular division of the cells perhaps as a result of their
covalent adduction to factors involved in proliferation.
1.5.3 Liver Toxicity
Liver injury can be determined through the use of serum markers, specifically alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALkP), and bilirubin. ALT and AST are indicators of hepatocellular damage while ALkP
and bilirubin are used to indicate biliary obstruction or cholestasis (Green and Flamm,
2002). ALT is more exclusive to the liver cells and is found in the cytosol while AST is
localized in both in the cytosol and mitochondria. Elevations of ALT and AST in the
blood may indicate that a degree of liver injury or necrosis has occurred. ALkP is useful
as an indicator of cholestasis due to its localization along the bile canalicular domain.
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Bilirubin is formed during the breakdown of heme, and its elimination is dependent upon
glucuronidation before excretion into the bile. The pattern of liver injury is contingent
upon the extent of elevations in the serum markers. For reference, the upper limit of
normal (ULN) for ALT, ALkP, and bilirubin are 40 U/L, 115 U/L, and 1.2 mg/dL,
respectively (livertox.nih.gov). A comparative score, R value, is used to categorize the
type of injury and is determined as follows:
Equation 1.2

As a general guideline, an R value > 5 indicates hepatocellular injury, an R of <2
represents cholestatic injury, and R values between 2 to 5 signify a mixture of
cholestatic and hepatocellular injury (Chalasani et al., 2014).
According to diclofenac prescribing information, hepatotoxicity from diclofenac can
manifest within one to two months of therapeutic use (Novartis, 2011). A composite of
reported diclofenac hepatotoxicity cases is shown in Table 1.3. The calculated R values
for the cases cited appear to indicate that the liver injury attributable to diclofenac usage
exhibited a pattern of hepatocellular damage while one of the cited cases seems to
have been a mixed cholestatic and hepatocellular phenotype. Presentation of jaundice,
which can occur during cholestasis, was positively correlated with severe liver injury
though several subjects with jaundice recovered once diclofenac treatment was stopped.
Manifestation of high ALT values did not reliably predict that mortality would necessarily
follow. As an example, Chalasani et al. (2015) followed 899 subjects for drug-induced
liver injury for which twelve subjects were identified as taking diclofenac. Of the twelve
subjects, one exhibited a peak ALT of 1,895 U/L before ultimately dying. The diclofenac
group as a whole had a mean ALT of 1,266 ± 680 U/L, a value that is approximately 3034

fold greater than the ALT ULN. Five of the diclofenac subjects were classified as having
mild injury (increased ALTs & bilirubin <2.5 mg/dL) while six were deemed to have
severe injury (bilirubin >2.5 mg/dL, hospitalization, jaundice, and organ failure). Liver
injury from diclofenac accounted for nearly 36% of the entire cohort of subjects taking
analgesics (12 of 33 total subjects) suggesting that diclofenac usage carries greater risk
of hepatic injury compared to other anti-inflammatory drugs.
One key feature of diclofenac patients who develop liver injury is the dosing regimen.
When liver injuries do occur, more often than not the patients are adherent to the
prescribed dosage indicating that the liver injury is likely not a function of diclofenac
overdose.

This is in stark contrast to acetaminophen for which overdose is more

common. An analysis by Larson et al. (2005) revealed that acetaminophen accidental
overdoses and suicide attempts accounted for 133 and 122 cases, respectively, out of
662 acute liver failures over a six year period. The majority of subjects overdosing on
acetaminophen survived, however 27% died and 8% needed liver transplants for which
29% of transplant patients did not survive beyond three weeks after surgery. Lastly, the
median acetaminophen dose was 24 g despite product labeling warnings not to exceed
4 g per day. The high incidence of acetaminophen is linked to ease of access as an
over-the-counter medication (Sheen et al., 2002).
Reports of diclofenac overdose are rare, however once such case was published by
Netter et al. (1984) in which a 19-year old man intentionally overdosed on 1.5 g of
diclofenac, which is 7.5-fold greater than the maximum recommended therapeutic dose
(MRTD). Diclofenac plasma concentration seven hours after ingestion was 60.1 µg/mL
(189 µM), which is 30-fold higher than the plasma Cmax after a 50 mg therapeutic dose.
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Despite the overdose and subsequent high diclofenac plasma concentrations, the
subject recovered after two days with no apparent injury to liver or kidneys. Diclofenac
overdose has been associated with renal dysfunction after an accidental overdose
(Kulling et al., 1995). In that case a 29-year old man consumed 2 g of diclofenac (10fold MRTD) and survived. No information regarding liver injury was given, however
renal function was affected as evidenced by peak serum creatinine levels of 2.6 mg/dL
compared to the normal range of 0.7 to 1.5 mg/dL (Lee, 2013). Tolerance of diclofenac
during an overdose is not consistent as seen in a case whereby a 30-year old woman
took 1 g of diclofenac (5-fold MRTD) and died two weeks after the overdose (Montiel et
al., 2010). Hepatic and renal injury were apparent, leading to organ failures for both,
with maximal ALT and serum creatinine levels of 4,710 U/L and 3.7 mg/dL, respectively.
The role that diclofenac may have had in that case is unclear due to ingestion of several
other medications including 8 g ibuprofen. In a study of 1,572 German subjects taking
analgesics, approximately 25% were found to be using diclofenac with ibuprofen usage
second-most at 21% (Freytag et al., 2014). In 426 subjects taking multiple analgesics,
diclofenac was consumed with ibuprofen in 8.9% of the cases with polypharmacy also
observed with acetaminophen (6.6%), metamizole (6.3%), and tramadol (4.9%).
Despite the fact that subjects took more than the recommended dosage of diclofenac or
consumed multiple analgesics, the most common risk was gastrointestinal bleeding.
The exact mechanisms of liver injury following diclofenac usage are not wholly clear. In
the examples cited above and Table 1.3, injury ranged from mild to severe/fatal without
clear distinction of the injury phenotype.

For instance, all fatalities presented with

jaundice, yet not all patients who developed jaundice died. Additionally, ALT values
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were minimally 20-fold higher than ULN in the cases where fatality was reported.
Subjects that eventually recovered had ALTs that were comparable to the fatalities.
Several of the cases showed evidence of hypersensitivity that was determined by the
presence of antinuclear antibodies.

Furthermore, accumulation of eosinophils was

found in livers of diclofenac subjects with hepatotoxicity supporting the hypersensitivity
hypothesis.

Eosinophils are part of the immune system and are involved in the

development of delayed-type hypersensitivity reactions (Akahira-Azuma et al., 2004).
Dunk et al. (1982) reported their finding of a 52-year old man who had been taking
diclofenac for the treatment of pain.

After four months of usage, the individual

developed jaundice with AST and bilirubin levels of 1,375 U/L and 7.4 mg/dL,
respectively. Upon cessation of diclofenac treatment, the jaundice gradually subsided
during the following week. The patient subsequently continued diclofenac treatment a
month later, and within several weeks the jaundice reappeared. A liver biopsy was
performed, and the presence of eosinophils as well as Kupffer cell proliferation was
detected in the liver signifying activation of the immune system. Such activation may
also result in production of anti-diclofenac antibodies, a point illustrated by Aithal et al.
(2004) who reported that subjects with hepatotoxicity due to diclofenac treatment had
anti-diclofenac antibodies.
Further evidence for immune modulation is provided by the work of Yano et al. (2012)
for which plasma IL-17 was induced in mice given an 80 mg/kg dose of diclofenac.
Hepatotoxicity in the mice was diminished when IL-17 was sequestered by an anti-IL-17
antibody indicating that IL-17 may have promoted injury through pro-inflammatory
pathways (Jin and Dong, 2013).

A recently published study characterized immune
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activation by diclofenac in an in vitro assay with human hepatoma cell lines wherein the
pro-inflammatory mediators IL-1, IL-8, and TNF as well as monocyte chemoattractant
protein and immune mediator S100 calcium-binding protein A9 were upregulated by 50
µM diclofenac (Oda et al., 2015). Yet antibody presence does not appear to be a
specific indicator of liver injury as antibodies were detected in 60% of subjects on
diclofenac who did not have liver injury. Presumably, the anti-diclofenac antibodies are
likely directed against the covalent adducts that were described in the preceding section.
Nonetheless, hypersensitivity to diclofenac is cause for concern in that there is the
possibility of adverse reaction to other structurally similar anti-inflammatory drugs (del
Pozo et al., 2000; Picaud et al., 2014).
Non-immune hepatotoxicity may be linked to formation of metabolites and blockade of
critical organelle function. For example, research by Castell et al. (1997) demonstrated
that generation of N,5-dihyroxy diclofenac was associated with hepatocellular injury.
Base on the results in a follow-up study, the authors postulated that continual
generation of the N,5-dihydroxy diclofenac from 5-hydroxy diclofenac by CYPs depletes
the cell of NADPH (Bort et al., 1999b). Furthermore, both diclofenac and N,5-dihydroxy
diclofenac were shown to deplete ATP.

The loss of both ATP and NADPH is

detrimental to the cell since ATP is needed to generate NADPH as well as to drive a
number of cellular functions. Under normal conditions, cells can replenish ATP in the
mitochondria, however diclofenac disrupts mitochondrial function. It has been shown
that diclofenac interferes with the mitochondrial permeability transition pore, allowing the
pore to remain open for a longer duration leading to mitochondrial swelling and cell
death (Gomez-Lechon et al., 2003b; Lim et al., 2006).
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1.5.3 Intestinal Toxicity
It has been well established that therapeutic usage of NSAIDs is correlated with
gastrointestinal injury. In a study of 1,800 subjects being treated for arthritis, ulceration
and gastrointestinal lesions occurred in 24% and 37%, respectively, of the patient
population (Geis et al., 1991). Just as for other NSAIDs, treatment with diclofenac is
associated with gastrointestinal ADRs such as abdominal pain, bleeding, perforation,
and ulceration (Novartis, 2011). Thomas et al. (2012) monitored 943 patients receiving
diclofenac by prescription and noted that of the 561 ADRs, 267 (48%) were
gastrointestinal in nature. Abdominal pain accounted for 19% with ulceration making up
6% of reported ADRs.
As a consequence of intestinal injury and to promote patient compliance, diclofenac can
be prescribed as a combination treatment with misoprostol (Pfizer, 2014). Misoprostol
is a synthetic PGE1 analogue, and its therapeutic benefit is a result of activating EP
receptors to stimulate the gastrointestinal secretion of bicarbonate and mucous (Karim
and Gels, 1995). Administration of 0.2 mg misoprostol one to three times daily was
effective in reducing the incidence of gastrointestinal ulcers after a twelve week
treatment period (ulceration in 4.4% of patients receiving combination therapy vs.
ulceration in 11% of subjects receiving diclofenac monotherapy (Verdickt et al., 1992).
Another therapeutic benefit of misoprostol co-administration with diclofenac was a
marked reduction in the number of patients experiencing abdominal pain, 19% vs. 70%
for monotherapy (Agrawal et al., 1995). Thus, as a PGE1 analogue, misoprostol is able
to partially restore the prostaglandin-mediated protection that is otherwise attenuated
following exposure to diclofenac.
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The intestinal injury during diclofenac treatment is linked to the inhibition of COX
enzymes by diclofenac.

That diclofenac inhibits both COX enzymes is part of the

pathogenesis in gastrointestinal ulcers (Tanaka et al., 2001; Sigthorsson et al., 2002).
Emery et al. (1999) conducted a study in which patients with arthritis received either
diclofenac or the selective COX-2 inhibitor celecoxib. Patients were followed for six
months, and a subset was analyzed for gastrointestinal injury via endoscopy.
Pharmacologically, both agents were effective in ameliorating inflammation and pain. A
higher percentage of patients taking diclofenac experienced abdominal pain (21%) and
developed gastrointestinal ulcers and/or erosions (45%) compared to the celecoxib
group (11% for pain and 23% for ulcers/erosions). The higher incidence of diclofenacinduced gastrointestinal injury resulted in a withdrawal rate from therapy that was more
than twice the withdrawal for celebrex (16% vs. 6%, respectively). Reanalysis of a
separate study was somewhat contradictory in that celecoxib and diclofenac appeared
to be comparable with respect to gastrointestinal injury (Silverstein et al., 2000; Juni et
al., 2002). A possible explanation for the parity may be attributable to a higher dosage
of celecoxib (800 mg) in the report by Silverstein et al. relative to the dose used in the
study by Emery and colleagues (200 mg twice a day).
The degree of intestinal injury following exposure to diclofenac is partially dependent on
the route of administration.

For instance, in a study wherein diclofenac was

administered either orally or via application to skin by gel, oral dosing resulted in 39% of
subjects developing gastrointestinal ADRs whereas 25% of patients with topical skin
application manifested gastrointestinal injury (Roth and Fuller, 2011). The withdrawal
rate in the oral dosing group was 2.5-fold greater than the rate observed in the skin
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application group. That gastrointestinal injury also occurred during topical application of
diclofenac is indicative of a systemic effect for which the magnitude was enhanced after
oral dosing due to the higher systemic concentration of diclofenac.

As per the

prescribing information for diclofenac topical gel, standard application of the gel (4 g gel,
4 times/day) results in a total daily dose of 160 mg with an average maximum plasma
concentration of 0.015 ng/mL (0.051 µM) while an oral daily regimen of 150 mg (50 mg,
3 times/day) yields an average maximum plasma concentration of 2.27 µg/mL (7.67 µM)
(Novartis, 2014). The lower maximum plasma concentration from topical application is
consistent with what was determined for ketoprofen for which plasma concentrations
following topical administration were 1% of the plasma concentrations following the
nominal oral dose of 200 mg (Kneer et al., 2009).
Gastrointestinal injury following diclofenac administration has been demonstrated to
occur in animal models of acute exposure. Rats given a single dose of diclofenac
developed intestinal ulcers within 24 hours of administration (Atchison et al., 2000a;
Atchison et al., 2000b).

Sequestration of diclofenac with cholestryramine, which is

therapeutically used to reduce bile reabsorption, decreased the incidence of gastric
injury but not intestinal damage compared to diclofenac monotherapy in rats (RamírezAlcántara et al., 2005).

It has been suggested that the reactive metabolites of

diclofenac, specifically the acyl glucuronide, may be linked to induction of intestinal
ulceration (Seitz and Boelsterli, 1998; Ware et al., 1998).

The theory is that the

glucuronide conjugate may compromise the integrity of the intestinal tract via covalent
modification to enterocytes.

An alternate hypothesis is that the acyl glucuronide

undergoes cleavage to the aglycone parent compound, which is then able to induce
41

enteropathy.

LoGuidice et al. (2012) demonstrated that chemical inhibition of β-

glucuronidase decreased the number and size of ulcers in mice treated with diclofenac
and inhibitor compared to mice that received only diclofenac.

The intestinal injury

observed both in animal models and human patients most likely involves contribution
from both diclofenac and its acyl glucuronide. As such, one of the key themes of the
research presented in this thesis is to further expand the probable mechanisms causing
intestinal injury.
1.6 Summary
The work presented throughout this thesis focuses on the roles that BCRP, MRP3, and
OATP2B1 may have in modulating the exposure of diclofenac and its primary
metabolites.

BCRP, OATP2B1, and MRP2 have been extensively studied for

substrates evidenced by 247, 84, and 141 studies, respectively, as listed in the
University of Washington (UW) in vitro Drug Interaction Database (UW, 1999-2015). In
comparison, MRP3 is underrepresented with respect to literature reports having 23
unique citations in that same database (see Table 1.2). Though the UW repository may
not contain all reported studies, its frequent update and breadth of data capture help to
underscore the relative obscurity of MRP3 findings. In consideration of the lack of data
regarding DCF elimination by transporters other than Mrp2, our initial investigations
included Bcrp and Mrp3 as potential canalicular and basolateral mediators of DCF
transporter-mediated clearance.
Our hypothesis was that deletion of Bcrp or Mrp3 would result in altered disposition of
DCF or its metabolites.

To assess the contribution of efflux transporters in DCF

disposition, we utilized whole-body in vivo transporter knockout animal models and
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administered a single low dose to mice. The doses used were presumed to be below
the threshold that would induce tissue damage.

Regardless of dose selection, a

potential consequence of gene deletion is an upregulation of other genes as a
compensatory response, a condition that may have potential ramifications for the overall
design and anticipated outcome of our studies. For instance, rats that are missing Mrp2
via a spontaneous mutation were demonstrated to have induction of Mdr1 in brain but
not liver (Hoffmann and Loscher, 2007). A similar situation can occur in humans. For
example, in a subset of patients with acute myeloid leukemia there is deletion of one or
both copies of MRP1, yet the overall MRP activity was found to be comparable to
normal hematopoietic cells taken from healthy patients (van Der Kolk et al., 2000). The
authors of that study speculate that upregulation of other efflux transporters was the
reason. As it pertains to our study design, the mice used in our studies were not
reported to have alterations in other efflux transporters such as Mrp2 (Manautou et al.,
2005; Zelcer et al., 2005). Thus the results detailed in Chapter 2 reflect bona fide
hepatic canalicular efflux of DCF and DCF-AG by Bcrp as well as basolateral efflux of
DCF-AG by Mrp3.
Based on the results observed in Chapter 2, we focused our efforts on Mrp3 and further
hypothesized that loss of Mrp3 would have a deleterious effect such that mice lacking
Mrp3 would be more susceptible to liver and/or intestinal injury after a single toxic
administration of DCF. The data in Chapter 3 support the claim that Mrp3 functions as
an important protective mechanism against injury. Indeed, the presence of Mrp3 was
able to attenuate the extent of intestinal injury after an acute toxic dose of DCF. Mice
that lacked Mrp3 exhibited an increase in the incidence of injury, in terms of number of
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erosions and ulcers, as well as severity of damage compared to wild-type mice.
Strikingly, there was no evidence of hepatic injury in either wild-type mice or Mrp3
knockout mice. Although DCF is implicated in liver injury in humans, the potential for
DCF-mediated hepatotoxicity was not readily apparent on an acute basis with the
mouse models implemented in our studies. It is possible that hepatotoxicity caused by
diclofenac manifests only after repeated dosing. Despite the null finding in liver, the
intestinal toxicity was unequivocal and emphasizes the importance of Mrp3 as a vital
clearance mechanism in the intestine.
Acyl glucuronides have low passive uptake (Zhou et al., 2005; Shackleford et al., 2006;
Patel et al., 2013; Kimoto et al., 2015), therefore the uptake of DCF-AG into enterocytes
would likely occur through active transport. Since glucuronide conjugates have been
reported to be substrates of OATP2B1, a major intestinal uptake transporter, the uptake
of DCF-AG was postulated to occur via OATP2B1.

To test this theory, an in vitro

system wherein OATP2B1 was stably transfected into human embryonic kidney (HEK)
cells was utilized. HEK cells provide an advantage to study transporter activity in an
overexpressed system as these cells have low to non-existent expression of many of
the uptake and efflux transporters shown in Table 1.1 (Ahlin et al., 2009). The uptake of
DCF-AG via OATP2B1 was quantified and determined to be saturable.

A mouse

homologue, Oatp2b1 (Slco2b1), likewise is expressed along the intestinal tract allowing
for a reasonable argument that DCF-AG intestinal uptake in the mouse studies was
mediated by Oatp2b1.
In prior sections, the intrinsic toxicity of DCF was detailed as was the reactivity of DCFAG. Given the high biliary DCF-AG concentrations detected in the acute toxicokinetic
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study, along with the apparent injury characterized in the Mrp3 knockout mice in the
toxicodynamic study, it seemed plausible that DCF-AG was a direct mediator of the
observed toxicity. Nonetheless, the manner by which DCF-AG causes toxicity is not
wholly clear.

Rather than focus on immunologic pathways, as suggested by those

supporting a hapten hypothesis, that may or may not manifest in a mouse model,
investigation into other causal mechanisms was considered.

Furthermore, immune

hypersensitivity would require multiple doses, which is not the case in our acute injury
model.
We theorized that DCF-AG was cytotoxic, and used HEK cells to measure the extent of
DCF-AG has on cell viability. The data in Chapter 4 provide evidence that DCF-AG is
indeed cytotoxic, and that DCF-AG can induce cell death more so than DCF. The
mechanism of the cytotoxicity was thought to occur through oxidative stress. Rationale
for the oxidative stress hypothesis stems from the report that suprofen acyl glucuronide
inhibited superoxide dismutase, an important component of antioxidant defense (Kakkar
et al., 1984; Chiou et al., 1999; Fukui and Zhu, 2010). Subsequently, DCF-AG was
analyzed for induction of oxidative stress by means of two distinct pathways. Not only
was DCF-AG able to generate reactive oxygen species, but it also exhibited a dosedependent inhibition of superoxide dismutase. Furthermore, DCF-AG was tested for
inhibition of cyclooxygenase enzymes and found to inhibit both COX-1 and COX-2. As
mentioned in the prior section, perturbation of COX metabolism of arachidonic acid
renders the intestinal tract more susceptible to injury and diminishes the capacity for
regeneration.
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Inhibition of efflux of either cytoprotective or danger signals from stressed cells can
interfere with cellular signaling and limit adaptive response to toxicants. PGE2 is an
important cytoprotective agent that was reported to be a substrate for MRP4 in addition
to other MRP4 cellular signaling substrates such as cyclic nucleotides and steroid
hormones (Reid et al., 2003b; Russel et al., 2008). Thus the final objective of current
work was to assess the effect of analgesics and their respective metabolites on the
function of MRP4. Further impetus for conducting MRP4 inhibition stems from two
findings: 1) MRP4 protein expression is inducible following challenge by hepatotoxicants,
and 2) the high concentrations of parent compound and metabolites after a toxic
challenge. A listing of reported inhibitors of MRP4 can be found in Table 1.4 (Morrissey
et al., 2012). Inhibition of MRP4, using leukotriene C4 as the substrate, was detected
for DCF, DC-OH, and DCF-AG.

Inhibition failed to surpass 50% up to 300 µM,

therefore IC50 values could not be determined.

Whereas DCF had low inhibition

potency for MRP4 efflux of methotrexate, its inhibition potency for MRP4 efflux of
leukotriene was decidedly weaker. The full significance of MRP4 inhibition as it pertains
to a clinical setting remains to be determined.
In summary, the research presented throughout the thesis provides evidence on the
complex interaction between efflux and uptake transporters. Specifically, OATP2B1
mediates the uptake of DCF-AG in an in vitro system, while the efflux of DCF-AG was
characterized both in vitro using MRP3 vesicles as well as in vivo with a Mrp3 knockout
mouse model. Perturbation of transporter activity, in the form of Mrp3 deletion, results
in increased susceptibility to intestinal injury following a toxic DCF dose. In vitro assays
showed that DCF-AG may have directly contributed to the intestinal enteropathy by
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causing a state of oxidative stress vis-à-vis induction of reaction oxygen species in
addition to inhibition of superoxide dismutase. Furthermore the pharmacological activity
of DCF-AG against COX-1 and COX-2 may have promoted injury by attenuating the
levels of cytoprotective prostaglandins. As it relates to the human condition, patients
taking DCF who possess polymorphic MRP3 may be at risk for greater intestinal injury.
At the very least, these data justify investigation of human MRP3 polymorphisms during
the course of treatment with DCF or similar therapeutic agents that have reactive acyl
glucuronides.
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Figure 1.1 Structure and organization of human liver

Source: Howard M. Reisner: Pathology: A Modern Case Study. 2015. McGraw-Hill
Education. Reproduced with permission of McGraw-Hill Education.
Copyright © McGraw-Hill Education. All rights reserved.
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Figure 1.1 Structure and organization of human liver.
Each lobe of the liver consists of lobules with a hexagonal appearance. The lobules are
anatomically structured such that blood flows from portal triads at the periphery of the
lobule toward the central vein in the middle of the lobule. In contrast bile flows from the
central vein towards bile ducts in the portal triad. The majority of the lobule is populated
with hepatocytes that are metabolically active.
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Figure 1.2 Structure and organization of human small intestine

"small intestine: regions and structures". Art. Encyclopædia Britannica Online. Web. 27 Oct. 2015.
http://www.britannica.com/science/duodenum/images-videos/Structures-of-the-small-intestine-The-inner-wall-of-the/68637
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Figure 1.2 Structure and organization of human small intestine.
The small intestine consists of three physically contiguous segments. Each segment
has a hallow cavity called the lumen. The effective surface area within the lumen and
magnified by folds termed plicae circulars that have fingerlike protrusions denoted as
villi. The villi are comprised of a single layer of enterocytes. Substances that are taken
up by the enterocytes from the lumen can be metabolized, transported back into the
lumen, or excreted into the villus.
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Table 1.1 Protein sequence homology of human efflux and uptake transporters involved in xenobiotic disposition
Gene
(alias)
ABCC1

ABCC1
(MRP1)
100

ABCC2

ABCC2
(MRP2)
48
100

ABCC3

ABCC3
(MRP3)
57

ABCC4
(MRP4)
38

ABCC5
(MRP5)
42

ABCC6
(MRP6)
45

ABCC7
(CFTR)
31

ABCC8
(SUR1)
33

ABCC9
(SUR2)
34

ABCC10
(MRP7)
35

ABCC11
(MRP8)
33

ABCC12
(MRP9)
33

ABCC13
(MRP10)
35

46

36

43

38

31

31

32

34

33

34

32

100

35

39

43

30

33

34

36

33

32

34

100

42

33

37

32

32

33

34

34

25

100

37

30

31

31

39

41

45

-

31

31

30

33

30

31

30

100

32

31

30

28

30

-

100

67

31

29

29

-

31

29

28

-

100

31

34

-

100

48

-

100

-

ABCC4
ABCC5
ABCC6

100

ABCC7
ABCC8
ABCC9

100

ABCC10
ABCC11
ABCC12
ABCC13

Gene
(alias)
ABCG1
ABCG2
ABCG4
ABCG5
ABCG8

100

ABCG1
(WHITE1)
100

ABCG2
(BCRP)
31
100

ABCG4
ABCG5
ABCG8
(WHITE2) (Sterolin-1) (Sterolin-2)
72
26
25
30
100

30

29

27

25

100

32
100

52

Gene
SLCO1A2 SLCO1B1 SLCO1B3 SLCO1B7
(alias)
(OATP1A2) (OATP1B1) (OATP1B3) (LST-3)
SLCO1A2
100
42
41
41
SLCO1B1
SLCO1B3
SLCO1B7
SLCO1C1
SLCO2A1

100

SLCO1C1
(OATP-F)
46

SLCO2A1 SLCO2B1 SLCO3A1
(PGT)
(OATP2B1) (OATP-D)
36
30
34

SLCO4A1
(OATP-E)
30

SLCO4C1
(OATP-H)
29

SLCO5A1
(OATP-J)
31

SLCO6A1
(GST)
22

80

73

45

34

31

34

29

30

33

25

100

78

47

33

32

35

30

30

33

24

42

34

32

34

29

28

33

24

100

33

31

34

31

28

30

23

100

42

36

31

32

32

26

100

34

29

30

32

24

35

35

35

26

100

44

37

33

100

34

44

100

SLCO2B1
SLCO3A1

100

SLCO4A1
SLCO4C1
SLCO5A1

100

SLCO6A1

27
100

53

Table 1.1 Protein sequence homology of human efflux and uptake transporters involved
in xenobiotic disposition.

Homology of transporter proteins for each gene was

determined with the online basic local alignment search tool (BLAST) using the wildtype amino acid sequence for every gene (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Each
number reflects the percentage of positive identification between two amino acid
sequences. A “-” indicates homology could not be determined by the BLAST algorithm.
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Table 1.2 Literature reports for MRP3 substrates using in vitro assays
Substrate

Therapeutic
Category

Km
Vmax
Vmax/Km
PubMed
Comments
(µM) (pmol/min/mg) (µL/min/mg)
ID

7-hydroxycoumarin
glucuronide

None (natural
product)

187

460

2.46

-

22415933

Cefadroxil

Antibiotics

2500

600

0.24

-

22166395

Dehydroepiandrosterone
sulfate

Androgens

46.3

281

6.07

MRP3
wild-type

15083066

Dehydroepiandrosterone
sulfate

Androgens

34.6

269

7.77

MRP3
R1297H

15083066

E3040 glucuronide

None (metabolite
of thromboxane
inhibitor)

-

-

-

Substrate 19628752

Erythromycin

Antibiotics

-

-

-

Substrate 21451505

Estradiol-17βglucuronide (E17βG)

Estrogens

9.1

116

12.7

-

24154606

E17βG

Estrogens

-

-

-

-

18698235

E17βG

Estrogens

24.2

71.5

2.95

MRP3
wild-type

15083066

E17βG

Estrogens

16

72.3

4.52

MRP3
R1297H

15083066

E17βG

Estrogens

-

-

-

Substrate 19628752

E17βG

Estrogens

-

-

-

Substrate 18245269

E17βG

Estrogens

-

-

-

Substrate 20360302

E17βG

Estrogens

56

2,220

39.6

Fexofenadine

H-1 Receptor
Antagonists

-

-

-

116

0.1

Gadoliniumethoxybenzyldiethylenetriamine
pentaacetic acid

Diagnostic Agents 1800

-

21511945

Substrate 18245269

-

24056116

Gemfibrozil glucuronide

Fibric Acid
Derivatives

-

-

-

Substrate 19628752

Glutathione
methylfluorescein

None (dye)

-

-

-

Substrate 17172311

Isoscutellarin

Food Products

-

-

-

Substrate 22822035

Leucovorin

Antidotes

-

-

-

Substrate 12874005

Leukotriene C4

None (metabolite
of arachidonic
acid)

-

-

-

MRP3
wild-type

Scutellarin

Herbal
Medications

-

-

-

Substrate 22822035

-

-

-

Substrate 19628752

Troglitazone glucuronide Thiazolidinediones

R1297H: arginine substituted for histidine at amino acid position 1297

Table adapted from http://didb.druginteractioninfo.org
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15083066

Table 1.3 Case studies of hepatotoxicity from diclofenac usage
Gender

Age
(years)

Dose
Regimen
Duration

ALT
(U/L)

ALkP
(U/L)

R value

Status

Reference

F

55

N/A
N/A
2 weeks

937

466

6

Jaundice,
Death

(Lascar et
al., 1984)

M

56

100 mg
QD
5 weeks

2,110

321

20

Jaundice,
Death

(Breen et
al., 1986)

F

21

200 mg
QD
14 days

1,113

269

12

Jaundice,
Death

(Snijder et
al., 1987)

M

45

75 mg
BID
3 months

922

213

12

Recovery
(DCF
stopped)

(Helfgott et
al., 1990)

F

54

75 mg
BID
6 weeks

763

186

12

Recovery
(DCF
stopped)

(Helfgott et
al., 1990)

83

50 mg
TID
9 days

4

Jaundice,
Recovery
(DCF
stopped)

(Nezic et
al., 2012)

F

60

50 mg
TID
88 days

1,829

168

31

Jaundice,
Recovery
(DCF
stopped)

(LiverTox,
2015)

F

60

N/A
N/A
46 days

1,895

303

18

Jaundice,
Death¹

(Chalasani
et al., 2015)

10F/2M

50 (15)

N/A
N/A
83 days

1,266 (680)

222 (100)

16 est.

F

314

230

11
Chalasani
recoveries,
et al., 2015)
1 death¹

Abbreviations: BID – two times a day, est – estimate, F – female, M – male, N/A – not available, QD –
once a day, TID – three times a day. Values in parentheses represent standard deviation
¹: indicates same subject
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Table 1.4 Reported in vitro inhibition of MRP4 using inside-out vesicles
Inhibitor

Substrate

IC50
(µM)

PubMed
ID

Benzbromarone

9-(2phosphonomethoxyethyl)adeni
ne (PMEA)

150

12695538

Candesartan

Uric acid

16

17674156

Celecoxib

Methotrexate

35

17005917

Diclofenac

Methotrexate

0.006

17005917

Dilazep

PMEA

20

12695538

Dipyridamole

PMEA

2

12695538

Dipyridamole

Cholyltaurine

<20

12883481

Indomethacin

Methotrexate

6.1

17005917

Ketoprofen

Methotrexate

11.9

17005917

Losartan

Uric acid

1.5

17674156

MK-571

PMEA

10

12695538

MK-571

Cholyltaurine

~2

12695538

Nitrobenzylmercaptopurine
riboside

PMEA

75

12695538

Probenecid

PMEA

2,300

12695538

Probenecid

Cholyltaurine

~100

12695538

Probenecid

Cyclic GMP

<100

11856762

Sildenafil

PMEA

20

12695538

Sulfinpyrazone

PMEA

420

12695538

Sulindac

Methotrexate

2.11

17005917

Telmisartan

Uric acid

11

17674156

Trequinsin

PMEA

10

12695538

Zaprinast

PMEA

250

12695538

Table adapted from http://dbts.ucsf.edu/fdatransportal
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Chapter 2 IDENTIFICATION

AND

CHARACTERIZATION

OF

EFFLUX

TRANSPORTERS THAT MODULATE THE DISPOSITION OF DICLOFENAC AND ITS
METABOLITES AT SUBTOXIC DOSES USING WHOLE-BODY TRANSPORTER
KNOCKOUT MODELS
2.1 Abstract
In the present work, in vivo transporter knockout (KO) mouse models were used to
characterize the pharmacokinetics of diclofenac (DCF) and the disposition of its primary
metabolites following a single sub-toxic dose. Mice that were lacking breast cancer
resistance protein (Bcrp) or multidrug resistance-associated protein (Mrp)3 were
administered 3 or 10 mg DCF by intraarterial injection and compared to a wild-type
(WT) strain of similar background. The results indicated that Bcrp acts a canalicular
efflux mediator for DCF as WT mice had biliary excretion values that were 2.2- to 2.6fold greater than Bcrp KO mice. Bcrp deletion did not affect the basolateral efflux of
DCF. Furthermore, diclofenac acyl glucuronide (DCF-AG) was found to be a substrate
of Bcrp, and the loss of Bcrp caused DCF-AG plasma levels to increase 1.8- to 3.2-fold
in KO animals compared to WT. In addition, the biliary excretion of DCF-AG increased
by 1.4-fold in WT versus KO. Furthermore, Mrp3 was found to mediate the basolateral
transport of DCF-AG, but not DCF nor 4ʹ-hydroxy diclofenac (OH-DCF). WT mice had
DCF-AG plasma concentrations that were 7.0- to 8.6-fold greater compared to Mrp3 KO
animals, however no change in DCF-AG biliary excretion was observed. The in vivo
mouse data were further supported by in vitro studies. Vesicular transport experiments
with human MRP3 demonstrated that MRP3 is able to transport DCF-AG. The data
suggest that MRP3 has both a low and high affinity binding site. The low affinity MRP3
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transport had a Vmax and Km of 170 pmol/min/mg and 98.2 µM, respectively. The high
affinity MRP3 Vmax and Km parameters were estimated to be 71.9 pmol/min/mg and 1.78
µM, respectively. In summary, we offer evidence that the disposition of DCF-AG can be
affected by both Bcrp and Mrp3, and these findings may be applicable to humans.
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2.2 Introduction
The non-steroidal anti-inflammatory drug diclofenac (DCF) has been used for a number
of years to treat arthritis and for pain management. Its primary mechanism of action is
to block the metabolism of arachidonic acid by cyclooxygenase enzymes (COX) into
pro-inflammatory mediators, and it is known that DCF can inhibit both COX-1 and COX2 (Menasse et al., 1978).

The pharmacokinetics of DCF has been extensively

characterized in animal and human models. In humans receiving either an intravenous
or oral dose, DCF administration resulted in 65% of dosage excretion in the urine with
the remaining 35% eliminated in feces (Riess et al., 1978). Conversely, elimination of
DCF in dogs and rats was reversed with 65% elimination in feces and 35% in urine.
The percentage contributions were determined using radiometric analysis, a sensitive
method that permits accurate mass balance assessment.
The metabolic profile of DCF has likewise been carefully profiled, and only a small
portion of DCF is eliminated as unchanged parent compound (Stierlin and Faigle, 1979;
Stierlin et al., 1979). DCF is metabolized in vivo into a variety of hydroxylated and
conjugated metabolites (Bort et al., 1999a; Tang et al., 1999; King et al., 2001; Kenny et
al., 2004). Using in vitro assays, a multitude of major and minor metabolites have also
been detected, and most of their structures have been elucidated (Pickup et al., 2012;
Sarda et al., 2012).

Though DCF is normally given orally, it has excellent

physicochemical qualities resulting in nearly 100% dose absorption. This is due in part
to the high passive uptake that DCF possess, categorizing it as an ECCS class 1B
compound (Varma et al., 2015). The complete absorption leads to a large fraction of
the dose entering portal circulation from which there is extensive partitioning of DCF into
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the liver.

Upon entering hepatic cells, primarily hepatocytes, DCF is subjected to

multiple clearance pathways. Since the Phase I and Phase II enzymes that metabolize
DCF have been characterized, there is a need to better understand which transporters
contribute to DCF clearance.
The liver is host to a variety uptake and efflux transporters, many of which are
exclusively localized to either the basolateral membrane or the (apical) canalicular
domain (Giacomini et al., 2010). Uptake transporters are expressed on the basolateral
membrane and modulate the transport of endogenous as well as xenobiotic compounds
from blood into the liver. Furthermore, the basolateral membrane is host to an array of
efflux transporters that translocate intracellular substrates into hepatic sinusoidal space.
Efflux transporters are also expressed on the canalicular domains and serve to excrete
their substrates into the bile canaliculi whereupon biliary flow carries the substrates into
the common bile duct, which ultimately terminates into the duodenal region of the small
intestine. The interplay of these transporters can result in extensive elimination and
reuptake of substances, prolonging their residence time in the body (Roberts et al.,
2002).
The efflux transporters have broad substrate affinity.

The multidrug resistance-

associated proteins (MRPs, encoded by ABCC genes) transport endogenous
substances such as organic anions, bile salts, glutathione, and steroids as well as
xenobiotics and their conjugated metabolites.
observed

to

transport

acetaminophen

For example, MRP3 (ABCC3) was

glucuronide,

estradiol-17β-glucuronide,

leukotriene C4, and morphine-3-glucuronide (Hirohashi et al., 1999; Manautou et al.,
2005; Zelcer et al., 2005). BCRP (ABCG2) has substrates such as estrone-3-sulfate,
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methotrexate, and SN-38 that is the pharmacologically active metabolite of irinotecan
(Kawabata et al., 2001; Vlaming et al., 2009a).
aforementioned

transporters

and

can

MRP2 (ABCC2) overlaps with the

mediate

the

excretion

of

pravastatin,

carboxydichlorofluorescein as well as 4-methylumbelliferone conjugated metabolites
(Zamek-Gliszczynski et al., 2006a; Elsby et al., 2011).
The rat homologue of MRP2 was determined, using mutant rats that lack Mrp2, to
modulate the elimination of DCF-AG from the liver into bile (Seitz et al., 1998). The
finding was particularly impactful as it was one of the first reports to ascribe the
importance of transporters in mediating toxicity from DCF exposure. In that study, rats
lacking Mrp2 had significantly lower intestinal injury compared to rats with functional
Mrp2. Thus, exploration of other efflux transporters that may have affinity for DCF or its
metabolites is warranted in order to enhance understanding of how transporter
clearance can modulate toxicity after DCF administration.
The purpose of the current work was to identify other efflux transporters that are
responsible for mediating the disposition of either DCF or its primary metabolites. To
accomplish this goal, mouse transporter knockout models in which either Bcrp or Mrp3
were genetically deleted were utilized. The selection of Bcrp and Mrp3 would allow
insight into how a major canalicular (in addition to Mrp2) or basolateral transporter,
respectively, can potentially impact the dispositional profile of DCF or its conjugated
metabolites. Furthermore, the affinity of DCF and its metabolites for human MRP3 was
also investigated via in vitro assays with commercial vesicles.
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2.3 Materials and Methods
Chemicals and Reagents. Alamethecin, AMP, ATP, DCF, formic acid, indomethacin
(used as the IS), KCl, MgCl2, MOPS, NADPH, OH-DCF, Tris-HCl, and UDPGA were
purchased from Sigma-Aldrich Corporation (St. Louis, MO). DCF-AG was purchased
from Toronto Research Chemicals Incorporated (Toronto, Canada). Solutol® HS 15
was provided by the BASF Corporation (Florham Park, NJ). MRP2 and MRP3 vesicles
were purchased from GenoMembrane Corporation (Kanazawa, Japan). All LC/MS/MS
solvents were of high analytical grade and were purchased from Burdick & Jackson
(Muskegon, MI).
Animals. Mrp3-null mice of FVB 129/Ola background were provided by Dr. Piet Borst
(Netherlands Cancer Institute, Amsterdam, Netherlands).

Bcrp-null mice having

C57BL/6 background were generated at the University of Kansas Medical Center. Mice
were housed in an American Animal Associations Laboratory Animal Care accredited
facility of University of Kansas Medical Center under a standard temperature-, light-,
and humidity-controlled environment. Mice had free access to Laboratory Rodent Chow
8604 (Harlan, Madison, WI) and drinking water. All animal studies were performed in
accordance with the Guide for the Care and Use of Laboratory Animals using protocols
reviewed and approved by the local Institutional Animal Care and Use Committee of
University of Kansas Medical Center (Kansas City, KS).
In Vivo Studies.

Male 2-4 month old FVB 129/Ola WT, FVB 129/Ola Mrp3 KO,

C57BL/6 WT, and C57BL/6 Bcrp KO mice were anesthetized intraperitoneally with a
ketamine/midazolam mixture (100 and 5 mg/kg, respectively), and both the right carotid
artery and the common bile duct were cannulated for sample collection. The mice
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received a single intraarterial dose of 3 or 10 mg/kg DCF in 10:90 (v/v) Solutol HS
15:0.9% saline at a dosing volume of 10 mL/kg. Bile flow was monitored, and bile
fractions were collected in fifteen minute intervals from -15 to 0, 0 to 15, 15 to 30, 30 to
45, 45 to 60, 60 to 75, and 75 to 90 minutes post administration. Blood samples were
collected into heparinized tubes at 2, 7.5, 22.5, 37.5, 52.5, 67.5, and 90 minutes after
administration, and the blood was subsequently centrifuged to yield plasma.

The

volumes of bile were determined gravimetrically, using 1.0 for specific gravity. Both bile
and plasma were stored at -20 °C until analysis. At the conclusion of the study (90 min
post-administration), animals were sacrificed by overdose with ketamine and midazolam.
Livers were harvested and quickly frozen in liquid nitrogen prior to storage at -80 °C.
Bioanalytical Analysis. Bile and plasma were diluted with 0.1% formic acid in water
(Solvent A) for LC/MS/MS detection as well as to stabilize DCF-AG. Liver samples
were homogenized by bead milling using Solvent A. A 50 µL aliquot of diluted biological
matrix was then precipitated with 400 µL of 0.1% formic acid in acetonitrile (Solvent B)
containing IS. Standard curves using naïve matrices were prepared in a similar fashion.
Samples and standards were vigorously vortex-mixed and centrifuged at 1000 × g for
15 min and 5 °C. A 200 µL aliquot of supernatant was removed and evaporated under
Nitrogen gas at 45 °C. The resulting residue was reconstituted with 200 µL of 90:10
(v/v) A:B, vigorously vortex-mixed, and centrifuged prior to injection onto LC/MS/MS.
The injection volume for all sample types was 10 µL.
In Vitro Metabolism. Untreated livers from three male FVB (WT & KO) and C57 (WT &
KO) mice were homogenized using a Dounce Teflon homogenizer in ice-cold Tris-HCL
buffer (50 mM Tris, 15.4 mM KCl, 2 mM EDTA) in a ratio of 4 parts buffer to 1 part liver.
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The homogenate was centrifuged at 9,000 × g for 30 min and 4 °C, and the S9
supernatant fraction was removed, separated into aliquots, and kept frozen at -80°C.
The S9 fraction was analyzed for protein content using a Pierce BCA kit (Thermo Fisher
Scientific Inc., Grand Island, NY) following the manufacturer’s recommendations.
Incubation reactions were conducted in duplicate in the presence of increasing DCF
concentrations. The reaction mixture consisted of DCF, 0.1 M phosphate buffer pH 7.4
at 37 °C, 1 mg/mL S9 protein, 10 µg/mL Alamethacin, 1 mM GSH, 5 mM MgCl2, 1 mM
NADPH, and 1 mM UDPGA. Incubations without cofactors (MgCl2, NADPH, UDPGA)
served as the control.

The total incubation volume was 300 µL, and the reaction

mixture was open to air. Aliquots of 50 µL were taken at 0, 7.5, 15, 30, and 45 min,
immediately quenched with 200 µL ice-cold Solvent B, and kept on ice. At the end of
the experiment, samples were mixed with 50 µL IS, and 200 µL of the mixture was
removed to be evaporated to dryness under N2 at 40 °C. The resulting residue was
reconstituted in 200 µL of 90:10 (v/v) solvents A:B, vigorously vortex-mixed, and
injected onto the LC/MS/MS. The samples were monitored for the disappearance of
DCF.

The LC/MS/MS response (DCF peak area/IS peak area) was converted to

percentage remaining with 0 min serving as 100%. All percentage values were log
transformed and plotted against incubation time to yield an elimination rate (k) that was
derived from the slope of the resulting line. The elimination rate was converted into an
apparent half-life using the formula:
Equation 2.1

The initial enzyme velocity was calculated using the equation:
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Equation 2.2

where v0 is expressed as pmol/min/min and [S] is the DCF substrate concentration in
µM. The kinetic parameters of Km and Vmax were then calculated by plotting v0 as a
function of [S].
In Vitro Transport. Commercially available MRP2 and MRP3 inside-out vesicles were
quickly thawed from storage and placed on ice.

Incubation reactions consisted of

uptake buffer at pH 7.0 (50 mM MOPS-Tris, 70 mM KCl, and 7.5 mM MgCl2), 25 µg
vesicle protein, 5 mm of AMP or ATP, and 2.5 mM GSH. After a 5 min pre-incubation
period of reaction mixture, incubations were commenced by addition of increasing
concentrations of DCF-AG. Incubations were conducted at 37 °C in a total volume of 75
µL. Reactions were quenched by the addition of 100 µL ice-cold stopping buffer (40
mM MOPS-Tris and 70 mM KCl), and the quenched mixtures were quickly transferred
to a 96-well glass-fiber filter plate (EMD Millipore, Billerica, MA). The filter plate was
subjected to vacuum filtration followed by 5 rapid washes of 100 µL/well ice-cold
stopping buffer. The filter plate was allowed to completely dry before extraction of
samples. DCF-AG was extracted by filling each well of the filter plate with 200 µL of
80:20 (v/v) methanol:0.1% formic acid in water. Plates were shaken for 15 min on ice,
and the filtrate was collected via centrifugation at 3,000 × g for 10 min and 4 °C. The
filtrate was evaporated to dryness under warm N2 at 40 °C. The resulting residue was
reconstituted with 200 µL of 90:10 (v/v) solvents A:B, vigorously vortex-mixed, and
injected onto the LC/MS/MS. The accumulation of DCF-AG was quantified against a
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standard curve, and the uptake data were expressed as pmol normalized to mg vesicle
protein.
LC/MS/MS Method.

Chromatographic separation of analytes was performed on a

Synergi™ 4 µm Max-RP 50 × 2 mm column (Phenomenex Incorporated, Torrance, CA).
The system front end consisted of a HTC PAL Autosampler (LEAP Technologies
Incorporated, Carrboro, NC), a SCL-10Avp system controller, two LC10ADvp pumps,
and a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD). Analytes
of interest were eluted using a gradient profile that began with 10% solvent B for the first
1.0 min, which was then increased to 90% solvent B at 3.5 min using a linear gradient
and held at this mixture for 0.5 min before reverting back to initial solvent conditions for
1.0 min to re-equilibrate the column. The flow rate was 0.4 mL/min, and the column
effluent was directed to waste for the initial 1.5 min before switching to the mass
spectrometer. Analytes were detected using an AB Sciex API™ 4000 LC/MS/MS triple
quad mass-spectrometer with a TurboIonSpray® probe and Analyst version 1.4.2
software (AB Sciex, Framingham, MA) that was operated in multiple reaction monitoring
mode. Ion spray voltage was -4250 V, and the source temperature was set to 400 °C.
The mass transitions in negative ion mode for monitoring DCF, OH-DCF, DCF-AG, and
indomethacin were m/z 294.0→249.9, 309.9→265.9, 470.1→192.9, and 356.0→311.8,
respectively. The retention times of DCF, OH-DCF, DCF-AG, and indomethacin were
3.25, 2.84, 2.69, and 3.20 min, respectively. Concentrations of analytes in the samples
were determined by comparing the peak area ratios (analyte/IS) to those in the standard
curve using a linear regression model. The criterion of acceptance for standards was
defined to be ±20% of nominal concentration.
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Statistical Analysis. Data are expressed as mean ± standard error of the mean. P
values < 0.05 were considered as statistically significant. Statistical analysis of data
was performed using R version 3.2.1 (R Core Team, 2015).

Two groups were

compared by Student’s t test, and multiple groups were compared by an analysis of
variance followed by Tukey’s post hoc test. GraphPad Prism version 6.0 (GraphPad
Software Incorporated, La Jolla, CA) was used to calculate kinetic parameters (Vmax and
Km).
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2.4 Results
In Vivo Studies. Plasma concentrations of DCF and OH-DCF in C57 WT and C57
Bcrp KO mice receiving 3 mg/kg DCF were nearly equal (Figure 2.1A-B), whereas KO
animals had on average 1.8-fold higher DCF-AG plasma levels compared to WT (Figure
2.1C).

Biliary excretion for DCF was 2.2-fold higher in WT animals relative to KO

(Figure 2.1D) with statistical significance observed at each time interval.

OH-DCF

biliary levels were relatively unchanged between WT and KO (Figure 2.1E) though
DCF-AG biliary WT concentrations were 1.4-fold greater than KO at 90 min, and the
difference was statistically significant (Figure 2.1F). The trends observed at the 3 mg/kg
dose were also evident following 10 mg/kg DCF administration. DCF and OH-DCF
plasma concentrations were approximately equal in WT and KO (Figure 2.2A-B), while
DCF-AG KO plasma levels were increased 3.2-fold compared to WT (Figure 2.3C).
DCF WT biliary excretion was higher by 2.6-fold compared to KO (Figure 2.2D). From
60 min and beyond, biliary OH-DCF and DCF-AG WT levels were elevated by 1.3- and
1.4-fold, respectively, versus KO animals. Analysis of whole liver collected 90 min after
3 or 10 mg/kg DCF showed no significant differences between WT and KO for DCF or
OH-DCF while DCF-AG was not detected in the samples (Figure 2.3A-C).
The plasma concentrations of DCF and its metabolites in FVB WT and FVB Mrp3 KO
animals are shown in Figure 2.4 and Figure 2.5. At the 3 mg/kg dose, the overall data
showed little statistical significance between WT and KO plasma concentrations for
DCF and OH-DCF (Figure 2.4A-B). Strikingly, there was nearly an 8.6-fold increase in
DCF-AG WT plasma levels versus that of KO animals (Figure 2.4C). With regards to
biliary excretion, all three analytes had similar concentrations between WT and KO
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subjects (Figure 2.4D-F). The 10 mg/kg data for the FVB mice exhibited comparable
trends for the plasma profiles of DCF and OH-DCF (Figure 2.4A-B). WT plasma DCFAG was greater than KO by 7.0-fold (Figure 2.4C). Biliary levels of DCF, OH-DCF, and
DCF-AG were unremarkable between WT and KO after a 10 mg/kg dose (Figure 2.4DF) though OH-DF began to show a slight increase in KO biliary output relative to WT.
Liver concentrations were determined 90 min post-administration and were not found to
be statistically different between genotypes for each analyte, which was true for both the
3 mg/kg and 10 mg/kg doses (Figure 2.5A-B).
The pharmacokinetics of DCF at each dose for all genotypes is summarized in Table
2.1.

The parameters listed in the table were calculated using non-compartmental

analysis.

The data show that the relative half-lives of DCF at each dose for each

genotype were comparable with the exception of the 10 mg/kg Mrp3 KO mice that had a
t1/2 of 52.9 ± 9.8 min, which was slightly elevated compared to the rest of the dosing
groups. The overall exposure of DCF, as assessed by AUC0-tlast normalized by dose,
further demonstrated that the absorption and distribution of DCF were fairly alike.
Metabolite Identification. In order to account for metabolism of DCF that extended
beyond generation of OH-DCF and DCF-AG, WT and Mrp3 KO bile were pooled from a
number of animals, extracted with organic solvent, and infused onto the LC/MS.
Spectra from 100 amu to 1000 amu were acquired in both positive ion and negative ion
mode and compared between genotypes. The WT spectra were subtracted from KO
spectra, and the resulting signals were analyzed for traces of DCF metabolites. As
shown in Figure 2.7, several metabolites possessing an isotopic distribution similar to
DCF were identified (for reference, DCF-AG is shown in Figure 2.7C). The masses of
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the primary peaks were compared using MetabolitePilot software (Framingham, MA,
CA). Structures of the proposed biliary metabolites are shown in Figure 2.8. M1 and
M2 are the hydroxylated metabolites, while M3 is DCF-AG. M4 is positively identified,
based on product ion fragmentation, as OH-DCF-AG (Figure 2.7D).

M6, a taurine

conjugate, corresponds to the peak shown in Figure 2.7A. M7, an S-cysteine conjugate,
matches the profile observed in Figure 2.7B. M9, a dihydroxylated glutathione adduct,
is putatively identified as the peak shown in Figure 2.7F. The structure of M9, for which
the profile is indicated by Figure 2.7E, is uncertain as its mass does not match up to
typical combinations.
In Vitro Metabolism.

To determine if the different strains of mice have similar

metabolic capacity, S9 fraction was generated by pooling naïve liver homogenates from
several WT or KO mice.

S9 was chosen for metabolic studies to afford a system

capable of multiple biotransformation pathways (Wu and McKown, 2004). The range of
DCF was selected to cover the plasma concentrations that were observed in the in vivo
studies. Conditions for the assay were based on the work by Fisher et al. (2000) in
order to promote Phase II metabolism.

Incubations conducted in the presence of

cofactors (e.g., GSH and UPDGA) required for Phase II metabolism showed that the
background-matched strains (e.g., C57 WT and C57 Bcrp KO) had indistinguishable
profiles (Figure 2.9A-B).

The metabolic data were analyzed to determine relevant

kinetic parameters, and these values are summarized in Table 2.2. C57 WT and Bcrp
KO mice had apparent Vmax values of 846 ± 31 and 882 ± 26 pmol/min/mg, respectively,
while the Km values were 69.3 ± 4.3 and 82.4 ± 1.1 µM, respectively. Likewise, the Vmax
data for FVB WT and Mrp3 KO mice were 734 ± 32 and 696 ± 79 pmol/min/mg,
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respectively, and the Km parameters were determined to be 44.3 ± 3.5 and 43.3 ± 9.0
µM, respectively. From the Vmax and Km data, the intrinsic metabolic clearances were
calculated with the equation:
Equation 2.3

The resulting CLint for C57 WT and Bcrp KO were 12.2 and 10.7 µL/min/kg, respectively,
while those for FVB WT and Mrp3 KO were 16.7 and 16.4 µL/min/mg, respectively.
In Vitro Transport. With the mouse models showing evidence that Mrp3 can mediate
the efflux of DCF-AG in vivo, the next objective was to determine the extent by which
DCF-AG interacts with human MRP3.

As rodent Mrp2 was previously shown to

modulate DCF-AG toxicity (Seitz et al., 1998), human MRP2 was also examined for
DCF-AG affinity.

MRP2 and MRP3 inside-out vesicles were assessed for DCF-AG

transport, and it was determined that uptake was linear for several minutes before
reaching an apparent plateau (Figure 2.10A-B). The uptake of DCF-AG with MRP2 and
MRP3 was found to be ATP- and time-dependent.

Having established an optimal

incubation time for further studies, vesicles were incubated for 5 min in the presence of
increasing DCF-AG concentrations. The concentration-dependent uptake by MRP2 and
MRP3 was determined to be saturable (Figure 2.11A-B). The Eadie-Hofstee plot for
MRP2 uptake suggests an allosteric sigmoidal interaction, hence the ATP-dependent
data were fit using this model. MRP3 uptake of DCF-AG, when graphed using an
Eadie-Hofstee plot, indicated a biphasic profile. Therefore, MRP3 data was fit using a
two Km model. The results of the model outputs for MRP2 and MRP3 are summarized
in Table 2.3. The Vmax and Km for MRP2 vesicular uptake of DCF-AG were determined
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to be 130 pmol/min/mg and 50.5 µM, respectively, yielding a transporter intrinsic
clearance (using Equation 2.3) of 2.58 µL/min/mg. Analysis of MRP3 kinetics led to
identification of a possible low affinity and high affinity binding site for DCF-AG transport.
The low affinity Vmax and Km for MRP3 were 170 pmol/min/mg and 98.2 µM, respectively,
with a transporter clearance of 2.37 µL/min/mg for the low affinity site. The high affinity
Vmax and Km parameters were estimated to be 71.9 pmol/min/mg and 1.78 µM,
respectively, and the high affinity transporter clearance was calculated to be 40.3
µL/min/mg.
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Figure 2.1 Plasma and biliary concentration versus time profiles of DCF, OH-DCF,
and DCF-AG in C57 WT and C57 Bcrp KO mice after 3 mg/kg DCF dose
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Figure 2.1 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and
DCF-AG in C57 WT and C57 Bcrp KO mice after 3 mg/kg DCF dose. Pharmacokinetics
of DCF and its metabolites in WT (○) and Bcrp KO (●) mice after a single intraarterial
dose of 3 mg/kg DCF. (A-C) Plasma concentration profiles for (A) DCF, (B) OH-DCF,
and (C) DCF-AG at discrete time points. (D-F) Biliary excretion profiles for (D) DCF, (E)
OH-DCF, and (F) DCF-AG. Time points represent accumulation of biliary flow during
successive 15 min intervals (0-15, 15-30, 30-45, 45-60, 60-75, and 75-90 min). All data
are expressed as mean ± standard error of the mean for 5-6 subjects/group. * P < 0.05;
** P < 0.01; *** P < 0.001 versus WT.
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Figure 2.2 Plasma and biliary concentration versus time profiles of DCF, OH-DCF,
and DCF-AG in C57 WT and C57 Bcrp KO mice after 10 mg/kg DCF dose
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Figure 2.2 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and
DCF-AG in C57 WT and C57 Bcrp KO mice after 10 mg/kg DCF dose.
Pharmacokinetics of DCF and its metabolites in WT (○) and Bcrp KO (●) mice after a
single intraarterial dose of 10 mg/kg DCF. (A-C) Plasma concentration profiles for (A)
DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points. (D-F) Biliary excretion
profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.

Time points represent

accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 4560, 60-75, and 75-90 min). All data are expressed as mean ± standard error of the
mean for 5-6 subjects/group. * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT.
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Figure 2.3 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in C57 WT
and C57 Bcrp KO mice after 3 or 10 mg/kg DCF dose
A : 3 m g /k g
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Figure 2.3 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in C57 WT and
C57 Bcrp KO mice after 3 or 10 mg/kg DCF dose. Hepatic concentrations of DCF, OHDCF, and DCF-AG in WT (□) and KO (■) mice were determined 90 min after DCF
administration. Data are expressed as mean ± standard error of the mean for 5-6
subjects/group.
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Figure 2.4 Plasma and biliary concentration versus time profiles of DCF, OH-DCF,
and DCF-AG in FVB WT and FVB Mrp3 KO mice after 3 mg/kg DCF dose
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Figure 2.4 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and
DCF-AG in FVB WT and FVB Mrp3 KO mice after 3 mg/kg DCF dose.
Pharmacokinetics of DCF and its metabolites in WT (○) and Mrp3 KO (●) mice after a
single intraarterial dose of 3 mg/kg DCF. (A-C) Plasma concentration profiles for (A)
DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points. (D-F) Biliary excretion
profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.

Time points represent

accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 4560, 60-75, and 75-90 min). All data are expressed as mean ± standard error of the
mean for 7 subjects/group. * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT.
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Figure 2.5 Plasma and biliary concentration versus time profiles of DCF, OH-DCF,
and DCF-AG in Mrp3 WT and KO mice after 10 mg/kg DCF dose
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Figure 2.5 Plasma and biliary concentration versus time profiles of DCF, OH-DCF, and
DCF-AG in FVB WT and FVB Mrp3 KO mice after 10 mg/kg DCF dose.
Pharmacokinetics of DCF and its metabolites in WT (○) and Mrp3 KO (●) mice after a
single intraarterial dose of 10 mg/kg DCF. (A-C) Plasma concentration profiles for (A)
DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points. (D-F) Biliary excretion
profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG.

Time points represent

accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 4560, 60-75, and 75-90 min). All data are expressed as mean ± standard error of the
mean for 7 subjects/group. * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT.
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Figure 2.6 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in FVB WT
and FVB Mrp3 KO mice after 3 or 10 mg/kg DCF dose
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Figure 2.6 Terminal liver concentrations of DCF, OH-DCF, and DCF-AG in FVB WT
and FVB Mrp3 KO mice after 3 or 10 mg/kg DCF dose. Hepatic concentrations of DCF,
OH-DCF, and DCF-AG in WT (□) and KO (■) mice were determined 90 min after DCF
administration. Data are expressed as mean ± standard error of the mean for 6-7
subjects/group.
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Table 2.1 Summary of DCF pharmacokinetic parameters in plasma of WT and KO
mice after a single 3 or 10 mg/kg DCF dose
Dose

Genotype

C0
(µM)

t1/2
(min)

AUC0-tlast
(µM × min)

3 mg/kg

C57 WT

57.8 ± 6.0

31.2 ± 4.0

1,050 ± 50

C57 BCRP KO

46.0 ± 5.1

27.8 ± 3.6

1,020 ± 80

C57 WT

132 ± 8

30.5 ± 3.1

3,420 ± 290

C57 BCRP KO

201 ± 44

33.5 ± 2.5

3,570 ± 340

FVB WT

51.4 ± 5.1

24.0 ± 4.1

862 ± 86

FVB Mrp3 KO

41.2 ± 3.3

37.5 ± 9.2

1,110 ± 130

FVB WT

178 ± 16

37.8 ± 5.6

4,220 ± 420

FVB Mrp3 KO

172 ± 13

52.9 ± 9.8

4,770 ± 280

10 mg/kg

3 mg/kg

10 mg/kg

86

Table 2.1 Summary of DCF pharmacokinetic parameters in plasma of WT and KO mice
after a single 3 or 10 mg/kg DCF dose.

C0 indicates the estimated DCF plasma

concentration at time zero, t1/2 is the DCF elimination half-life, and AUC0-tlast is the area
under the plasma concentration versus time curve for DCF from time zero to the last
collected time point. Parameters were calculated using non-compartmental analysis.
Each value represents the mean ± standard error of the mean of 5-7subjects/group.
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Figure 2.7 Mass spectral identification of major DCF conjugated metabolites
excreted in bile
A: M6

D: M4

B: M7

E: M8

C: M3

F: M9
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Figure 2.7 Mass spectral identification of major DCF conjugated metabolites excreted in
bile. Bile from WT and Mrp3 KO mice were pooled, extracted with organic solvent, and
infused onto a mass spectrometer. The infusion was then scanned across a range of
masses for which multiple acquisitions were made to determine masses of putative
metabolites. The WT spectral profile was subtracted from the KO profile resulting in a
range of masses (i.e., metabolites) that can be considered to be in excess in KO
compared to WT. (A) DCF taurine conjugate, (B) DCF cysteine conjugate, (C) DCF-AG,
(D) either 4ʹ- or 5-OH-DCF-AG, (E) unknown DCF conjugate, and (F) di-hydroxy-DCF
glutathione.
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Figure 2.8 Structures of DCF metabolites based on biliary MS/MS infusion data
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Figure 2.8 Structures of DCF metabolites based on biliary MS/MS infusion data. M1
and M2 are hydroxylated metabolites (OH-DCF) that have the same parental mass as
do M4 and M5 (OH-DCF-AG) which can be generated from M1, M2, or M3 (DCF-AG).
DCF can also be conjugated to M6 (taurine conjugate), M7 (cysteine conjugate), and
M9 (di-hydroxy glutathione conjugate) which were identified in spectral scans. The
structure of M8 has not been elucidated, however is appears to have a negative ion
mode mass (m/z) of 572.

91

Figure 2.9 In vitro metabolism of DCF using hepatic S9 fraction from C57 and FVB
mice
A : C 57
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Figure 2.9 In vitro metabolism of DCF using hepatic S9 fraction from C57 and FVB
mice. Pooled S9 fraction was prepared from (A) C57 WT and C57 Bcrp KO and (B)
FVB WT and FVB Mrp3 KO mice. Incubations consisted of 1 mg/mL S9 protein and
were conducted at 37 °C. Cofactors (e.g., GSH and UDPGA) were added to permit
Phase II metabolism. Initial incubations were conducted in duplicate at 0, 7.5, 15, 30,
and 45 min, and the responses at each concentration were used to generate a velocity
for the corresponding concentration. The results indicate the two WT and KO pairings
(i.e., FVB and C57) have nearly equal intrinsic metabolic capacity. Each data point
represents the velocity for a given concentration from 2 separate studies.
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Table 2.2 Summary of in vitro DCF metabolism in mouse models
Genotype

Vmax
(pmol/min/mg)

Km
(µM)

Metabolic CLint
(µL/min/mg)

C57 WT

846 ± 31

69.3 ± 4.3

12.2

C57 KO

882 ± 26

82.4 ± 1.1

10.7

FVB WT

734 ± 32

44.3 ± 3.5

16.7

FVB KO

696 ± 79

43.3 ± 9.0

16.4
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Table 2.2 Summary of in vitro DCF metabolism in mouse models.

Metabolic

parameters were determined using S9 fraction from FVB and C57 strains of mice that
were WT or KO for Bcrp or Mrp3. Data represent the mean ± standard error of the
mean from 2 separate studies.
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Figure 2.10 Time-dependent transport of DCF-AG by MRP2 and MRP3 using
inside-out vesicles
A: M RP2
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Figure 2.10 Time-dependent transport of DCF-AG by MRP2 and MRP3 using inside-out
vesicles. DCF-AG was incubated with vesicles in the presence of 5 mM AMP (○) or 5
mM ATP (●) at 37 °C. (A) Uptake of 10 µM DCF-AG by MRP2. (B) Uptake of 1 µM
DCF-AG by MRP3. The dotted lines in both plots represent the nonlinear fit of DCF-AG
active uptake and were determined by subtracting the AMP values (background and
passive uptake) from the ATP response.

Each data point reflects the mean ± the

standard error of the mean for n=3 measurements per time point.
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Figure 2.11 Determination of the concentration-dependent transporter kinetics of
MRP2 and MRP3 for DCF-AG
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Figure 2.11 Determination of the concentration-dependent transporter kinetics of MRP2
and MRP3 for DCF-AG. MRP2 and MRP3 vesicles were incubated with increasing
concentrations of DCF-AG in the presence of 5 mM AMP or ATP for 5 min at 37 °C.
AMP response was subtracted from ATP, and the resulting data was fit to determine
kinetic parameters. (A) MRP2 data was fit according to an allosteric sigmoidal model
that yielded an apparent Hill slope of 2.2. Insert: Eadie-Hofstee plot. (B) MRP3 data
was fit according to a two-Km indicating the presence of high affinity and low affinity
binding sites. Insert: Eadie-Hofstee plot.

Each data point reflects the mean ± the

standard error of the mean for n=3 measurements per concentration.
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Table 2.3 Summary of MRP2 and MRP3 vesicle kinetic studies for DCF-AG
Transporter

Vmax
(pmol/min/mg)

Km
(µM)

Transport CLint
(µL/min/mg)

MRP2

130

50.5

2.58

MRP3 (low affinity)

170

98.2

2.37

MRP3 (high affinity)

71.9

1.78

40.3
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Table 2.3 Summary of MRP2 and MRP3 vesicle kinetic studies for DCF-AG. MRP2
had single Km transport affinity for DCF-AG whereas MRP3 demonstrated biphasic
kinetics. Intrinsic transporter clearance (Vmax/Km) for MRP2 and the low affinity MRP3
clearance were comparable. In contrast, the high affinity MRP3 efflux clearance was
over an order of magnitude greater than that of MRP2.

101

2.5 Discussion
Currently, more is known about which transporters are inhibited by DCF rather than
which transporters mediate the disposition of DCF and its primary metabolites. Thus
the intention of the present work was to investigate the impact of efflux transporters on
DCF disposition. Studies in TR- rats, which are of a Wistar background and have a
spontaneous mutation for the Abcc2 gene thereby lacking functional expression of Mrp2
(Kitamura et al., 1990), demonstrated that the those mutants are resistant to intestinal
injury compared to non-mutant Wistar rats (Seitz et al., 1998). Though intestinal injury
in the TR- rats was significantly lower compared to non-mutants, GI damage was not
completely abolished. The mechanism of the decreased injury stems from the reduced
biliary translocation of reactive intermediates, such as DCF-AG, from the hepatocyte
into the bile canaliculi. That seminal work laid the foundation for further investigation
into transporter-mediated modulation of DCF-associated toxicity.
The results presented herein demonstrate the involvement of other efflux transporters to
modulate disposition of not only reactive metabolites, but also of DCF itself. Data from
two subtoxic doses of DCF indicate that Bcrp, which is expressed on the canalicular
domain along with Mrp2, is partially responsible for the active transport of DCF. This
discovery was supported by the observations that C57 Bcrp WT animals had statistically
higher DCF biliary excretion compared to KO after a dose of 3 or 10 mg/kg DCF (Figure
2.1D and Figure 2.2D). The reduction in DCF biliary output in the KO did not result in
any increase in the KO DCF plasma concentration. KO mice exhibited a statistically
significant increase in DCF-AG plasma concentrations compared to WT (Figure 2.1C
and Figure 2.2C), and this increase was paralleled in KO by a decrease in DCF-AG
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biliary excretion (Figure 2.1F and Figure 2.2F). Taken together the results indicate that
Bcrp is operative, in vivo, with respect to modulation of DCF and DCF-AG transport
activity.
Lagas et al. (2009) reported the involvement of Bcrp to transport DCF, though this was
conducted using a transfected cell system with polarized MDCK cells in a transwell
format. For that study, murine Bcrp exhibited greater transport of DCF compared to
human BCRP (transport was assessed by comparing A→B to B→A vectorial transport).
Curiously, a follow-up study by Lagas et al. (2010) with an in vivo Bcrp knockout mouse
model from a FVB background contradicted their earlier findings. Whereas we report
that C57 WT had DCF biliary excretion 2.2- to 2.6-fold greater compared to that of C57
Bcrp KO, the Lagas Bcrp KO mice had 1.2-fold more biliary DCF compared to WT
though this difference was not statistically significant. The authors acknowledge the
disconnect between their in vitro and in vivo data, yet there was no rationale given for
the divergent results.

DCF-AG WT plasma levels in the Lagas in vivo study were

modestly higher without statistical significance in contrast to the present data that reflect
1.8- and 3.2-fold greater KO plasma concentrations relative to WT (Figure 2.1C and
Figure 2.2C). That said, the Lagas study did indicate biliary DCF-AG levels were 2.1fold greater in WT compared to KO. There is some limitation to the Lagas report,
primarily the selection of a single time point, 60 min post-administration, from which to
make comparisons between genotypes. In contrast, we report plasma and bile profiles
over a span of time giving greater power to make dispositional characterizations. We
also assessed the pharmacokinetics from two doses compared to a single 5 mg/kg IV
dose for the Lagas work.
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In addition to demonstrating the interplay of Bcrp activity, we also report that Mrp3 is
responsible for the in vivo translocation of DCF-AG. This key outcome was observed in
the plasma profiles at each sub-toxic dose for which C57 WT mice had 7.0- to 8.6-fold
greater DCF-AG plasma concentrations compared to C57 Mrp3 KO (Figure 2.4C and
Figure 2.5D). In the same 2010 Lagas publication referenced previously, FVB WT mice
had approximately 2-fold greater DCF-AG plasma concentrations (at 60 min) compared
to FVB Mrp3 KO, hence our data are confirmatory.

Considering the degree of

separation between WT and KO, it is evident Mrp3 plays a major role in the disposition
of DCF-AG. Whereas Bcrp deletion led to altered disposition of plasma and biliary
profiles for DCF and DCF-AG, deletion of Mrp3 only affected basolateral excretion of
DCF-AG. There were no changes to DCF-AG biliary output (Figure 2.4F and Figure
2.5F) nor were there changes in hepatic levels of DCF-AG (Figure 2.6A-B). The lack of
elevated biliary DCF-AG was unexpected given the published reports of increased
biliary excretion of 4-methylumbelliferyl glucuronide and acetaminophen glucuronide in
Mrp3 KO mice (Manautou et al., 2005; Zamek-Gliszczynski et al., 2006b).
All mouse strains were evaluated for their intrinsic metabolic capacity using S9 fraction.
S9 was chosen as the modality for this assessment due to the presence of an array of
metabolic enzymes (Lu, 2014). The results from in vitro metabolism studies suggest
that mice of C57 and FVB backgrounds have similar metabolic capacity (Figure 2.9A-B).
From these data, it can be inferred that deletion of transporters did not result in any
compensatory changes to enzymatic (Phase I and Phase II) expression or activity.
Therefore, changes in the biliary excretion or plasma dispositional profiles are reflective
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of diminished transporter capacity, due to selective genetic deletion, rather than innate
differences in metabolic competency.
Upon consideration that the FVB strain of mice had such a large differential regarding
WT and KO plasma DCF-AG concentrations without concomitant changes in biliary
output, the bile from WT and KO were infused into a LC/MS/MS system to permit
rudimentary metabolite identification. The WT spectra was subtracted from the KO
spectra and analyzed for likely candidates that could account for the fraction of DCF-AG
not present in KO plasma. The spectral scans revealed several important findings.
Firstly, of the three quantified analytes, DCF-AG biliary levels were 10-fold greater than
DCF and OH-DCF, and the DCF-AG excreted in bile accounted for nearly 12% of the
total DCF dose. Secondly, a diclofenac taurine conjugate (designated as M6 in Figure
2.8) was also detected and found to have a signal intensity (Figure 2.7A) nearly equal to
DCF-AG (Figure 2.7C). The DCF-TAU response is suggestive that taurine conjugation
may be as dominant of a metabolic process as glucuronidation. Taurine conjugates of
DCF in mice were likewise reported by Sarda et al. (2012) and Pickup et al. (2012). In
fact, both Sarda’s and Pickup’s respective works provided evidence that multiple taurine
conjugates were detectable furthering the notion that taurine conjugation constitutes a
significant clearance mechanism.

Taurine conjugation is an important detoxification

step since the amide that is formed results in less reactive compared to the ester bond
that is present in DCF-AG (Montalbetti and Falque, 2005). The significance of the
spectral scans and identification of other conjugated metabolites implies that the portion
of DCF-AG which was not excreted into plasma was putatively converted into other
metabolites that were ultimately transported into bile. Another biliary metabolite of high
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intensity observed at m/z of 572 was categorized as M7 (Figure 2.8). The structure of
M7 remains to be elucidated, however it may be similar to a metabolite, which was
detected using human liver microsomes, that was described as being 4ʹ-OH-2ʹglutathion-deschloro-diclofenac (Yu et al., 2005).
Bearing in mind that these data and that of the TR- rat study provided conclusive
evidence of DCF-AG in vivo transport, the last component of the work was to assess the
affinity of DCF-AG to be transported by human MRP2 and MRP3. The purpose of the
investigation was to gauge if human MRPs had similar potential to interact with DCF-AG.
To that end, studies with commercial inside-out vesicles were carried out. In keeping
with the TR- rat data, our results indicated that DCF-AG is a substrate of MRP2 (Figure
2.10A) and that transport by MRP2 was saturable (Figure 2.11A). The affinity of DCFAG for MRP2 was relatively weak in that the ATP incubation responses ranged from
1.5- to 2.0-fold greater than the AMP responses. Furthermore, the activity of MRP2 for
DCF-AG appears to have an element of allosteric modulation, evident by a Hill slope
estimate of 2.2. The Eadie-Hofstee plot for MRP2 is in agreement with an allosteric
effect (Hutzler and Tracy, 2002). The allosterism is a function of MRP2 having multiple
binding sites (Zelcer et al., 2003a).

Like DCF-AG, estradiol-17β-glucuronide was

demonstrated to be transported with cooperative binding by human MRP2 vesicles as it
had a Hill slope of 2.4 (Elsby et al., 2011; Li et al., 2011). MRP3-mediated transport of
DCF-AG was determined be biphasic with a high affinity and low affinity binding site
(Figure 2.11B).

Whereas the dynamic response by MRP2 was low, MRP3 had a

maximal fold-ratio (ATP/AMP) of 37 at the low end of the concentration range while the
minimal ratio was 1.5-fold at the highest tested concentration. The intrinsic transporter
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clearance of the high affinity site indicated that DCF-AG can be transported by MRP3 to
a greater degree at low DCF-AG concentrations compared to MRP2 (Table 2.3).
Overall these data offer insight on the disposition of DCF and its metabolites. We offer
proof that Bcrp can mediate DCF translocation from the hepatocyte into bile, and that
DCF-AG can also be transported by Bcrp. The deletion of Bcrp not only diminished
biliary DCF-AG efflux, but it also resulted in an increase in plasma DCF-AG
concentrations. In contrast, Mrp3 was involved in the basolateral excretion of DCF-AG
from the liver into blood. Despite the profound differences between WT and KO for
DCF-AF levels, there was no effect on DCF-AG biliary excretion suggesting only
basolateral disposition was affected. Finally, we report that human MRP3, through the
means of an in vitro assay, appeared able to transport DCF-AG. Based on the in vitro
MRP3 vesicle assay and the in vivo Mrp3 KO study, it is highly likely that MRP3 is an
operative transporter of DCF-AG in vivo for humans. As such investigations into human
MRP3 polymorphisms are warranted to ascertain the extent to which patients may
experience dispositional changes to MRP3 substrates.
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Chapter 3 MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3 (MRP3) PLAYS
AN IMPORTANT ROLE IN PROTECTION AGAINST ACUTE TOXICITY OF
DICLOFENAC
3.1 Abstract
Diclofenac (DCF) is a non-steroidal anti-inflammatory drug commonly prescribed to
reduce pain in acute and chronic inflammatory diseases.

One of the main DCF

metabolites is a reactive diclofenac acyl glucuronide (DCF-AG) that covalently binds to
biological targets and may contribute to adverse drug reactions arising from DCF use.
Cellular efflux of DCF-AG is partially mediated by multidrug resistance-associated
proteins (Mrp).

The importance of Mrp2 during DCF-induced toxicity has been

established, yet the role of Mrp3 remains largely unexplored. In the present work, Mrp3
knockout (KO) mice were used to study the toxicokinetics and toxicodynamics of DCF
and its metabolites. DCF-AG plasma concentrations were 90% lower in KO mice than
in wild-type (WT) mice, indicating that Mrp3 mediates DCF-AG basolateral efflux. In
contrast, there were no differences in DCF-AG biliary excretion between WT and KO
suggesting that only DCF-AG basolateral efflux is compromised by Mrp3 deletion.
Susceptibility to toxicity was also evaluated after a single high DCF dose. No signs of
injury were detected in livers and kidneys, however ulcers were found in the small
intestines. Furthermore, the observed intestinal injuries were consistently more severe
in KO compared to WT.

DCF covalent adducts were observed in liver and small

intestines, however staining intensity did not correlate with the severity of injuries
implying that tissues respond differently to covalent modification.

Overall, the data

provides strong evidence that (1) in vivo Mrp3 plays an important role in DCF-AG
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disposition and (2) compromised Mrp3 function can enhance injury in the
gastrointestinal tract after DCF treatment.

Reprinted with permission of the American Society for Pharmacology and Experimental
Therapeutics. All rights reserved.
Copyright © 2015 by The American Society for Pharmacology and Experimental
Therapeutics
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3.2 Introduction
Diclofenac (DCF) is a non-steroidal anti-inflammatory drug (NSAID) that is prescribed to
alleviate symptoms associated with ankylosing spondylitis, osteoarthritis, rheumatoid
arthritis, and migraine (McNeely and Goa, 1999; Novartis, 2011; Depomed, 2014). DCF
is generally well tolerated although long term usage has been implicated with a variety
of adverse drug events (ADR) in a subset of patients. The most common side effects of
DCF are discomfort, ulceration, and bleeding in the gastrointestinal (GI) tract. These
ADRs are related to DCF pharmacodynamics, namely chronic inhibition of
cyclooxygenase (COX) enzymes causing a decrease of prostaglandins that protect the
GI mucosa (Menasse et al., 1978; Wallace, 2008). NSAIDs as a group have a mean
liver injury rate of 1 per 100,000 users. However, chronic DCF administration increases
the risk of liver injury to 6 per 100,000 users (de Abajo et al., 2004). More recently, a
meta-analysis of cardiovascular safety implicated DCF with a higher risk of
cardiovascular death and stroke among a group of seven NSAIDs (Trelle et al., 2011).
DCF undergoes extensive first-pass metabolism in humans, and approximately 50% of
the dose is systemically available (Willis et al., 1979). The majority of DCF is converted
into metabolites of which 65% are eliminated in urine with the remainder excreted in bile
(Riess et al., 1978; Novartis, 2011).

Among the main products are hydroxylated

metabolites, the predominant being 4′-hydroxy diclofenac (OH-DCF), that can form
reactive quinone imines that adduct and deplete glutathione causing a state of oxidative
stress (Tang et al., 1999). Another key metabolite is the highly reactive diclofenac acyl
glucuronide (DCF-AG), which is primarily catalyzed in humans by uridine 5′-diphosphoglucuronosyltransferase (UGT) 2B7 (King et al., 2001).
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It has been shown that

inheritance of one or two copies of the UGT2B7*2 allele was associated with an
increased risk of DCF-induced hepatotoxicity compared to UGT2B7*1 homozygotes as
the *2 variant possesses higher catalytic activity (Daly et al., 2007).
DCF-AG is initially formed as a β-1-O-acyl glucuronide (β-anomer) which can be
cleaved by β-glucuronidase into DCF and glucuronic acid. β-anomers spontaneously
isomerize into β-glucuronidase-resistant 2-, 3-, and 4-O-acyl isomers (Sallustio et al.,
2000). DCF-AG undergoes these rearrangements as the pH changes from acidic to
physiologic conditions such as those that occur in the GI tract (Ebner et al., 1999;
Kenny et al., 2004). DCF-AG can form adducts with multiple proteins in the liver and GI
tract, and dipeptidyl peptidase IV was identified as a DCF-AG target in rat liver where
adduction resulted in decreased activity (Hargus et al., 1995).

Furthermore, it was

found that broad-acting UGT inhibitors can significantly diminish the covalent binding of
DCF metabolite to hepatocellular proteins in vitro (Kretz-Rommel and Boelsterli, 1993).
There is consensus that repeated exposure to DCF-AG contributes to the idiosyncratic
drug reaction seen with clinical usage, however the exact nature of how DCF-AG
contributes to the etiology of these reactions remains unclear.
The potential for DCF-AG to cause extrahepatic covalent binding modifications is
contingent upon active transport. For instance, DCF-AG was not detected in the bile of
rats lacking canalicular multidrug resistance-associated protein 2 (Mrp2, Abcc2) (Seitz
et al., 1998).

A follow-up study revealed that Mrp2 mutant rats also had reduced

intestinal ulceration compared to wild-type (WT) rats (Seitz and Boelsterli, 1998). These
findings are important as they suggest that Mrp2 is at least partially responsible for
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DCF-AG excretion from hepatocytes into bile. The mechanism by which DCF-AG is
transported from hepatocytes into blood remains less understood.
Among the MRPs that are expressed along the basolateral membrane, MRP3 (ABCC3)
has been demonstrated to export glucuronide conjugates of other compounds (Zelcer et
al., 2001; Zelcer et al., 2006). In a Caucasian sample pool, fifty-one single nucleotide
polymorphisms (SNP) in MRP3 were found (Lang et al., 2004). A pharmacogenomic
study of healthy Japanese subjects identified twenty-one novel SNPs, with two resulting
in immature transcript due to insertion of a stop codon (Fukushima-Uesaka et al., 2007).
Functional significance of MRP3 SNPs was demonstrated whereby several MRP3
SNPs expressed in an in vitro system had impaired transporter function either by
reductions in transporter activity or disruption of intracellular transporter trafficking to the
cell membrane (Kobayashi et al., 2008).
Because MRP3 has been shown to transport both endogenous and exogenous
glucuronide conjugates, it can be hypothesized that perturbation of MRP3 expression or
function may affect the disposition and toxicity of DCF-AG in vivo. To investigate the
role of MRP3 in the disposition and toxicity of DCF, a mouse Mrp3 knockout (KO) model
is used to assess the disposition of DCF-AG and whether Mrp3 deletion increases
likelihood of injury.
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3.3 Materials and Methods
Chemicals and Reagents.

DCF, OH-DCF, Dulbecco’s phosphate buffered saline

(DPBS), formic acid, indomethacin (as the IS), and sodium citrate were purchased from
Sigma-Aldrich Corporation. (St. Louis, MO).

DCF-AG was purchased from Toronto

Research Chemicals Incorporated (Toronto, ON, Canada).

Solutol® HS 15 was

provided by the BASF Corporation (Florham Park, NJ). DCF antiserum was graciously
donated by Dr. Dietmar Knopp (Technische Universität München, München, Germany).
Animals. Mrp3-null mice of FVB 129/Ola background were provided by Dr. Piet Borst
(Netherlands Cancer Institute, Amsterdam, Netherlands). An additional set of Mrp3 KO
mice having C57BL/6J background were generated at the University of Kansas Medical
Center. Mice were housed in an American Animal Associations Laboratory Animal Care
accredited facility of University of Kansas Medical Center under a standard
temperature-, light-, and humidity-controlled environment.

Mice had free access to

Laboratory Rodent Chow 8604 (Harlan, Madison, WI) and drinking water. All animal
studies were performed in accordance with the Guide for the Care and Use of
Laboratory Animals using protocols reviewed and approved by the local Institutional
Animal Care and Use Committee of University of Kansas Medical Center (Kansas City,
KS).
In Vivo Studies.

Toxicokinetics.

Male 2-3 month old FVB 129/Ola WT and FVB

129/Ola KO mice were anesthetized intraperitoneally with a ketamine/midazolam
mixture (100 and 5 mg/kg, respectively), and both the right carotid artery and the
common bile duct were cannulated for sample collection. The mice received a single
intraarterial dose of 75 mg/kg DCF in 10:90 (v/v) Solutol HS 15:DPBS at a dosing
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volume of 5 mL/kg. Bile flow was monitored, and bile fractions were collected in fifteen
minute intervals from -15 to 0, 0 to 15, 15 to 30, 30 to 45, 45 to 60, 60 to 75, and 75 to
90 minutes post administration. Blood samples were collected into heparinized tubes at
2, 7.5, 22.5, 37.5, 52.5, 67.5, and 90 minutes after administration, and the blood was
subsequently centrifuged to yield plasma.

The volumes of bile were determined

gravimetrically, using 1.0 for specific gravity. Both bile and plasma were stored at 20 °C until analysis.

At the conclusion of the study (90 min post-administration),

animals were sacrificed by overdose with ketamine and midazolam.

Livers were

harvested and quickly frozen in liquid nitrogen prior to storage at -80 °C.
Toxicodynamics. 2-3 month old male WT and KO (C57BL/6 background) were injected
a single intraperitoneal dose of either vehicle, 10:90 (v/v) Solutol HS15: DPBS, or 90
mg/kg DCF in vehicle at a dosing volume of 5 mL/kg. The mice were then allowed
access to food and water ad libitum. Twenty four hours after dosing, the mice were
anesthetized for sacrifice with an intraperitoneal injection of 50 to 70 mg/kg
pentobarbital. Blood was collected and centrifuged to yield plasma and kept frozen at 20 °C. Kidneys, liver, and small intestines were harvested, fixed in buffered formalin for
24 hours with gentle shaking at room temperature, and then transferred into 70%
ethanol. Tissues were subsequently paraffin embedded and sectioned onto glass slides
for histopathology and immunohistochemistry.
Bioanalytical Analysis. Bile and plasma were diluted with 0.1% formic acid in water
(Solvent A) for LC/MS/MS detection as well as to stabilize DCF-AG. Liver samples
were homogenized by bead milling using Solvent A. A 50 µL aliquot of diluted biological
matrix was then precipitated with 450 µL of 0.1% formic acid in acetonitrile (Solvent B)
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containing IS. Standard curves using naïve matrices were prepared in a similar fashion.
Samples and standards were vigorously vortex-mixed and centrifuged at 1350 × g for
10 min and 4 °C. A 200 µL aliquot of supernatant was removed and evaporated under
Nitrogen gas at 45 °C. The resulting residue was reconstituted with 200 µL of 90:10
(v/v) A:B, vigorously vortex-mixed, and centrifuged prior to injection onto LC/MS/MS.
The injection volume for all sample types was 10 µL.
LC/MS/MS Method.

Chromatographic separation of analytes was performed on a

Synergi™ 4 µm Max-RP 50 × 2 mm column (Phenomenex Incorporated, Torrance, CA).
The system front end consisted of a HTC PAL Autosampler outfitted with a Coolstack
set to 4 °C (LEAP Technologies Incorporated, Carrboro, NC), a SCL-10Avp system
controller, two LC10ADvp pumps, and a DGU-14A degasser (Shimadzu Scientific
Instruments, Columbia, MD). Analytes of interest were eluted using a gradient profile
that began with 10% solvent B for the first 1.0 min, which was then increased to 90%
solvent B at 3.5 min using a linear gradient and held at this mixture for 0.5 min before
reverting back to initial solvent conditions for 1.0 min to re-equilibrate the column. The
flow rate was 0.4 mL/min, and the column effluent was directed to waste for the initial
1.5 min before switching to the mass spectrometer. Analytes were detected using an
AB Sciex API™ 4000 LC/MS/MS triple quad mass-spectrometer with a TurboIonSpray®
probe and Analyst version 1.4.2 software (AB Sciex, Framingham, MA) that was
operated in multiple reaction monitoring mode. Ion spray voltage was -4250 V, and the
source temperature was set to 400 °C. The mass transitions in negative ion mode for
monitoring DCF, OH-DCF, DCF-AG, and indomethacin were m/z 294.0→249.9,
309.9→265.9, 470.1→192.9, and 356.0→311.8, respectively. The retention times of
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DCF, OH-DCF, DCF-AG, and indomethacin were 3.25, 2.84, 2.69, and 3.20 min,
respectively. Concentrations of analytes in the samples were determined by comparing
the peak area ratios (analyte/IS) to those in the standard curve using a linear regression
model. The dynamic range was 10 to 5,000 ng/mL for bile, liver homogenate, and
plasma samples. The criterion of acceptance for standards was defined to be ±20% of
nominal concentration.
Immunohistochemistry.

Slides for immunohistochemistry were deparaffinized by

xylene, and the xylene was removed by sequentially decreasing concentrations of
ethanol followed by hydration in water. After a 30 min heat induced epitope retrieval in
sodium citrate buffer, endogenous peroxidase activity was blocked with 3% hydrogen
peroxide for 15 min. Slides were subsequently treated with an Avidin/Biotin Blocking Kit
(Vector Laboratories Incorporated, Burlingame, CA) as per the manufacturer’s
recommendations and incubated with a Dako Serum-free Protein Block (Dako
Incorporated, Carpinteria, CA) for 30 min. A rabbit polyclonal primary antibody against
DCF at a 1:5000 (v/v) dilution was applied for 60 min at room temperature after which
slides were incubated for 30 min with a 1:300 dilution of a Dako biotinylated swine antirabbit secondary antibody. The slides were then exposed to streptavidin-horseradish
peroxidase (BD Biosciences, San Jose, CA) for 30 min. To develop the chromagen, a
30 min treatment with a Vector® NovaREDTM Substrate Kit was utilized, and slides were
counterstained with Mayer’s Hematoxylin (Thermo Fisher Scientific Inc., Grand Island,
NY). Finally, slides were dehydrated with ethanol and xylene and cover-slipped using
Histomount Mounting Solution (Life Technologies). For negative controls, samples from
the vehicle-only groups were treated in the same manner as subjects dosed with DCF.
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Clinical Chemistry. Plasma samples from the toxicodynamic study were analyzed for
alanine transaminase (ALT) and blood urea nitrogen (BUN) using kits purchased from
Thermo Fisher Scientific Incorporated (Grand Island, NY) as per the manufacturer’s
recommendations.
functionality.

Positive and negative controls were utilized to assess assay

A BioTek UV/Vis microplate spectrophotometer (BioTek Instruments

Incorporated, Winooski, VT) was used to measure assay endpoints.
Histopathology. Liver & Kidney. Liver and kidney samples were fixed in 10% neutralbuffered zinc formalin prior to processing and paraffin embedding. Tissue sections (5
μm) were stained with hematoxylin and eosin.

Sections were examined by light

microscopy for the presence and severity of necrosis and degeneration using an
established grading system (Ishiguro et al., 2008).
Gastrointestinal Tract.

The gastrointestinal tract was examined histologically with

multiple transverse sections of the stomach and large intestine and Swiss Roll sections
of the small intestine (Moolenbeek and Ruitenberg, 1981). Histological examination
used a scoring system adapted from a method described by Krieglstein et al. (2007).
Briefly, 3 independent parameters were measured for a combined semi quantitative
injury score; the degree of villus/crypt damage, the severity of inflammation (none,
minimal, mild, moderate, marked, and severe), and the depth of injury (mucosa with
epithelium and lamina propria, submucosa, muscularis, and serosa).
Statistical Analysis. Data are expressed as mean ± standard error of the mean. P
values < 0.05 were considered as statistically significant. Statistical analysis of data
was performed using R version 3.2.1 (R Core Team, 2015).
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Two groups were

compared by Student’s t test, and multiple groups were compared by an analysis of
variance followed by Tukey’s post hoc test.
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3.4 Results
Toxicokinetic Study. In animals that remained anesthetized for surgical exposure of
the abdominal cavity and bile duct cannulation, the maximal tolerated dose without
morbidity was 75 mg/kg. Plasma concentrations for 75 mg/kg DCF (Figure 3.1A) were
significantly higher in KO compared to WT, and the increases were generally less than
40%. Conversely, OH-DCF concentrations in plasma (Figure 3.1B) were significantly
higher in WT with a 90% increase observed at 37.5 min. There was a dramatic disparity
in plasma concentrations between WT and KO for DCF-AG (Figure 3.1C) with WT
having nearly 9-fold higher concentrations in plasma compared to KO. A summary of
pertinent toxicokinetic parameters is presented in Table 3.1 Both genotypes had similar
estimated DCF plasma concentrations at time zero (C0). Though there was a difference
in the DCF elimination half-life (t1/2) between the 2 genotypes, the DCF plasma
exposure (AUC0-tlast) for WT and KO was comparable.
To determine whether the loss of Mrp3 affected the biliary disposition of DCF and the
two metabolites under consideration, the biliary excretion of DCF and its metabolites
were quantified. There was no difference in bile flow between WT and KO (data not
shown). The biliary excretion of DCF and its metabolites were equivalent between the
two genotypes (Figure 3.1D, E, and F). Of the three analytes, DCF-AG was most
predominant in bile constituting nearly 10% of the total DCF dose for each genotype,
whereas DCF and OH-DCF biliary concentrations accounted for 0.2 and 0.1% of total
DCF dose, respectively, irrespective of genotype. The limited availability of KO mice
permitted assessing hepatic concentrations of DCF and its metabolites only at the
terminal time point of 90 min post-administration. The KO livers had more DCF though
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the difference was not statistically significant. OH-DCF and DCF-AG concentrations in
KO livers were statistically lower compared to WT (Figure 3.2). In contrast to bile for
which the major detected analyte was DCF-AG, unchanged DCF in both genotypes was
most abundant compared to OH-DCF and DCF-AG.
Clinical Chemistry. Having established a role for Mrp3 to modulate systemic exposure
of DCF-AG in vivo, the next objective was to evaluate to susceptibility of KO to DCFinduced injury. For these studies, the DCF dose was increased to 90 mg/kg as that was
the maximal non-lethal dose in animals that were non-surgerized and freely moving.
Rather than oral gavage, intraperitoneal administration was used to maximize dose
absorption and delivery of DCF via portal circulation for immediate uptake into the liver.
ALT concentrations (Figure 3.3A) were not significantly different between WT and KO
suggesting no injuries in the liver. Furthermore, ALT values in all vehicle control and
DCF-treated groups were less than 40 U/L, which is the upper limit of normal range for
ALT. BUN levels (Figure 3.3B) were statistically higher in KO mice compared to WT,
however the lack of difference between vehicle and DCF treated groups in KO mice
suggest there was no DCF-induced renal injury.
Histopathology.

Histopathological examination of liver and kidneys showed no

obvious injuries at the administered dose confirming the clinical chemistry results (data
not shown). The small intestines were also examined and scored according to three
categories of injury. WT which received DCF showed a trend of higher injury compared
to vehicle treated subjects (Figure 3.4), though these differences were not statistically
significant. In addition, KO dosed with DCF had significantly greater incidence and
severity of erosions and ulcers compared to treatment-matched WT mice. For both WT
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and KO, ulcers were observed in the jejunal and ileal but not duodenal regions of the
small intestine. Thus, the data suggest that the loss of Mrp3 increased the susceptibility
to intestinal injury from an acute dose of DCF.
Immunohistochemistry.

Sections of livers, kidneys, and small intestines were

subjected to immunohistochemistry in order to determine the extent of DCF adduction.
The rationale for conducting this assay was that reactive intermediates or metabolites of
DCF are known to covalently bind to proteins. Thus the goal was to establish possible
links between covalent binding of reactive DCF products and tissue injury. Kidneys
were entirely devoid of DCF adduct staining implying that reactive DCF metabolites
were not likely to be generated or accumulated by transit in kidneys (data not shown).
In contrast, WT and KO livers showed strong evidence of DCF adduction after DCF
administration compared to vehicle controls.

The staining was robust and was

observed in centrilobular, midzonal, and periportal regions (Figure 3.5B, C, E, and F).
Vehicle controls did not exhibit staining suggesting that the primary antibody was
specific for diclofenac adducts (Figure 3.5A and C). Interestingly, the livers showed
intense staining for DCF adduct yet this organ did not manifest any apparent signs of
injury either through clinical chemistry or histopathology. Lastly, compared to small
intestines from vehicle controls which were unremarkable (Figure 3.5G and J), the small
intestines from WT and KO also exhibited positive staining of DCF adducts (Figure 3.5H,
I, K, L). The level of adduct staining in the small intestine was notably weaker than that
observed in the liver as qualitatively assessed by chromagen intensity and the degree of
scatter. Adduct formation was detected along the brush border of villi and extended
inwards towards the basement membrane. In terms of regiospecificity, staining was
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scattered throughout the small intestine and did not appear to be confined to any
particular location.
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Figure 3.1 Toxicokinetics of DCF and its metabolites in FVB WT and FVB Mrp3-KO
mice after a single intraarterial dose of 75 mg/kg DCF
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Figure 3.1 Toxicokinetics of DCF and its metabolites in FVB WT (●) and FVB Mrp3 KO
(○) mice after a single intraarterial dose of 75 mg/kg DCF. (A-C) Plasma concentration
profiles for (A) DCF, (B) OH-DCF, and (C) DCF-AG at discrete time points. (D-F) Biliary
excretion profiles for (D) DCF, (E) OH-DCF, and (F) DCF-AG. Time points represent
accumulation of biliary flow during successive 15 min intervals (0-15, 15-30, 30-45, 4560, 60-75, and 75-90 min). All data are expressed as mean ± standard error of the
mean for 10-12 subjects/group. * P < 0.05; ** P < 0.01; *** P < 0.001 versus WT.
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Table 3.1 Summary of DCF toxicokinetic parameters in plasma of FVB WT and
FVB Mrp3 KO after a single 75 mg/kg DCF dose
Genotype

C0
(µM)

t1/2
(min)

AUC0-tlast
(µM × min)

WT

699 ± 31

74.1 ± 12.8

34,600 ± 2,100

KO

701 ± 38

108 ± 10

35,900 ± 2,500
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Table 3.1 Summary of DCF toxicokinetic parameters in plasma of FVB WT and FVB
Mrp3 KO after a single 75 mg/kg DCF dose. C0 indicates the estimated DCF plasma
concentration at time zero, t1/2 is the DCF elimination half-life, and AUC0-tlast is the area
under the plasma concentration versus time curve for DCF from time zero to the last
collected time point. Data are expressed as mean ± standard error of the mean for 1012 subjects/group.
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Figure 3.2 Hepatic concentrations of DCF, OH-DCF, and DCF-AG in FVB WT and
FVB Mrp3 KO mice
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Figure 3.2 Hepatic concentrations of DCF, OH-DCF, and DCF-AG in FVB WT (■) and
FVB Mrp3 KO (□) mice. Mice were injected with 75 mg/kg DCF. Livers were harvested
90 min following administration of vehicle or DCF. Data are expressed as mean ±
standard error of the mean for 10-12 subjects/group. * P < 0.05; ** P < 0.01 versus WT.
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Figure 3.3 Clinical chemistry of WT and KO mice 24 hours after a single dose of
90 mg/kg DCF
A : ALT
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Figure 3.3 Clinical chemistry of C57 WT and C57 Mrp3 KO mice 24 hours after a single
dose of 90 mg/kg DCF. (A) Plasma alanine aminotransferase (ALT). (B) Plasma blood
urea nitrogen (BUN). Results are expressed as mean ± standard error of the mean for
3-7 subjects/group. ** P < 0.01 versus WT.
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Figure 3.4 Summary of histopathology of small intestines from C57 WT and C57
Mrp3 KO mice 24 hours after administration of vehicle or 90 mg/kg DCF
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Figure 3.4 Summary of histopathology of small intestines from C57 WT and C57 Mrp3
KO mice 24 hours after administration of vehicle or 90 mg/kg DCF.

Results are

expressed as mean ± standard error of the mean for 3-7 subjects/group. The overall
grade was based on the following scheme: 0 = none, 1= minimal, 2 = mild, 3 =
moderate, 4 = marked, and 5 = severe. Ulcers and erosions reflect the number of
findings that were indentified on an entire tissue section. ** P < 0.01; *** P < 0.001
versus treatment-matched WT.

132

Figure 3.5 Immunohistochemistry of tissues taken from C57 WT and C57 Mrp3 KO
mice treated with vehicle or 90 mg/kg DCF
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Figure 3.5 Immunohistochemistry of tissues taken from C57 WT and C57 Mrp3 KO
mice treated with vehicle or 90 mg/kg DCF (immunoperoxidase with hematoxylin
counterstain).

Tissues were harvested 24 hours after administration.

(A-C) Liver

sections at 4× magnification. (A) Representative liver section from vehicle treated WT.
(B and C) WT liver from subjects 3 and 6 after 90 mg/kg. (D) Liver from vehicle treated
KO. (E and F) KO liver from subjects 4 and 7 after 90 mg/kg. (G-L) Small intestine
sections at 15× magnification. (D) Representative small intestine from vehicle treated
WT. (H and I) WT small intestine from subjects 4 and 6 after 90 mg/kg. (J) Small
intestine from vehicle treated KO. (K and L) KO small intestine from subjects 2 and 4
after 90 mg/kg.

The presence of DCF adducts is visualized by the presence of

red/brown staining.
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3.5 Discussion
This work explores the role of Mrp3 on the disposition and acute toxicity of DCF. DCF
has high passive permeability, therefore its uptake into tissues should not be limited by
active transport processes (Huang et al., 2010). The elevated DCF and lower OH-DCF
plasma concentrations in KO compared to WT (Figure 3.1A-B) may indicate metabolic
saturation. In vitro studies using mouse hepatic S9 fraction did not show differences in
DCF metabolism as the WT and KO Km values were comparable (Chapter 2 Figure 2.9).
Further evidence of metabolic saturation comes from the OH-DCF plasma
concentration-time profile which was relatively flat at 75 mg/kg DCF whereas at lower
doses plasma OH-DCF was initially high before decreasing by first-order kinetics
(Chapter 2 Figure 2.4).
The present DCF-AG data are consistent with low dose studies and demonstrate Mrp3mediated DCF-AG efflux (Figure 3.1C). Our data confirm the observation reported by
Lagas et al. (2010) that DCF-AG is an in vivo substrate of mouse Mrp3. KO had DCFAG plasma concentrations that were nearly 90% lower compared to WT.

Plasma

concentrations of several glucuronide metabolites have been reported to be lower in
Mrp3 KO compared to WT mice (Manautou et al., 2005; Zamek-Gliszczynski et al.,
2006b). As KO mice were comparable to WT in terms of overall transporter expression
except for Mrp3, the results indicate that Mrp3 mediates DCF-AG basolateral efflux in
vivo.
DCF, OH-DCF, and DCF-AG biliary excretion showed no evident distinction between
WT and KO. Because Mrp3 acts as a basolateral efflux pump for bile acids (Zelcer et
al., 2003c), the bile flow in WT and KO was measured and found to be equal suggesting
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that Mrp3 deletion and DCF treatment did not affect bile flow. That DCF-AG biliary
excretion was similar between WT and KO was unexpected considering the pronounced
plasma differences. Other studies in KO mice reported that low plasma or perfusate
concentrations of glucuronides were inversely correlated with increased glucuronide
biliary concentrations compared to WT (Manautou et al., 2005; Zamek-Gliszczynski et
al., 2006b).

Similar to rats, canalicular DCF-AG excretion would likely have been

mediated by Mrp2 given the 88% protein sequence homology between mouse and rat
Mrp2 (Altschul et al., 2005). Another canalicular transporter, breast cancer resistance
protein (Bcrp, Abcg2), has been also demonstrated to transport DCF (Lagas et al.,
2009).

Exploratory studies in our laboratory with Bcrp-KO mice resulted in slight

reductions of DCF-AG biliary excretion compared to WT (Chapter 2 Figure 2.1 and
Figure 2.2).
To account for other possible DCF metabolites, bile fractions were pooled and infused
onto the LC/MS/MS for qualitative metabolite profiling. Peaks corresponding to DCF
taurine conjugate and diclofenac acyl glucuronide (OH-DCF-AG) were detected in prior
exploratory studies (Chapter 2 Figure 2.7).

Identification of these metabolites is

consistent with their formation in rodent (Kenny et al., 2004; Sarda et al., 2012).
Nonetheless, the OH-DCF-AG signal in KO bile would not have wholly accounted for
the DCF-AG fraction that was diverted from entering the blood. Despite the DCF-AG
mass balance inequity between WT and KO, there are instances in which Mrp3 ablation
affects basolateral but not canalicular efflux.

Zelcer et al. (2006) noted that

hyodeoxycholate glucuronide perfusate concentrations were 4-fold greater in WT
compared to KO while bile concentrations were similar between genotypes. Moreover,
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fexofenadine plasma concentrations decreased 50% in Mrp3-KO mice relative to WT,
yet biliary and hepatic fexofenadine concentrations between the genotypes were the
same (Tian et al., 2008). Thus, Mrp3 deletion solely affected DCF-AG basolateral efflux.
The other aim of this study was to assess the susceptibility of Mrp3-null subjects to
DCF-induced injury.

Initial studies in FVB 129/Ola mice at a 90 mg/kg DCF dose

resulted in KO, but not WT, exhibiting greater intestinal injury (data not shown). As FVB
129/Ola KO mice were unavailable, further studies were conducted in C57BL/6 KO mice.
Neither the liver nor kidneys showed any evidence of damage by serum biomarker
analysis (Figure 3.3).

DCF has been shown to induce nephrotoxicity in ICR mice

evidenced by a 2.5-fold increase in BUN concentrations 24 hours following an oral 100
mg/kg dose (Hickey et al., 2001). The finding in ICR mice likely reflects that strain’s
higher sensitivity to renal injury since C57BL/6 mice (Figure 3.3B) had no changes in
BUN concentrations compared to vehicle treatment 24 hours after 90 mg/kg
intraperitoneal administration. Regarding the liver, Lagas et al. (2010) reported that a
25 mg/kg intraperitoneal DCF injection caused ALT concentrations to increase 2-fold
compared to WT leading the authors to conclude that slight liver toxicity occurred.
However, the mice used in that study were triple knockouts for Bcrp, Mrp2, and Mrp3
making it difficult to ascribe which transporter was truly responsible for enhancing the
toxic effect. Additionally, ALT, bilirubin, liver weights, and triglycerides were also slightly
elevated in the triple KO versus WT suggesting that the mice may be more susceptible
to challenge by a toxicant (Vlaming et al., 2009b). Though liver and kidney were devoid
of injury for the present study, the small intestines in both genotypes exhibited damage
with KO mice sustaining greater injury (Figure 3.4). The intestinal injury is consistent
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with published reports on DCF ulcerogenicity (Atchison et al., 2000b; Ramirez-Alcantara
et al., 2009).
Reactive DCF metabolites form adducts with a number of hepatic proteins (Seitz et al.,
1998; Sallustio and Holbrook, 2001; Kenny et al., 2004).

Immunohistochemistry

revealed widespread covalent binding in the liver and small intestine but not in kidneys
of both WT and KO (Figure 3.5). Qualitative assessment of the extent of staining did
not provide meaningful distinction between the two genotypes (data not shown). DCF
adduct staining was most intense in the liver, yet this organ did not appear to have any
obvious histopathological damage. DCF-AG synthesis would be high in the liver, and it
is plausible that DCF-AG adducted albumin, which is synthesized in the liver, and/or
sequestered by thiols (protein and non-protein) that are not critical cellular targets.
Though staining in small intestines was less robust, histopathology revealed significant
damage (Figure 3.4).

DCF-AG adduction to enterocytes potentially compromised

enterocyte function and viability and possibly induced an immune-mediated response.
Modulation of the immune function within 24 hours of toxicant exposure has previously
been demonstrated for drugs such as acetaminophen (APAP). Administration of a toxic
APAP

dose

activates

hepatic

macrophages

(i.e.,

Kupffer

cells)

to

release

proinflammatory cytokines (Blazka et al., 1995b). This in turn stimulates the migration
and infiltration of immune cells into the liver, influencing the ultimate toxic outcome. The
role of the immune system in intestinal toxicity following DCF administration was beyond
the scope of the present work and will be a focus of future studies.
DCF-AG could adduct enterocyte proteins on the extracellular surface or alternatively
adduct from within after uptake by various transporters. Glucuronide conjugates can be
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transported by organic anion transporting polypeptides (OATPs) of which OATP2B1
(SLCO2B1) is the predominant isoform in the human intestine (Ishiguro et al., 2008;
Drozdzik et al., 2014). It is likely through the mouse Oatp2b1 homologue, which is also
expressed in the intestines, that DCF-AG uptake occurs (Cheng et al., 2005).
Nonetheless, the fact that the liver had intense adduct formation without apparent injury
compared to the intestine which had extensive damage but moderate adduction may
indicate that protein adducts of DCF metabolite(s) do not necessarily contribute to or
cause toxicity.
DCF administration resulted in two diverse outcomes: 1) rapid generation of DCF-AG
that was excreted into bile or plasma and 2) COX inhibition that decreased local and/or
systemic prostaglandins that protect the GI mucosa. Based on the data, we propose
the following series of events to occur in our model of DCF-induced toxicity. DCF-AG is
taken up and covalently binds to targets (plasma membrane, intracellular proteins, etc.)
compromising the integrity of the enterocyte. In KO, the DCF-AG basolateral efflux is
attenuated potentially leading to higher accumulation of intracellular DCF-AG within
enterocytes compared to WT. Meanwhile, intestinal mucosal protection is weakened
due to DCF’s pharmacological inhibition of both COX-1 and COX-2 (Menasse et al.,
1978) causing a decrease in protective prostaglandins.

Simultaneously, the highly

permeable DCF enters enterocytes and exerts further injury through mitochondrial
dysfunction leading to apoptosis (Gomez-Lechon et al., 2003a; Lim et al., 2006).
Unbound DCF-AG may also dissociate into DCF and glucuronic acid intensifying
diclofenac-induced mitochondrial dysfunction. Mrp2, which normally confers a measure
of protection via DCF-AG efflux, could be affected as Mrp2 translocates intracellularly
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from its apical membrane localization during oxidative stress (Sekine et al., 2006). The
proposed events would, in theory, breakdown the overall intactness of the GI tract.
There are several issues that remain to be addressed: (1) the relationship between
DCF-AG exposure and developing injury is unclear, (2) determining the DCF-AG
concentrations in the small intestine that can cause damage, and (3) assessing why the
small intestines but not liver or kidneys were affected. It will be necessary to devise
experiments wherein the mechanism of injury by DCF-AG can be studied with minimal
interference from its parent or hydroxylated metabolites. The degree of intestinal COX
inhibition also warrants examination as a contributing cause for the GI injury observed
following DCF administration.
In conclusion, the present work demonstrates that (1) Mrp3 is responsible for DCF-AG
basolateral efflux during a toxic DCF challenge, (2) hepatic canalicular efflux is not
perturbed by Mrp3 deletion, (3) KO mice have greater gastrointestinal damage
compared to WT, and (4) appearance of adducts does not necessarily signify the
occurrence of injury as certain organs are more sensitive to injury than others.
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Chapter 4 ELUCIDATION

OF

THE

MECHANISMS

THROUGH

WHICH

THE

REACTIVE METABOLITE DICLOFENAC ACYL GLUCURONIDE CAN MEDIATE
TOXICITY
4.1 Abstract
We have previously investigated the toxicity of diclofenac (DCF) following a single high
dose and reported significant intestinal injury in mice lacking the efflux transporter Mrp3.
One proposed mechanism was that diclofenac acyl glucuronide (DCF-AG), as a
substrate of Mrp3, played a part in mediating injury. Thus the goal of the current work
was to determine the role that DCF-AG had in the observed enteropathy. Since both
humans and mice express the uptake transporter OATP2B1 (SCLO2B1) in the
intestines, this transporter was characterized for DCF-AG uptake. In vitro assays using
HEK-OATP2B1 cells demonstrated that DCF-AG was a substrate with a Vmax and Km of
17.6 ± 1.5 pmol/min/mg and 14.3 ± 0.1 µM, respectively. It was also determined that
DCF-AG has low passive diffusion, thus its uptake into cells would be highly dependent
on active uptake. Another key finding from our in vitro assays was that DCF-AG was
not only cytotoxic, but that its cytotoxicity was greater compared to DCF and occurred
within 1 to 3 hours of exposure. The potential for DCF-AG to induce reactive oxygen
species (ROS) was also addressed. We report that 1 mM DCF-AG caused a 6-fold
increase in ROS by 3 hours. Further investigation focused on induction of oxidative
stress through inhibition of superoxide dismutase (SOD). We observed that whereas
DCF increased SOD activity, DCF-AG had 100% inhibition of SOD at the highest tested
dose of 1 mM. Taken together, the cytotoxicity, SOD, and ROS results strongly suggest
DCF-AG induced oxidative stress in our in vitro models. Lastly, DCF-AG was screened
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for pharmacologic activity against COX-1 and COX-2 and was found to have IC50 values
of 0.620 ± 0.105 and 2.91 ± 0.36 µM, respectively.

Despite the weaker potency

compared to its parent compound, that DCF-AG was able to inhibit the COX enzymes
constituted a novel finding. Since COX inhibition can lead to intestinal ulceration, it is
plausible that DCF-AG can also contribute to enteropathy via COX inhibition. Taken
into context, the work presented herein demonstrated the multifactorial pathways by
which DCF-AG can act as a direct contributor to toxicity following DCF administration.
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4.2 Introduction
Prior work on DCF focused on its disposition and the contribution of efflux transporters
in modulating toxic outcomes. In one notable report using rats that lacked the efflux
transporter Mrp2 (Abcc2), these mutant rats exhibited resistance to intestinal injury after
DCF administration (Seitz and Boelsterli, 1998). This discovery was followed up by the
observation that DCF-AG administration led to increased GI ulceration compared to
DCF administration. Our own work with efflux transporters demonstrated that Bcrp
(Abcg2) and Mrp3 (Abcc3) had functional roles with respect to the disposition of DCF
and DCF-AG (Chapter 2). Furthermore, toxicodynamic studies conducted in Mrp3 KO
mice showed conclusively that KO mice developed increased intestinal damage
compared to WT (Scialis et al., 2015). Despite the susceptibility differences between
genotypes, the mechanisms involved in the increased injury remain unclear.
Our work, as well as that of others, demonstrated that administration of DCF leads to
the formation of covalent adducts along the intestinal epithelia (Ware et al., 1998;
Atchison et al., 2000b). In these instances, adduct formation was detected not only
along the brush border of the intestinal villi, but was also observed within the enterocyte
as well.

It is reasonable to assume that adduction on the extracellular surface of

plasma membrane was followed by internalization of the adducted protein (Boelsterli,
2003).

Another pathway may involve the active transport of DCF-AG by intestinal

uptake transporters followed by intracellular adduction. Indeed, the GI tract expresses a
number of transporters that have recently been quantified by proteomic analysis using
LC/MS/MS (Groer et al., 2013). One of the major uptake transporters is OATP2B1
(SCLO2B1), a known carrier for conjugated substances (Gao et al., 2012).
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There exists then a distinct possibility that uptake of DCF-AG by OATP was contributory
to the enteropathy observed in the aforementioned animal models. Evidence for uptake
transporter activity, as a causative means towards injury, has gained recent attention.
For instance, stably transfected HEK-OATP cells were used to explore toxicity due to
transporter-mediated uptake of statins in a report by Zhang and colleagues (2013). For
that work, active uptake of several compounds in the statin class of drugs by OATP1B1
(SCLO1B1) was shown to cause a left-shift in cytotoxicity potency compared to the
toxicity observed in HEK-WT cells. The Zhang study takes on meaningful significance
upon consideration that OATP1B1 is a major hepatoselective transporter.

Since

OATP2B1 intestinal expression is also correlated with uptake activity in the intestines
(Sai et al., 2006), understanding the relationship between uptake and toxicity should be
pursued.
Toxicity from DCF-AG cannot purely arise through its active uptake or decreased
excretion. Other processes must occur to account for the increased GI injury attributed
to DCF-AG compared to parental compound. A possible modality is involvement of the
immune system either by activation of liver-specific Kupffer cells or immune response
caused by covalent adduct recognition (Yano et al., 2012).

The covalent adduct

immune response hypothesis is difficult to test on an acute basis since the presence of
antibodies due to covalent adducts does not always result in injury (Vojdani et al., 2015).
Case in point, there was intense hepatic adduct formation in our DCF toxicodynamic
study, yet despite the presence of resident macrophages which are known to be
activated during a cytotoxic challenge, no hepatotoxicity was apparent (Chapter 3).
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The findings in the liver strongly suggest that DCF-mediated enteropathy is not
mediated by protein adduction in enterocytes.

Nevertheless, there are alternative

explanations for how DCF-AG is directly causing injury after DCF administration. A
possibility is oxidative stress through inhibition of superoxide dismutase (SOD). SOD is
a critical cellular defense mechanism for coping with reactive oxygen species (ROS)
(Fridovich, 1978). Precedent of SOD inhibition by xenobiotic metabolites comes from a
study by Chiou et al. (1999) in which suprofen acyl glucuronide inhibited SOD. Given
the structural class similarity between DCF-AG and suprofen acyl glucuronide, DCF-AG
inhibition of SOD becomes a distinct prospect. In addition to SOD perturbation, DCFAG may induce oxidative stress by generation of ROS just as DCF has been shown to
incite (Lim et al., 2006).
Gastrointestinal injury after DCF administration can occur through its pharmacologic
effects, namely inhibition of cyclooxygenase (COX) enzymes.

COX metabolism of

arachidonic acid gives rise to a number of physiologically important derivatives such as
prostaglandin E2 (PGE2) which functions to protect the GI mucosa (Kotani et al., 2006).
DCF, a non-selective inhibitor of COX-1 and COX-2, promotes GI injury though
decreased PGE2 signaling. Inhibition of both COX isoforms is necessary for injury to
develop.

Toxicity studies wherein a selective COX-1 or COX-2 inhibitor was

administered to mice failed to show significant GI damage (Tanaka et al., 2001). Yet,
when a cocktail of a selective COX-1 and COX-2 inhibitors was given, profound injury
became evident. DCF potency for COX-1 and COX-2 is weaker compared to selective
inhibitors such as SC-560 and DuP-697 (Seibert et al., 1996; Smith et al., 1998a), so its
ability to provoke injury is a reflection that promiscuity for general COX inhibition, rather
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than potency against a single COX isoform, is a determining factor. In that context and
considering that some DCF metabolites have shown pharmacological activity against
COX, the capability of DCF-AG to inhibit COX enzymes presents an intriguing avenue
to explore.

Though conjugated metabolites are normally thought to be devoid of

pharmacological activity compared to parent compounds, examples exist to the contrary.
Such cases include morphine-6-glucuronide and mycophenolic acyl glucuronide
(Osborne et al., 1992; Schutz et al., 1999). The pharmacologic potencies of those two
glucuronide metabolites are equivalent to their parent compounds. In light of this, DCFAG may possess enough COX inhibition pharmacology to promote injury.
Thus the goal of the current work was to identify the various mechanisms that DCF-AG
can promote injury. This was accomplished through analysis of uptake by OATPs to
determine if active uptake of DCF-AG can occur, and by conducting in vitro assays to
quantify the extent of cytotoxicity as a result of ROS generation or inhibition of COX and
SOD enzymes.
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4.3 Materials and Methods
Chemicals and Reagents. DCF, DCFDA, DMEM, formic acid, hydrogen peroxide,
HEPES, indomethacin (used as the IS), MOPS, and SC-560 were purchased from
Sigma-Aldrich Corporation. (St. Louis, MO).

DCF-AG was purchased from Toronto

Research Chemicals Incorporated (Toronto, Canada). AA, COX-1, COX-2, Dup-697,
and SOD were purchased from Cayman Chemical (Ann Arbor, MI). Calcein-AM was
purchased from Thermo Fisher Incorporated (Waltham, MA). Ethidium homodimer-1
was purchased from Biotium Inc. (Hayward, CA). Stably-transfected HEK-OATP2B1
cells were created at Pfizer Inc (Sandwich, UK) and were previously described
(Kalgutkar et al., 2013). All LC/MS/MS solvents were of high analytical grade and were
purchased from Burdick & Jackson (Muskegon, MI).
In Vitro Transport. HEK-WT and HEK-OATP2B1 cells were seeded at 60,000 and
90,000 cells/well, respectively, in 96-well poly-D-lysine coated microplates. Cells were
grown in DMEM containing 10% heat-inactivated fetal bovine serum and 5 mM sodium
pyrutate. Plates were kept in an incubator set to 95% relative humidity, 5% CO2, and
37 °C.

Upon reaching confluency 48 hours after seeding, the growth media was

discarded, and cells were washed three times with 100 µL uptake buffer at 37 °C. Two
types of buffer were used for the studies: 1) HBSS supplemented with 20 mM HEPES
and titrated to pH 7.4, and 2) HBSS fortified with 20 mM MOPS and titrated to pH 6.0.
The last wash was left on the cells for 15 min to equilibrate the cells before dosing
commenced. After the equilibration period had passed, the last wash was removed and
cells were dosed with 50 µL uptake buffer containing increasing DCF-AG concentrations.
Plates were quickly placed on a shaker set to 150 rpm and 37 °C and incubated for 0.1,
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0.5, 1, and 2 min. Termination of uptake was performed by quickly removing the uptake
buffer, and the cells were washed 4 times with 200 µL ice-cold uptake buffer.
Intracellular DCF-AG was extracted by adding IS in 100 µL ice-cold methanol and
shaking the cell plates for 15 min at 4 °C. Cellular extracts were transferred into a clean
1 mL deep-well microplate and mixed with 100 µL solvent A. Sample plates were
vigorously vortex-mixed and injected onto the LC/MS/MS. A DCF-AG standard curve
was prepared using naïve cells and extracted using the same process described for
samples. The injection volume for all sample types was 10 µL. Total DCF-AG uptake
was quantified using the standard curve, and the data were reported as pmol. Cell
counts and cell size were measured using a Millipore Scepter device (EMD Millipore,
Billerica, MA), and total protein was determined using a Pierce BCA kit following the
manufacturer’s recommendations (Thermo Fisher Scientific Incorporated, Waltham,
MA). Concentrations were then normalized to pmol per µL of total cell volume in each
well.
Kinetic Modeling. The DCF-AG uptake data was subsequently analyzed using a 2compartamental model previously described for OATP-mediated uptake (Poirier et al.,
2008; Poirier et al., 2009). Essentially the model is governed by three processes: 1)
Pdif,in defined as passive diffusion from the media into the cell, 2) Kactive which is active
transport from the media into the cell, and 3) Pdif,out representing passive diffusion from
the cell into the media. A schematic of the model is shown in Figure 4.1. Each process
is described using the following equations:
Equation 4.1
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Equation 4.2

Equation 4.3

where Pdif was a passive diffusion constant (µL/min), Cmedia was the DCF-AG
concentration of the media (µM), Kactive is the saturable OATP2B1-mediated active
transport that follows Michaelis-Menten kinetics, Vmax is the maximal transport velocity
(pmol/min), Km is the substrate affinity (µM) at half the Vmax, and Ccell is the intracellular
DCF-AG concentration (µM).

The Pdif and Vmax parameters noted above were

normalized by the total cellular protein per well to yield units of µL/min/mg and
pmol/min/mg, respectively. The amount of DCF-AG in each compartment was defined
by:
Equation 4.4

Equation 4.5

where Amedia and Acell were the DCF-AG amounts (pmol), Vmedia was the volume of the
dosing buffer (50 µL), and Vcell was the total cellular volume per well (µL) that was
determined during the cell counting procedure using total cell counts and cell diameter.
Utilizing the previously described relationships, the temporal uptake of DCF-AG into
cells was based on the following differential equation:
Equation 4.6

The concentrations from the uptake studies were imported into Berkeley Madonna
software v8.3.18 (Macey et al., 2000). A fourth order Runge-Kutta integration algorithm
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was implemented using a proportional error model in which the time course data were
log transformed. The software was used to fit the data and determine values for Km, Pdif,
and Vmax. Each modeling run consisted of 6 concentrations, 4 time points in duplicate,
and 2 cell types (HEK-WT and HEK-OATP2B1) giving 96 total data points.

Model

performance in Berkeley Madonna was assessed by selection of initial guesses and
parameter ranges that resulted in the lowest root mean square error.
Cytotoxicity Assay. HEK-OATP2B1 cells were seeded at 100,000 cells/well in 96-well
Optilux microplates (BD Gentest, Waltham, MA). Cells were grown in DMEM containing
10% heat-inactivated fetal bovine serum and 5 mM sodium pyrutate. Plates were kept
overnight in an incubator set to 95% relative humidity, 5% CO2, and 37 °C.

The

following day, the growth media was discarded, and cells were washed twice with 100
µL uptake buffer at 37 °C (HBSS, 20 mM HEPES, pH 7.4). After washing, cells were
dosed in triplicate with 100 µL vehicle (uptake buffer with organic solvent), DCF, or
DCF-AG and incubated for 3, 6, or 12 hours at 37°C.

Thirty minutes before the

incubation period ended, the cells were briefly removed from the incubator, overlaid with
100 µL of a cocktail containing 2 µM Calcein-AM (CAM) and 4 µM Ethidium
Homodimer-1 (EthD-1), and placed back in the incubator for a final 30 minutes. Plates
were then removed, and fluorescence was measured on a SpectraMax Gemini XPS
reader (Molecular Devices, Sunnyvale, CA). The excitation/emission wavelengths for
CAM were 490/520 nm while the excitation/emission wavelengths for EthD-1 were
530/620 nm. Responses for CAM and EthD-1 were normalized against the vehicle
control cells.
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ROS Assay. HEK-OATP2B1 cells were seeded, grown, and washed as detailed in the
preceding section. After washing, the cells were dosed in triplicate with 100 µL vehicle
or increasing concentrations of hydrogen peroxide, DCF, or DCF-AG and incubated for
1, 2, or 3 hours at 37 °C. At the end of the incubation period, the cells were removed
from the incubator, the dosing media carefully aspirated, and the cells were gently
washed once with 100 µL uptake buffer. Cells were overlaid with 100 µL of 1 µM CAM
or 20 µM Dichlorofluorescein diacetate (DCFDA) and were placed back in the incubator
for an additional 30 minutes at 37 °C. At the end of the incubation period, plates were
removed, and fluorescence of the cells was measured on a SpectraMax Gemini XPS
reader (Molecular Devices, Sunnyvale, CA). The excitation/emission wavelengths for
both CAM and DCFDA were 490/530 nm.

Responses for CAM and DCFDA were

normalized against the vehicle control cells.
SOD Inhibition Assay. The SOD assay was conducted using a Cayman Chemical
SOD kit with minor modifications to the recommended protocol.

Briefly, SOD

incubations consisted of 198 µL radical detector, 10 µL of copper/zinc SOD, and 2.3 µL
vehicle or increasing concentration of inhibitor.

Reactions commenced upon the

addition of 20 µL xanthine oxidase, and the mixtures were shaken at 60 rpm in the dark
for 30 min at room temperature.

Samples were then read on a BioTek UV/Vis

microplate spectrophotometer (BioTek Instruments Incorporated, Winooski, VT) at a
wavelength of 450 nm. The SOD activity in all samples was compared against a SOD
standard curve.

Absorption responses were background subtracted, and the

percentage SOD inhibition was determined by normalizing the inhibitor response to
vehicle controls.
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COX Inhibition Assay. The COX assay was performed using a Cayman Chemical
COX kit with minor modifications to the recommended protocol.

Briefly, COX

incubations consisted of 194 µL reaction buffer, 2 µL heme, 2 µL COX (1 or 2) enzyme,
2 µL of arachidonic acid (AA), and 4 µL of vehicle or increasing concentration of
inhibitor. Reactions were conducted for 2 min in duplicate at 37 °C and were quenched
by the addition of 10 µL 1 M HCl. A 200 µL aliquot of the quenched reaction was
transferred into a 1 mL deep-well microplate and diluted with 200 µL ice-cold methanol.
From the diluted mixture, a 100 µL aliquot was mixed with 100 µL IS in ice-cold
methanol, vigorously vortex-mixed, and injected onto the LC/MS/MS. Methodology for
detecting analytes of interest were modified from Shinde et al. (2012). The injection
volume for all sample types was 10 µL. Rather than merely follow AA depletion, COX
inhibition was determined by monitoring the appearance of PGE2 (PGE2/IS peak area
ratio) in all samples and normalizing the inhibitor response to vehicle controls.
LC/MS/MS Method. Chromatographic separation of analytes was performed on a 2.6
µm Kinetex XB-C18 30 × 2 mm column (Phenomenex Incorporated, Torrance, CA).
The system front end consisted of a HTC PAL Autosampler (LEAP Technologies
Incorporated, Carrboro, NC), a CBM-20A system controller, two LC20ADvp pumps, and
a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD). Analytes of
interest were eluted using one of two gradient profiles: method 1 (for DCF-AG) began
with 10% solvent B for the first 0.5 min, which was then increased to 90% solvent B at
1.25 min using a linear gradient and held at this mixture for 0.25 min before reverting
back to initial solvent conditions for 0.5 min to re-equilibrate the column, and method 2
(for PGE2) began with 10% solvent B for the first 0.5 min, which was then increased to
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95% solvent B at 2.00 min using a linear gradient and held at this mixture for 0.5 min
before reverting back to initial solvent conditions for 0.5 min to re-equilibrate the column.
The flow rate for both methods was 0.3 mL/min, and the column effluent was directed to
waste for the initial 0.5 min before switching to the mass spectrometer. Analytes were
detected using an AB Sciex API™ 4000 LC/MS/MS triple quad mass-spectrometer with
a TurboIonSpray® probe and Analyst version 1.5.2 software (AB Sciex, Framingham,
MA) that was operated in multiple reaction monitoring mode. Ion spray voltage was 4250 V, and the source temperature was set to 400 °C.

The mass transitions in

negative ion mode for monitoring AA, DCF-AG, PGE2, and indomethacin were m/z
303.3→259.0, 470.1→192.9, 351.1→271.0, and 356.0→311.8, respectively.

The

retention times of AA, DCF-AG, PGE2, and indomethacin were 2.46, 1.32, 1.55, and
1.47 (1.85 for method 2) min, respectively. Concentrations of analytes in the samples
were determined by comparing the peak area ratios (analyte/IS) to those in the standard
curve using a linear regression model. The criterion of acceptance for standards was
defined to be ±20% of nominal concentration.
Statistical Analysis. Data are expressed as mean ± standard error of the mean. P
values < 0.05 were considered as statistically significant. Statistical analysis of data
was performed using R version 3.2.1 (R Core Team, 2015).

Two groups were

compared by Student’s t test, and multiple groups were compared by an analysis of
variance followed by Tukey’s post hoc test. GraphPad Prism version 6.0 (GraphPad
Software Incorporated, La Jolla, CA) was used to calculate the IC50 for COX inhibition
assays.
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4.4 Results
In Vitro Transport.

The uptake of DCF-AG by a major intestinal transporter was

measured using stably transfected HEK-OATP2B1 cells. DCF-AG kinetic uptake by
OATP2B1 was measured at pH 6.0 and 7.4 to reflect the physiological conditions that
OATP2B1 is exposed to in the intestine and liver, respectively (Fallingborg, 1999).
DCF-AG was incubated at six concentrations ranging from 1 to 300 µM with time points
taken at 0.1, 0.5, 1, and 2 min.

The uptake of DCF-AG was both time- and

concentration-dependent (Figure 4.2).

Concentration versus time data were then

analyzed using a 2-compartmental model as shown in Figure 4.1. The model was used
to estimate transporter kinetic parameters that are summarized in Table 4.1.

The

kinetic parameters of Vmax, Km, and Pdif at pH 6.0 were 27.8 ± 4.1 pmol/min/mg, 15.2 ±
0.8 µM, and 0.0522 ± 0.0120 pmol/min/mg, respectively. It was determined that at pH
7.4, DCF-AG has Vmax, Km, and Pdif values of 17.6 ± 1.5 pmol/min/mg, 14.3 ± 0.1 µM,
and 0.0245 ± 0.0030 pmol/min/mg, respectively. The higher Vmax and Pdif values at pH
6.0 were found to be statistically significant compared to the parameter estimates at pH
7.4.
Cytotoxicity Assay. Having established a role for OATP2B1-mediated uptake of DCFAG, HEK-OATP2B1 cells were incubated with DCF or DCF-AG and monitored over time.
Cell viability was assessed using two fluorescent dyes that offer different modalities and
are complementary to each other. Cell viability measured by CAM, which detects intact
cells through esterase activity, indicated that as early as 3 hours, cell death by DCF was
apparent at the 1 mM dose and by 12 hours 29% of the total cells were dead (Figure
4.3A). The cell viability was confirmed by EthD-1 that detects cell death by binding to
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DNA once the nuclear envelope becomes compromised, and EthD-1 response
increased by a maximum of 1.3-fold for the 12 hour 1 mM incubation (Figure 4.3C).
Compared to DCF, DCF-AG induced greater cell death. After 3 hours, approximately
61% of cells were dead at the 1 mM dose, and the number of dead cells increased to
85% by 12 hours for the 1 mM condition. (Figure 4.3B). EthD-1 in DCF-AG incubations
corroborated the CAM results. The EthD-1 response for a 12 hour incubation with 1
mM DCF increased over 2-fold compared to vehicle control (Figure 4.3D).
ROS Assay. Taking into account that DCF had been shown to promote generation of
reactive oxygen species, we investigated if DCF-AG had a similar potential. As for the
cytotoxicity assay, HEK-OATP2B1 cells were exposed to DCF or DCF-AG and
observed for ROS generation. Since cytotoxicity was evident by 3 hours, the ROS
assay was conducted from one to three hours to determine if ROS preceded cell death.
ROS production was measured with the fluorescent probe DCFDA. Hydrogen peroxide,
a known ROS producer, was used as positive control and exhibited an increase in
DCFDA signal in a dose-dependent manner (Figure 4.4A).

All hydrogen peroxide

incubations achieved statistical significance compared to vehicle controls.

ROS

production by DCF was relatively modest by comparison resulting in a statistically
significant 1-2 fold increase at 3 hours for the 1 mM dose (Figure 4.4B). DCF ROS
induction appeared to indicate a dose response at 3 hours. DCF-AG demonstrated a
clearer time-dependent ROS production culminating with a 5.5-fold increase at 3 hours
for the 1 mM dose (Figure 4.4C). The 500 µM DCF-AG showed trends of increased
ROS generation, though only for the 3 hour incubation, which yielded a 1.8-fold
increase versus vehicle that was statistically significant.
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SOD Inhibition Assay. The SOD inhibition assay was utilized to explore whether DCF
or DCF-AG could inhibit SOD enzymatic activity. SOD incubations were non-cell based
and consisted of a mixture of substrate, enzymes, inhibitor, and detection reagent.
Rather than inhibiting SOD activity over the concentration range, DCF caused an
apparent stimulation with the stimulus becoming statistically significant at the 250 µM
dose and beyond (Figure 4.5). DCF-AG had an opposite effect and was associated
with a dose-dependent decrease in SOD activity such that there was a striking 100%
inhibition of SOD at the 1 mM dose (Figure 4.5). Furthermore, a statistically significant
inhibition of 27% was observed at the 250 µM DCF-AG dose.
COX Inhibition Assay.

The pharmacology of DCF for COX enzymes has been

thoroughly evaluated, yet the pharmacology for DCF-AG has not been characterized.
Hence, the final aspect of our work was to explore DCF-AG inhibition of COX enzymes.
COX inhibition assays were non-cell based and used isolated COX enzymes that were
mixed with substrate, co-factor, and inhibitor. Selective inhibitors of COX-1 and COX-2
were used as controls. Inhibition was assessed by measuring the decreased synthesis
of PGE2 from AA. A summary of the findings is listed in Table 4.2. SC-560 and DuP691, as selective COX-1 and COX-2 inhibitors, had IC50 values of 0.00166 ± 0.00022
µM and 0.00714 ± 0.0007 µM, respectively (Figure 4.6A and Figure 4.7A). DCF, as a
non-selective COX inhibitor had COX-1 and COX-2 IC50 concentrations of 0.0206 ±
0.0037 µM and 0.103 ± 0.005 µM, respectively (Figure 4.6B and Figure 4.7B). OH-DCF
was more potent against COX-1 than COX-2 and reached an apparent plateau for
COX-2 inhibition. The OH-DCF IC50 values were estimated to be 0.375 ± 0.075 µM and
21.2 ± 0.3 µM for COX-1 and COX-2, respectively (Figure 4.6C and Figure 4.7C).
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Lastly, DCF-AG was demonstrated to inhibit PGE2 synthesis with COX-1 and COX-2
IC50 estimates of 0.620 ± 0.105 µM and 2.91 ± 0.36 µM, respectively (Figure 4.6D and
Figure 4.7D). COX-1 inhibition potency of DCF-AG was weaker compared to OH-DCF,
however COX-2 inhibition potency by DCF-AG was more intermediate with respect to
DCF and OH-DCF.
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Figure 4.1 Visual representation of a mechanistic 2-compartmental transporter
model
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Figure 4.1 Visual representation of a mechanistic 2-compartmental transporter model.
The movement of DCF-AG in the proposed model is described by three vectorial
processes: 1) passive diffusion from the buffer into the cell, 2) active transport from the
buffer into the cell, and 3) passive diffusion from the cell into the buffer. Active transport
for this model applies for the OATP2B1-mediated uptake of DCF-AG.
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Figure 4.2 Concentration versus time profiles of DCF-AG uptake by OATP2B1
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Figure 4.2 Concentration versus time profiles of DCF-AG uptake by OATP2B1. HEKWT and HEK-OATP2B1 cells were seeded for 48 hours and incubated with increasing
concentrations of DCF-AG at multiple time points in buffer titrated to either pH 6.0 or 7.4
at 37 °C.

Intracellular concentrations were determined by LC/MS/MS, and the

concentrations were modeled in Berkeley Madonna. (A) and (B) show the uptake of
DCF-AG by HEK-OATP2B1 cells at pH 6.0 and 7.4, respectively. Fitted lines from a 2compartment model represent the best fit. Data are the individual replicates from a
typical study.
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Table 4.1 Summary of DCF-AG uptake kinetics mediated by OATP2B1
Media pH

Vmax
(pmol/min/mg)

Km
(µM)

Uptake CLint
(µL/min/mg)

Pdif
(µL/min/mg)

6.0

27.8 ± 4.1*

15.2 ± 0.8

1.82 ± 0.19

0.0522 ± 0.0120*

7.4

17.6 ± 1.5

14.3 ± 0.1

1.23 ± 0.11

0.0245 ± 0.0030
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Table 4.1 Summary of DCF-AG uptake kinetics mediated by OATP2B1. Each value
represents the mean ± standard error of the mean from 3 studies (n=2 replicates per
study). * P < 0.05 for pH 6.0 versus pH 7.4.

163

Figure 4.3 Cytotoxicity of DCF and DCF-AG using HEK cells
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Figure 4.3 Cytotoxicity of DCF and DCF-AG using HEK cells. HEK-OATP2B1 cells
were incubated in the absence or presence of increasing concentrations of compound.
Incubations were conducted for 3, 6, or 12 hours at 37 °C. Cytotoxicity was assessed
using Calcein AM (CAM) to determine live cells and Ethidium Homodimer-1 (EthD-1) as
an indicator of dead cells. The CAM and EthD-1 responses indicate concentrationdependent cell death by DCF, and the cytotoxicity was more pronounced for DCF-AG.
Each bar represents the mean ± the standard deviation of n=3 measurements per
condition. * P < 0.05, ** P < 0.01; *** P < 0.001 compound versus its time-matched
Vehicle incubation.
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Figure 4.4 Generation of reactive oxygen species by in HEK cells
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Figure 4.4 Generation of reactive oxygen species by in HEK cells. HEK-OATP2B1
cells were incubated in the absence or presence of increasing concentrations of
compound. Incubations were conducted for 1, 2, or 3 hours at 37 °C after which ROS
were detected with the use of DCFDA, which becomes oxidized by ROS to a
fluorogenic form. Fluorescence was normalized to vehicle controls and expressed as
percentage change from vehicle.

Each bar represents the mean ± the standard

deviation of n=3 measurements per condition. * P < 0.05, ** P < 0.01; *** P < 0.001
compound versus its time-matched vehicle incubation.
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Figure 4.5 Inhibition of superoxide dismutase as an indication of oxidative stress
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Figure 4.5 Inhibition of superoxide dismutase as an indication of oxidative stress.
Copper/zinc SOD was incubated in the absence or presence of increasing
concentrations of DCF (□) or DCF-AG (■) for 30 min at room temperature (ca. 25 °C).
Vehicle shows assay performance in the presence of the same level of organic solvent
(DMSO) used in the inhibitor incubations. Each bar reflects the mean ± standard error
of the mean from 3 separate studies (n=2 replicates per study). ** P < 0.01; *** P <
0.001 inhibitor versus its Vehicle incubation. # P < 0.05, ### P < 0.001 for DCF versus
DCF-AG.
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Figure 4.6 COX-1 inhibition profiles of DCF, OH-DCF, and DCF-AG
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Figure 4.6 COX-1 inhibition profiles of DCF, OH-DCF, and DCF-AG. Recombinant
COX-1 was incubated in the presence of inhibitors for 2 min at 37 °C, and the formation
of PGE2 from AA was monitored via LC/MS/MS. Data reflect the mean ± standard error
of the mean from 3 separate studies (n=2 replicates per study). Inhibition data were fit
with a three parameter model to calculate IC50. Dotted lines reflect the 95% confidence
intervals of the fit.
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Figure 4.7 COX-2 inhibition profiles of DCF, OH-DCF, and DCF-AG
B: DCF
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Figure 4.7 COX-2 inhibition profiles of DCF, OH-DCF, and DCF-AG. Recombinant
COX-2 was incubated in the presence of inhibitors for 2 min at 37 °C, and the formation
of PGE2 from arachidonic acid was monitored via LC/MS/MS. Data reflect the mean ±
standard error of the mean from 3 separate studies (n=2 replicates per study). Inhibition
data were fit with a three parameter model to calculate IC50. Dotted lines reflect the
95% confidence intervals of the fit.
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Table 4.2 Summary of in vitro COX inhibition assays
Compound

COX-1 IC50
(µM)

COX-2 IC50
(µM)

SC-560 (COX-1 selective)

0.00166 ± 0.00022

N.D.

DuP-697 (COX-2 selective)

N.D.

0.00714 ± 0.0007

DCF

0.0206 ± 0.0037

0.103 ± 0.005

OH-DCF

0.375 ± 0.075

21.2 ± 0.3

DCF-AG

0.620 ± 0.105

2.91 ± 0.36
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Table 4.2 Summary of in vitro COX inhibition assays. IC50 values reflect the mean ±
standard error of the mean from 3 experiments (n=2 replicates per experiment). N.D.:
not determined.
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Figure 4.8 Proposed pathways on the disposition and mechanism of intestinal
toxicity for DCF-AG
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Figure 4.8 Proposed pathways on the disposition and mechanisms of toxicity for DCFAG. DCF-AG is generated in the liver after DCF (IP or PO) administration where it
undergoes excretion into bile or blood via ABC transporters. Luminal DCF-AG is taken
up by OATPs where it exerts various effects that lead to intestinal injury. The absence
of MRP3 exacerbates GI injury from DCF-AG due to the loss of a clearance mechanism
from enterocytes.

Solid arrows indicate vectorial transport via uptake or efflux

transporters, or via blood flow. Dotted arrows signify transport by passive processes.
Dashed lines demonstrate possible enzymatic reactions such as inhibition of COX,
generation of ROS, or cleavage by bacterial β-glucuronidases.

The question mark

denotes uncertainty regarding the efflux pathways for the indicated metabolites.
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4.5 Discussion
Our interest in exploring the toxicity attributed to DCF-AG was borne through our initial
work of characterizing the role that efflux transporters have in modulating toxicity
following acute administration of DCF. Our research led to the discovery that mice
lacking the efflux transporter Mrp3 were more susceptible to intestinal injury compared
to WT (Scialis et al., 2015). Though the intestinal toxicity differences between WT and
KO were unequivocal, the mechanisms behind those differences were uncertain.
Hence the research presented herein sought to elucidate the probable causes through
which injury occurred.
In light of the findings that immunohistochemical staining of intestinal tissues detected
covalent adducts on the brush border of enterocytes as well as deep within the villi, we
postulated that DCF-AG, as a causative agent to the covalent adducts, was subjected to
an active transport process.

The intestines are host to an array of transporters

(Drozdzik et al., 2014) some of which may be operative with respect to DCF-AG
transport. One of the likely candidates for uptake of DCF-AG would be OATP2B1, a
transporter known to mediate influx of glucuronide conjugates of other compounds (Gao
et al., 2012; Grosser et al., 2014). Thus, OATP2B1 was investigated for affinity of DCFAG using a stably transfected cell system.

By implementing a mechanistic model

(Poirier et al., 2008), we were able to define the kinetic parameters describing DCF-AG
uptake by OATP2B1. Compartmental modeling is becoming more frequently used due
to the versatility it offers to define multiple processes in addition to allowing
simultaneous fitting of several datasets (Poirier et al., 2009; Menochet et al., 2012; De
Bruyn et al., 2015). Preliminary studies with transfected cells showed that after six
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minutes of

incubation, OATPs were

able to

increase intracellular

DCF-AG

concentrations to levels exceeding the initial buffer conditions (Supplement 3). Based
on those observations, we investigated the activity of OATP2B1 as a concentrative
force for DCF-AG uptake.
We report that OATP2B1 acts an uptake transporter for DCF-AG, and that its affinity for
DCF-AG varies with extracellular pH. OATP2B1 transporter clearance for DCF-AG was
1.82 µL/min/mg at pH 6.0 while the transport clearance at pH 7.4 was 1.23 µL/min/mg
(Table 4.1).

These findings are relevant in that they indicate OATP2B1 activity is

greater at pH 6.0 which is a typical pH in the intestines (Evans et al., 1988). The
differential affinity is not surprising given that pravastatin uptake by OATP2B1 was also
found to be sensitive to pH. (Varma et al., 2011). The transporter clearance values at
pH 7.4 would be applicable for hepatic OATP-mediated uptake of DCF-AG as several
OATPs, including OATP2B1, are expressed on the basolateral membrane in the liver
(Hagenbuch and Meier, 2003; Wang et al., 2015). The mechanistic modeling permitted
estimation of the passive diffusion clearance for DCF-AG. We determined that DCF-AG
had a passive uptake clearance that was nearly 2.1-fold greater at pH 6.0 compared to
pH 7.4 (0.0522 versus 0.0242 µL/min/mg, respectively). The OATP-dependent uptake
of the two positive controls that are known to be OATP2B1 substrates, estrone-3-sulfate
and rosuvastatin, were similarly increased at pH 6 compared to pH 7.4 (data not shown).
A study by Ming and colleagues likewise indicated that fexofenadine uptake at pH 6.0
was increased compared to pH 7.4 transport (Ming et al., 2011). The increase in DCFAG passive permeability can be explained through analysis of its structure.

The

carboxylic acid moiety on the glucuronide ring of DCF-AG has an apparent pKa of 2.7
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that becomes less ionized at acidic pH (ACD/Labs).

Thus the increased passive

diffusion at pH 6.0 was driven by increased flux of unionized DCF-AG. This rationale
has been used to explain the tissue distribution of ionized and neutral species at various
pH using OATP-mediated uptake (Ghosh et al., 2014). The same cells used by Ghosh
and colleagues were implemented for DCF-AG uptake, hence the two findings are
comparable. Despite the increased passive diffusion at pH 6.0, DCF-AG uptake would
be dominated by active uptake as the intrinsic uptake clearance by OATP2B1 was 35fold greater than passive diffusion. This categorizes DCF-AG as an ECCS class 3b
compound making it dependent on active uptake to attain meaningful intracellular
concentrations (Varma et al., 2015). DCF, in contrast, as a smaller molecule with high
passive uptake, has no such limitations and can more freely enter cells (Huang et al.,
2010). Though OATP2B1 is a human transporter, there exists a mouse homologue
Oatp2b1 that has been shown to be expressed in the intestinal tract (Cheng et al.,
2005).

Overall, the OATP2B1 studies provide insight as to how the intracellular

covalent adducts observed in our previous mouse studies (Chapter 3 Figure 3.5) may
have arisen.
Having established a potential role for OATP2B1-mediated uptake of DCF-AG, we next
theorized that toxicity from DCF-AG could be enhanced due to OATP2B1 transport. To
that end, we conducted cytotoxicity assays with HEK-OATP2B1 cells.

Our studies

indicated that DCF-AG is indeed cytotoxic, and that cytotoxicity can manifest within 3
hours of exposure (Figure 4.3B). Furthermore, the cytotoxicity by DCF-AG was found to
be greater than that of the parent compound. The DCF-AG concentrations chosen for
the cytotoxicity assays were physiologically relevant in that they are in the same range
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as the biliary concentrations detected in mice after an IA administration of 75 mg/kg
DCF (Chapter 3 Figure 3.2). In our toxicodynamic studies with 90 mg/kg diclofenac, we
were only able to observe intestinal injury 24-hours post-administration since that was
the sole time point chosen for tissue harvesting (Chapter 3 Figure 3.4). The cytotoxicity
data here indicate that injury, in terms of cell death, may occur with early onset. Cell
death by DCF reached a maximum of 29% by 12 hours at 1 mM compared to nearly
62% cell death for DCF-AG by 3 hours at 1 mM with a maximal cell death of 85%
reached after 12 hours. DCF can cause higher cytotoxicity than what was observed in
our assays.

These data substantiate the findings reported in TR- rats wherein

administration of bile containing DCF-AG elicited greater intestinal injury compared to
an equimolar dose of DCF (Seitz and Boelsterli, 1998). It is conceivable that Oatpmediated uptake of DCF-AG in our mouse model, along with the cytotoxicity potential of
DCF-AG, may have contributed to the increased enteropathy in Mrp3 KO mice since
those mice had reduced capacity to eliminate DCF-AG compared to WT.
Oxidative stress is another means by which cell toxicity can occur.

Specifically,

generation of reactive oxygen species may overwhelm a cell’s ability to maintain
homeostatic redox levels. For instance, the pesticide rotenone is a known inducer of
ROS, and exposure to rotenone results in cell death (Tamilselvam et al., 2013).
Accordingly, we conducted ROS assays with DCF and DCF-AG to determine their ROS
activity. The positive control in the assay, hydrogen peroxide, increased ROS in a
dose-dependent manner (Figure 4.4A) verifying its role as a ROS-inducting agent (Alia
et al., 2005).

DCF ROS induction was relatively weak, yet ROS production was

significantly increased after 2 hours of exposure (Figure 4.4B).
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The modest ROS

increase by DCF in our assay was less than a nearly 6-fold increase in ROS caused by
DCF after a 30 hour exposure in a hepatocyte model of cytotoxicity (Lim et al., 2006).
DCF-AG exhibited a dose-dependent increase in ROS with a maximal increase of 5.5fold after 3 hours (Figure 4.4). Given that the ROS assay was carried out from 1-3
hours compared to the cytotoxicity assay time frame of 3-12 hours, an argument can be
made that DCF-AG ROS production is a contributing factor to the observed cell death in
our assays. As to how ROS production promotes cell death, possible pathways are
through inhibition of ATPases, oxidation of DNA, perturbation of the mitochondrial
permeability transition pore, or protein inactivation (Cantoni et al., 1989; Martinez-Reyes
and Cuezva, 2014).
Oxidative stress can come about through means other than generation of ROS. For
instance, administration of high doses of acetaminophen promotes oxidative stress in
the liver through depletion of hepatic glutathione due to the formation of a reactive
intermediate NAPQI that immediately reacts with glutathione (van de Straat et al., 1987).
Glutathione depletion following DCF exposure has been shown to occur using an in
vitro hepatotoxicity model (Pourahmad et al., 2011). Nonetheless, oxidative stress via
other pathways remained a possibility. One such route is the inhibition of superoxide
dismutase, an important part of the cell’s antioxidant response system (Fukui and Zhu,
2010). Therefore, we conducted SOD inhibition assays using the same concentrations
of DCF and DCF-AG as applied in the aforementioned in vitro assays. The SOD assay
was not cell-based hence incubations were executed within a relatively short time span
since inhibitor uptake was not necessary.

DCF failed to yield any inhibition and

surprisingly appeared to stimulate SOD activity (Figure 4.5).
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The nature of this

stimulation is unknown to us. A striking observation was the clear dose-dependent
inhibition of SOD by DCF-AG, so much so that at the highest tested DCF-AG
concentration of 1 mM, SOD activity was reduced to non-detectable levels (Figure 4.5).
Prior evidence for SOD inhibition by an NSAID metabolite was reported by Chiou and
colleagues (1999). In their study, 5 mM of suprofen acyl glucuronide reduced SOD
activity by 88% after a 14-day treatment using a non-cell based in vitro model. In the
same study, 5 mM suprofen decreased SOD activity by 5% after a 14-day incubation.
Our data show that DCF-AG can elicit as great an inhibition but at lower doses and
within a shorter time scale. Taken into context, the SOD inhibition along with ROS
generation by DCF-AG may lead to sustained oxidative stress, culminating in cell death.
A last part of our research focused on the inherent pharmacology of DCF-AG. DCF was
developed as a treatment for inflammation and pain, and it is through its ability to inhibit
COX enzymes that pharmacologic efficacy is achieved. Hydroxylated metabolites of
DCF have been tested for COX inhibition, but there has been no investigation of DCFAG’s pharmacology. Hence, we sought to identify if DCF-AG possessed COX inhibitory
activity. Our inhibition assays with COX-1 and COX-2 led to a novel finding. DCF-AG
had apparent COX-1 and COX-2 IC50 values of 0.620 ± 0.105 µM and 2.91 ± 0.36 µM,
respectively (Figure 4.6, Figure 4.7, Table 4.2). The COX inhibition potency by DCF-AG
was notably weaker compared to DCF for which we determined IC50 values of 0.0206 ±
0.0037 µM and 0.103 ± 0.005 µM for COX-1 and COX-2, respectively, values that are in
line with published findings (Johnson et al., 1995).
The IC50 concentrations determined in the COX inhibition assays take on greater
meaning when considering that the inhibition values are physiologically relevant both in
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terms of circulating plasma concentrations that were observed in our mouse
toxicokinetic studies as well as human plasma levels (professional communiqué,
publication pending). Furthermore, the inhibition assays were performed with the intent
to monitor formation of PGE2 which has several important physiological functions such
as immune system modulation (Nicolaou et al., 2014). Critically, PGE2 is responsible
for the protection of the GI mucosa, and deficiencies in PGE2 signaling were associated
with increased GI injury (Takeuchi, 2014). There is a deeper significance to the COX
inhibition findings. Mere inhibition of COX-1 or COX-2 is not sufficient as a causal factor
of gastrointestinal injury. As an example, administration to rats of the selective COX-1
inhibitor SC-560 or the selective COX-2 inhibitor rofecoxib, which was recalled as a
marketed drug, did not induce any gastrointestinal damage (Tanaka et al., 2001).
However, when SC-560 and rofecoxib were co-administered, extensive damage was
observed implying that inhibition of the two isoforms of COX is essential to injury
formation.
(diclofenac,

Using the same model, administration of non-selective COX inhibitors
indomethacin,

and

naproxen)

resulted

in

gastrointestinal

injury.

Furthermore, studies with COX-1 or COX-2 KO mice demonstrated that COX-1 activity
promotes intestinal intactness while COX-2 activity is necessary for healing of ulcers
(Schmassmann et al., 2006). That DCF-AG, like its parent compound, can inhibit both
COX enzymes represents a novel finding and offers a possible cause during
enteropathy associated with exposure to DCF-AG.
The results from the in vitro assays in the preceding sections can be interwoven into a
mechanistic paradigm for injury directly attributable to DCF-AG.

In Figure 4.8 we

propose a tox model describing the multiplicity of transporters, pharmacologic, and
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inhibitory activities that capture our current and past investigations.

The model is

predicated on the transfer of DCF into the liver after administration (the route of
administration is not a defining factor at this point) whereupon it undergoes extensive
biotransformation. The metabolite DCF-AG can be excreted into the blood via MRP3 or
alternatively transported into the bile by BCRP or MRP2. In our toxicokinetic studies,
we determined that the biliary concentration of DCF-AG were between 1.3 to 4.0 mM
(Chapter 3). Any remaining DCF-AG in the liver may undergo adduct formation either to
albumin or sequestration by glutathione (Grillo et al., 2003).

In addition, we have

characterized DCF-AG stability and determined that its half-life in the presence of S9
esterases was approximately 15 min (Supplement 1), setting up a scenario where
residual hepatic DCF-AG reverts to parent compound reinitializing another round of
metabolism. It is important to note that this proposed injury model does not apply to the
liver since the in vivo studies (Chapter 3) showed no hepatotoxicity by DCF. Biliary
DCF-AG traverses the common bile duct and enters the small intestine at the proximal
duodenal region. The acidic environment of the intestinal lumen acts as a stabilizing
force on DCF-AG decreasing the rate of non-enzymatic hydrolysis (Supplement 2).
Once in the GI lumen, DCF-AG may undergo conversion back to parent compound by
the activity of bacterial β-glucuronidase present in the gut microflora (Louis et al., 2014).
Free DCF-AG may also take one of two steps: 1) covalent adduction to the outside of
the enterocytes, or 2) active uptake by OATP2B1. Once inside the cell, DCF-AG can
induce cytotoxicity either through ROS generation or SOD inhibition ultimately leading to
oxidative stress. DCF-AG may be cleared from enterocytes if MRP3 is present and
functional. However, lack of MRP3 (as in the null mice) may result in greater DCF-AG
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retention and more aggravated damage by the aforementioned mechanisms. The tox
mechanistic model also includes the inhibitory attributes of DCF-AG against COX
enzymes. COX-mediated inhibition by DCF-AG may potentiate enteropathy via loss of
PGE2 protection as well as interference of COX-2 directed wound healing. Lastly, DCF
is expected to contribute to intestinal injury in conjunction to DCF-AG via similar
pathways of COX inhibition, oxidative stress, and ROS generation.
It may not be clear which of the proposed mechanisms are dominant and which have
minor roles.

Nonetheless, our results lay the foundation of a novel multifactorial

process of intestinal injury attributable directly to DCF-AG. The in vitro assays detailed
in the current work along with our previous findings offer potential explanations and
insight that have not been previously explored. In conclusion, we believe we have
made a rational argument of the potential for DCF-AG to directly mediate toxicity and
have provided credible mechanistic leads that could explain this toxicity.
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Chapter 5 THE

MODULATION

OF

TRANSCRIPTIONAL

EXPRESSION

AND

INHIBITION OF MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4 (MRP4) BY
ANALGESICS AND THEIR PRIMARY METABOLITES
5.1 Abstract
During the course of a toxic challenge, changes in gene expression can manifest such
as induction of metabolizing enzymes as a compensatory detoxification response. We
currently report that a single 400 mg/kg IP APAP dose to C57BL/6J mice led to an
increase

in

Mrp4

(Abcc4)

mRNA

12

hours

after

administration.

Alanine

aminotransferase, as a marker of liver injury, was also elevated indicating hepatotoxicity
had occurred. Therefore, induction of Mrp4 mRNA was likely attributable to APAPinduced liver injury. Mrp4 has been shown to be upregulated during oxidative stress,
and it is well-established that APAP overdose causes oxidative stress due to depletion
of glutathione. Given the importance of Mrp4 induction as an adaptive response during
cholestatic and oxidative liver injury, we next investigated the extent by which human
Mrp4 can be inhibited by the analgesics, APAP, DCF, and their metabolites. Using an
in vitro assay with inside out human MRP4 vesicles, we determined that APAP-cysteine
inhibited MRP4-mediated transport of leukotriene C4 with an apparent IC50 of 125 µM.
APAP-glutathione also attenuated MRP4 activity though it achieved only 28% inhibition
at 300 µM. DCF-AG inhibited MRP4 transport by 34% at 300 µM. The MRP4 in vitro
inhibition occurs at APAP-cysteine and DCF-AG concentrations seen in vivo after a
toxic dose of APAP or DCF in mice, hence the findings are important given the role that
Mrp4 serves as a compensatory response during oxidative stress following toxic
challenge.
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5.2 Introduction
Injury following overdose with analgesics is relatively common and can result in
extensive damage to multiple organs that may ultimately lead to death in severe cases
(Jones, 2002). Mild to moderate toxicity may induce changes vis-à-vis regulation of
genes.

Such changes involve modulation of transcription factors or induction of

transporters as a compensatory response (Blazka et al., 1995a; Barnes et al., 2007).
Intoxication with APAP, for example, has been demonstrated to result in upregulation of
the efflux transporter Mrp4 (Campion et al., 2008) as well as the metabolic enzyme
flavin containing monooxygenase 3 (Rudraiah et al., 2014a), a particularly novel finding
given that Fmo3 was previously thought to be non-inducible (Cashman and Zhang,
2002).

The mechanism of Mrp4 induction has been demonstrated to be linked to

activation of nuclear factor erythroid 2-like 2 (Nrf2, Nfe2l2) as evidenced by lack of Mrp4
upregulation in Nrf2 knockout mice (Ghanem et al., 2015). Furthermore, Mrp4 induction
by APAP was found to be dependent on Kupffer cell activation (Campion et al., 2008).
Mrp4 expression also was induced after administration of clofibrate via activation of
peroxisome proliferator-activated receptor α (Moffit et al., 2006). In a mouse model, the
elevated expression of Mrp4 after an initial toxic APAP insult results in mice becoming
refractory to injury following subsequent toxic doses, an effect termed autoprotection
(Aleksunes et al., 2008a).
In the previously cited work by Campion and colleagues, protein induction became
evident two to three days after administration of toxic doses of APAP. Measurement of
ALT as an indicator of hepatocellular injury has been utilized in human and rodents
(McGill et al., 2012; Singhal et al., 2012), and there is a clear relationship between ALT
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and manifestations of injury. Furthermore, Rudraiah and colleagues (2014b) reported
elevations in ALT and Fmo3 mRNA following toxic APAP treatment leading the authors
to conclude that induction of Fmo3 was likely a protective mechanism in response to
APAP-induced hepatotoxicity. To date, transporter expression as a function of ALT has
not been thoroughly investigated.
As expected, administration of xenobiotics results in the generation of metabolites that
can be eliminated through biliary or urinary excretion.

Work from our group has

previously shown that metabolites of APAP and DCF (Figure 5.1) can be generated in
high concentrations, with respect to the parent compound, after toxic doses (Chen et al.,
2003; Manautou et al., 2005; Scialis et al., 2015). Though metabolite disposition has
been characterized, and in some instances the affinity for a transporter to mediate
metabolite clearance quantified (Zelcer et al., 2003b; Zamek-Gliszczynski et al., 2006c),
there has not been systematic examination as to the potential for these metabolites to
interfere with normal transporter function.
Thus the goals of our current work were to first assess the relationship, if one exists,
between elevations in ALT and transcriptional regulation of Mrp4. To accomplish this
objective, a toxic dose of APAP will be given to C57BL/6J mice with measurement of
ALT and Mrp4 mRNA at several time points post-administration. The second aspect of
our inquiry focuses on the inhibition of MRP4 by APAP, DCF, and their primary
metabolites.

The MRP4 inhibition assays were conducted using APAP and DCF

metabolite concentrations that reflect those observed during in vivo studies from our
laboratory.
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Figure 5.1 Structures of APAP, DCF, and their major metabolites
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Figure 5.1 Structures of APAP, DCF, and their major metabolites.

The various

conjugated metabolites of APAP as the result of Phase II metabolism or spontaneous
adduction

to

the

CYP450-mediated

reactive

intermediate

NAPQI.

APAP:

acetaminophen, APAP-CYS: acetaminophen cysteine, APAP-GLU: acetaminophen
glucuronide, APAP-GSH: acetaminophen glucuronide, APAP-NAC: acetaminophen Nacetylcysteine, APAP-SUL: acetaminophen sulfide, DCF: diclofenac, 4ʹ-OH-DCF: 4ʹhydroxy diclofenac, DCF-AG: diclofenac acyl glucuronide.
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5.3 Materials and Methods
Chemicals and Reagents. APAP, AMP, ATP, DCF, formic acid, indomethacin (used
as the IS), KCl, MgCl2, MOPS, OH-DCF, and Tris-HCl, were purchased from SigmaAldrich Corporation. (St. Louis, MO). DCF-AG was purchased from Toronto Research
Chemicals Incorporated (Toronto, Canada).

APAP metabolites were obtained from

McNeil-PPC Incorporated (Fort Washington, PA). Leukotriene C4 and MK-571 were
purchased from Santa Cruz Biotechnology (Dallas, TX).

MRP4 vesicles were

purchased from GenoMembrane Corporation (Kanazawa, Japan).

All LC/MS/MS

solvents were of high analytical grade and were purchased from Burdick & Jackson
(Muskegon, MI).
Animals. Male C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice were housed in an American Animal Associations Laboratory Animal Care
accredited facility at the University of Connecticut under a standard temperature-, light-,
and humidity-controlled environment.

Mice had free access to Harlan Teklad 2018

chow (Harlan, Madison, WI) and drinking water. All animal studies were performed in
accordance with the Guide for the Care and Use of Laboratory Animals using protocols
reviewed and approved by the local Institutional Animal Care and Use Committee at the
University of Connecticut.
In Vivo Studies. Mice were used at 2-3 months of age. The mice received a single IP
dose of 400 mg/kg APAP in 0.9% saline. Mice were sacrificed by decapitation at 6, 12,
and 24 hours after APAP administration.

Blood samples were collected and

subsequently centrifuged at 1,200 × g for 15 min to yield plasma. Livers were harvested,
rinsed in ice-cold saline, and quickly frozen in liquid nitrogen prior to storage at -80 °C.
192

RNA Isolation and RT-PCR.

Total liver RNA was extracted using TRIzol reagent

(Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's protocol. The
concentration of total RNA in each sample was quantified spectrophotometrically at 260
nm, and the integrity was evaluated by agarose gel electrophoresis. RNA (1 µg) was
reverse transcribed to cDNA using a M-MLV Reverse Transcriptase kit (Thermo Fisher
Scientific). mRNA expression of Abcc4 and was quantified using specific primers (Table
5.1) by the CT method and normalized to the housekeeping gene Actb. Primer pairs
were synthesized by Integrated DNA Technologies (Coralville, IA). Amplification was
performed using an Applied Biosystems 7500 Fast Real-Time PCR System (Thermo
Fisher Scientific) and carried out in a 20 µL reaction volume containing diluted cDNA,
Fast SYBR Green PCR Master Mix (Thermo Fisher Scientific), and 1 µM of each primer.
Clinical Chemistry.

Plasma samples were analyzed for alanine aminotransferase

(ALT) using a kit purchased from Thermo Fisher Scientific as per the manufacturer’s
recommendations. A BioTek UV/Vis microplate spectrophotometer (BioTek Instruments
Incorporated, Winooski, VT) was used to measure assay endpoints.
In Vitro Transport.

Commercially available MRP4 inside-out vesicles from

GenoMembrane were quickly thawed from storage and placed on ice.

Incubation

reactions consisted of uptake buffer at pH 7.0 (50 mM MOPS-Tris, 70 mM KCl, and 7.5
mM MgCl2), 25 µg vesicle protein, 5 mM of AMP or ATP, and 2.5 mM GSH. After a 5
min pre-incubation period of reaction mixture, incubations were commenced by addition
of increasing concentrations of LTC4 for substrate studies. For inhibition studies, the
concentration of LTC4 was fixed while increasing concentrations of inhibitor was added.
Incubations were conducted at 37 °C in a total volume of 75 µL.
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Reactions were

quenched by the addition of 100 µL ice-cold stopping buffer (40 mM MOPS-Tris and 70
mM KCl), and the quenched mixtures were quickly transferred to a 96-well glass-fiber
filter plate (EMD Millipore, Billerica, MA). The plate was subjected to vacuum filtration
followed by 5 rapid washes of 100 µL/well ice-cold stopping buffer. The filter plate was
allowed to dry before extraction of samples. Once the filter plate was dry, LTC4 was
extracted by filling each well of the filter plate with 200 µL of 80:20 (v/v) methanol: water.
Plates were shaken for 15 min on ice, and the filtrate was collected via centrifugation at
3,000 × g for 10 min and 4 °C. The filtrate was evaporated to dryness under warm N2 at
40 °C. The resulting residue was reconstituted with 100 µL water and 100 µL IS in
methanol, vigorously vortex-mixed, and injected onto the LC/MS/MS. The accumulation
of LTC4 was quantified against a standard curve, and the data were expressed as pmol
uptake normalized to mg vesicle protein.
LC/MS/MS Method. Chromatographic separation of analytes was performed on a 2.6
µm Kinetex XB-C18 30 × 2 mm column (Phenomenex Incorporated, Torrance, CA).
The system front end consisted of a HTC PAL Autosampler (LEAP Technologies
Incorporated, Carrboro, NC), a CBM-20A system controller, two LC20ADvp pumps, and
a DGU-14A degasser (Shimadzu Scientific Instruments, Columbia, MD). Analytes of
interest were eluted using a gradient program that began with 10% solvent B for the first
0.5 min, which was then increased to 90% solvent B at 1.25 min using a linear gradient
and held at this mixture for 0.25 min before reverting back to initial solvent conditions for
0.5 min to re-equilibrate the column. The flow rate for was 0.3 mL/min, and the column
effluent was directed to waste for the initial 0.5 min before switching to the mass
spectrometer. Analytes were detected using an AB Sciex API™ 4000 LC/MS/MS triple
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quad mass-spectrometer with a TurboIonSpray® probe and Analyst version 1.5.2
software (AB Sciex, Framingham, MA) that was operated in multiple reaction monitoring
mode. Ion spray voltage was -4250 V, and the source temperature was set to 400 °C.
The mass transitions in negative ion mode for monitoring LTC4 and IS were m/z
626.4→189.5 and 356.0→311.8, respectively. The retention times of LTC4 and IS were
1.33 and 1.47 min, respectively. Concentrations of analytes in the samples were
determined by comparing the peak area ratios (analyte/IS) to those in the standard
curve using a linear regression model. The criterion of acceptance for standards was
defined to be ±20% of nominal concentration.
Data Analysis.

Where IC50 estimates could be determined for Mrp4 inhibition, Ki

values for the inhibitors were calculated according to the following equation (Cheng and
Prusoff, 1973):
Equation 5.1

where Ki is the affinity of the inhibitor, IC50 is the inhibitor concentration producing 50%
inhibition, [S] is the substrate concentration in the incubation, and Km is the Michaelis
constant representing substrate affinity for the transporter.
Statistical Analysis. Data are expressed as mean ± standard error of the mean. P
values < 0.05 were considered as statistically significant. Statistical analysis of data
was performed using R version 3.2.1 (R Core Team, 2015).

Two groups were

compared by Student’s t test, and multiple groups were compared by an analysis of
variance followed by Tukey’s post hoc test. GraphPad Prism version 6.0 (GraphPad
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Software Incorporated, La Jolla, CA) was used to calculate kinetic parameters (Vmax and
Km) as well as the IC50 inhibition parameter.
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Table 5.1 Primer sequences for quantitative RT-PCR
Gene (Protein)

Primer Sequence
Forward: 5′-GCA ACG AGC GGT TCCG-3′

Actb (β-actin)
Reverse: 5′-GCA GAC AGC CAA GGA GCC CAA AGA CC-3′
Forward: 5′-ACC TCT GCT CGC GCG TGT TCT-3′
Abcc4 (Mrp4)

Reverse: 5′-CCA GTA CCG TTG AAG CTC CTC TCC-3′
Reverse: 5′-CTC AGC ATG ATG GAC TTG GA-3′
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5.4 Results
In Vivo Study. C57BL/6J male mice were administered a single IP dose of 400 mg/kg
APAP in 0.9% saline. Animals were sacrificed 6, 12, and 24 hours post administration,
and livers were harvested. Plasma was used to assess liver injury using ALT as a
marker. The mean ALT values at 6, 12, and 24 hours were, 930, 1,080, and 1,750 U/L,
respectively (Figure 5.2). Transcriptional changes of Mrp4 were assessed at the same
time points used for ALT analysis. An increase in Mrp4 mRNA was observed at 12
hours, and this increase was statistically significant (P < 0.05). Taken together, the data
suggest that APAP-induced liver injury, evidenced by high ALT values, resulted in the
induction of Mrp4 mRNA.
LTC4 Kinetics.

Human MRP4 was characterized for transport of LTC4 prior to

conducting inhibition studies. The linearity of MRP4-mediated transport for 0.1 µM LTC4
was evaluated and determined to be time-dependent (Figure 5.3A).

The dynamic

response reached a maximal value of 19-fold (ATP response divided by AMP response)
by 20 minutes. Next, LTC4 was characterized for concentration-dependent transport.
Kinetic parameters of Vmax and Km for MRP4 LTC4 transport were determined to be 245
pmol/min/mg and 4.25 µM, respectively (Figure 5.3B). Kinetic data were fitted using a
single Km model without assuming cooperativity.
MRP4 Inhibition. The potential for MRP4 inhibition was carried out in the presence of
parent compounds and their metabolites. MK-571 was used as inhibitor control yielding
an IC50 of 14.2 µM (Figure 5.4), a value that is close to its reported IC50 against other
probes (Reid et al., 2003a; Rius et al., 2003). APAP, APAP-SUL, APAP-GLU, and
APAP-NAC did not manifest any significant inhibition. APAP-CYS inhibited transport
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with an IC50 of 125 µM. APAP-GSH decreased MRP4 transport, but only at the two
highest doses resulting in 29% inhibition at 300 µM. DCF and its metabolites likewise
inhibited MRP4, with DCF-AG showing the greatest inhibition reaching a maximal
inhibition of 34% at the highest tested concentration of 300 µM. The apparent Ki values
using Equation 5.1 for MK-571 and APAP-CYS were calculated to be 13.9 and 122 µM,
respectively.
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Figure 5.2 Relationship between ALT values and Mrp4 gene expression following
acute exposure to APAP
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Figure 5.2 Relationship between ALT values and Mrp4 gene expression following acute
exposure to APAP. Male C57BL/6J mice were administered 400 mg/kg APAP and
sacrificed 6, 12, or 24 hours after administration. ALT was determined from plasma
while Mrp4 mRNA expression was determined via RT-PCR using RNA extracted from
whole liver homogenate. Data are expressed as the mean ± standard error of the mean
for n=5-7 subjects/group. The vertical dotted line reflects the ALT upper limit of normal
value of 40 U/L.
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Figure 5.3 Time-dependent and concentration-dependent transporter kinetics of
LTC4 with MRP4 vesicles
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Figure 5.3 Time-dependent and concentration-dependent transporter kinetics of LTC4
with MRP4 vesicles. MRP4 vesicles were incubated with LTC4 in the presence of either
AMP or ATP. (A) The time-dependent transport of 0.1 µM LTC4 in the presence of 5
mM AMP (○) or 5 mM ATP (●) at 37 °C. The dotted line represents the nonlinear fit of
LTC4 active transport and was calculated by subtracting the AMP values (background
and passive uptake) from the ATP response.
transport of LTC4 at 37 °C.

(B) The concentration-dependent

The fitted line indicates the ATP-dependent transport

assuming typical Michaelis-Menten kinetics.

Insert: Eadie-Hofstee plot.

Each data

point reflects the mean ± the standard error of the mean for n=3 measurements per time
point or concentration.
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Figure 5.4 Inhibition of MRP4 activity by APAP, APAP metabolites, DCF, and DCF
metabolites
B: APAP
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Figure 5.4 Inhibition of MRP4 activity by APAP, APAP metabolites, DCF, and DCF
metabolites. In vitro inhibition was conducted using MRP4 vesicles with 0.1 µM LTC4 in
the presence of 5 mM ATP at 37 °C for 5 min. The ATP-dependent transport of LTC4 in
the absence of inhibitor was set to 100%. Inhibition data were fit with a three parameter
model to calculate IC50. Dotted lines reflect the 95% confidence intervals of the fit.
Each data point reflects individual values (n=2 per inhibitor concentration).
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5.5 Discussion
The objective of our current work was to evaluate the regulation and function of Mrp4
following a toxic challenge by APAP.

Analysis of major hepatic transporters in

untreated C57BL/6J mouse livers showed that Mrp4 has one of the lowest expression
levels in a comparative profile panel of uptake and efflux transporters (Supplement 4).
Despite its seemingly low hepatic expression during homeostatic conditions, Mrp4 is
quite inducible and plays a major role after intoxication by xenobiotics. As an example,
work by Campion et al. (2008) showed that among the Mrp class of transporters, Mrp4
was the most inducible after a 500 mg/kg IP APAP dose to C57BL/6J mice, and its
protein expression increased 10- and 33-fold by 48 and 72 hours, respectively.
Furthermore, the mechanism of induction was shown to be dependent on the functional
presence of hepatic macrophages known as Kupffer cells. Loss of Kupffer cell viability,
via targeted cell death by the agent clodronate, resulted in loss of Mrp4 induction.
Moreover, induction of Mrp4 following APAP challenge was found to be dependent on
the transcription factor Nrf2 as mice lacking Nrf2 did not show any changes to Mrp4
mRNA or protein levels after a toxic APAP dose (Aleksunes et al., 2008b). During the
course of our current study, we observed that Mrp4 mRNA was significantly upregulated
12 hours after a 400 mg/kg APAP challenge (Figure 5.2). Curiously, the Mrp4 mRNA
levels were essentially the same at 6 and 24 hours. Given the prior protein expression
data, we postulate that the transcriptional upregulation at 12 hours was sufficient to be
the driving factor for Mrp4 protein levels to reach maximal expression at 48 hours.
We next sought to draw correlation between liver injury and Mrp4 mRNA. Serum ALT
has been used a reliable indicator for liver injury, and we detected ALT levels that were
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consistent with APAP toxicity (Figure 5.2). ALT levels were elevated at all the time
points examined, while Mrp4 mRNA reached maximal induction 12 hours post-dose.
Ghanem et al. (2015) similarly reported that ALT and Mrp4 mRNA levels were
significantly increased 24 hours following toxic challenge by APAP.

Rudraiah and

colleagues (2014b) observed an association between ALT and flavin containing
monooxygenase-3 (Fmo3) mRNA where both reached maximal values 48 hours after a
400 mg APAP dose. Thus the results suggest that liver injury following toxic APAP
administration may have lead to the induction of Mrp4 mRNA.
Given the importance Mrp4 has as a compensatory response during APAP toxicity, we
investigated the potential for Mrp4 inhibition by APAP and its metabolites. The rationale
for investigating Mrp4 inhibition is based on the finding that Mrp4 is upregulated as a
compensatory mechanism during oxidative stress (Xu et al., 2010). Considering APAP
metabolism can cause oxidative stress that can lead to hepatotoxicity, inhibition of Mrp4
by APAP or its metabolites may further exacerbate liver injury. In lieu of mouse Mrp4,
we chose to use vesicles containing human MRP4 as a surrogate. Our first course of
action was to characterize the assay for performance. Among the substrates for MRP4
are estradiol-17β-glucuronide, ferosemide, and methotrexate (Chen et al., 2001; Chen
et al., 2002; Hasegawa et al., 2007). The choice of estradiol-17β-glucuronide as a
probe can result in potentially misleading findings as it was shown to be stimulated by
several compounds that were able to inhibit the vesicular transport for other substrates
(Kidron et al., 2012). Hence, we decided to use Leukotriene C4 as our probe based on
the work of Rius et al. (2008) that identified LTC4 as a substrate for MRP4. LTC4 as a
measure of MRP4 activity is advantageous since it is a naturally occurring derivative of
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arachidonic acid and plays a role during pro-inflammatory responses (Dahlen et al.,
1983; Zipser et al., 1987). Using inside-out MRP4 vesicles, we determined that the
transport of LTC4 was time-dependent (Figure 5.3A). Furthermore, the transport of
LTC4 was concentration-dependent with a Vmax and Km of 253 pmol/min/mg and 4.25
µM, respectively (Figure 5.3B).
We next proceeded to conduct MRP4 inhibition assays, and expanded our assay to
include two analgesics and their metabolites. Our results show that APAP has no effect
on MRP4, and neither did APAP-SUL, APAP-GLU or APAP-NAC.

However, we

observed that APAP-CYS had concentration-dependent inhibition of MRP4 with an
apparent IC50 of 125 µM.

Based on the in vitro parameters from our assays, we

calculate a Ki of 122 µM for APAP-CYS.

Bearing in mind the low LTC4 substrate

concentration relative to its Km and ratio of IC50 to Ki, it is likely the inhibition of MRP4 by
APAP-CYS was of a competitive nature (Burlingham and Widlanski, 2003). That APAPNAC did not manifest inhibition was surprising considering the structural resemblance it
shares with APAP-CYS (Figure 5.1). Yet, APAP-GSH, which has a longer side chain
compared to APAP-NAC and would potentially have greater steric hindrance, was able
to inhibit LTC4 transport by 29% inhibition at 300 µM.

The results show the high

specificity and discretionary recognition by MRP4 of closely related chemical entities.
Inhibition by APAP-GSH is intriguing in light of the fact that it is a major metabolite
stemming from sequestration of the highly reactive APAP intermediate NAPQI (Mitchell
et al., 1973; Moore et al., 1985).
Akin to APAP-GSH, DCF and two of its main metabolites produced inhibition of MRP4
with DCF-AG achieving 34% inhibition. The DCF inhibition was not surprising as a
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previous investigation established that DCF was able to inhibit the MRP4-mediated
uptake of methotrexate (El-Sheikh et al., 2007).

In that study, DCF was found to

possess a two-site affinity with IC50 values of 326 and 0.006 µM for the high and low site,
respectively. Since DCF only achieved 22% for the current study, the difference in
potency is likely reflective of substrate selection. MRP4 inhibition by DCF parent and
metabolites may have physiological ramifications.

Studies point to MRP4 being an

efflux transporter for PGE2 (Reid et al., 2003b). In light of PGE2’s role in promoting cell
survival and repair (Takeuchi, 2014), abrogation of its efflux could interfere with
localized signaling in response to DCF-induced injury.

It should be noted that the

concentrations chosen for the in vitro inhibition were physiologically relevant as they
reflect the in vivo metabolite concentrations observed in prior animal studies (Chen et
al., 2003; Manautou et al., 2005; Scialis et al., 2015).
To summarize our findings, we report that Mrp4 mRNA expression was induced after a
single toxic dose of APAP, and that induction was maximal at 12 hours. ALT, as a
marker of hepatic injury, was also elevated. Also, we show that human MRP4 function
was inhibited by APAP metabolites with APAP-CYS achieving an apparent IC50 that is
physiologically relevant. We believe these findings demonstrate the intricate balance
between compensatory transporter upregulation due to xenobiotic intoxication and the
possible deleterious effects that xenobiotics continue to exert in the form of their
circulating metabolites.
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Chapter 6 SUMMARY
DCF is a non-steroidal anti-inflammatory drug that has been used for the past several
decades to treat a variety of conditions such as arthritis, pain, and migraine (Novartis,
2011; Depomed, 2014). In the United States, DCF is available only by prescription, and
it is normally tolerated by a majority of patients. However, patient compliance with DCF
treatment can become problematic owing to ADRs such as gastrointestinal bleeding,
perforation, and ulceration.

In these cases, patients are alternatively prescribed a

combination of DCF with misoprostol which can significantly lessen the occurrence of GI
injury (Reyes-Garcia et al., 2007; Pfizer, 2014).
DCF has been extensively studied for its pharmacology, pharmacokinetics, and
metabolism (Menasse et al., 1978; Riess et al., 1978; Tang et al., 1999; Kenny et al.,
2004).

DCF has nearly 100% absorption after oral dosing due to its high passive

uptake (Kalgutkar and Daniels, 2010).

DCF undergoes extensive first-pass hepatic

metabolism resulting in approximately 50% bioavailability in humans.

Among the

primary metabolites generated by the liver are hydroxylated metabolites (4ʹ-OH-DCF, 5OH-DCF, 4ʹ,5-(OH)2-DCF, 3ʹ-OH-DCF, 3ʹ,4ʹ-(OH)2-DCF) and conjugated metabolites
(acyl glucuronides, ether glucuronides, hydroxylated acyl glucuronides, sulfated
conjugates, and taurine conjugates).

Many of these metabolites have been

characterized using animal models (Stierlin and Faigle, 1979; Stierlin et al., 1979;
Pickup et al., 2012; Sarda et al., 2012). Despite the notion that metabolism serves to
detoxify the body of xenobiotics, in the case of DCF, biotransformation leads to the
creation of reactive metabolites that can potentially cause injury. The 4ʹ-OH-DCF and 5OH-DCF metabolites undergo rearrangement to form quinone imines which can adduct
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proteins via covalent binding.

These quinone imines can be neutralized by

sequestration with glutathione that is present in millimolar concentrations in the liver
(Kaplowitz, 1981).

In general, depletion of hepatic glutathione without subsequent

replenishment may result in oxidative stress and hepatocellular damage (Grewal and
Racz, 1993; Rafeiro et al., 1994; Hinson et al., 2010). Biotransformation of DCF also
results in production of the reactive metabolite diclofenac acyl glucuronide which was a
major focus of the work presented herein.
The reactive nature of DCF-AG has been the subject of intense investigation. DCF-AG
had been previously shown to covalently adduct to a number of hepatic proteins and
enzymes such as albumin, Mg2+-ATPase, and dipeptidyl peptidase IV (Hargus et al.,
1995; Sallustio and Holbrook, 2001; Kenny et al., 2004), an enzyme that has emerged
as a pharmacological target in the treatment of diabetes (Rohrborn et al., 2015). An
early study reported that though DCF-AG can covalently bind to hepatic proteins, DCFAG itself did not appear to contribute to hepatotoxicity in vitro (Kretz-Rommel and
Boelsterli, 1993).

In contrast, a follow-up study indicated DCF-AG could directly

mediate intestinal injury in vivo.

Specifically, rats that were administered DCF-AG

exhibited greater intestinal damage, in terms of ulcer number and length, compared to
rats that received an equimolar dose of DCF (Seitz and Boelsterli, 1998). In that same
study, it was determined that mutant rats lacking the efflux transporter Mrp2 had less
intestinal injury compared to rats that expressed Mrp2. The reduction in intestinal injury
was from reduced canalicular excretion of DCF-AG from the liver into bile, a transport
process mediated by Mrp2 (Seitz et al., 1998). These studies were significant as they
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demonstrated that transporters were able to modulate toxicity after exposure to a single
DCF dose.
Based on the earlier work with mutant Mrp2 rats, we chose to investigate if other efflux
transporters were operative in the transport of DCF or its metabolites. Our preliminary
studies used mouse models in which either breast cancer resistance protein (Bcrp) or
Mrp3 was genetically knocked out (Chapter 2). Whereas the loss of Bcrp led to a
reduction in DCF biliary excretion in KO mice compared to WT, there was no
concomitant increase in KO plasma DCF concentrations. On the other hand, a marginal
decrease of biliary DCF-AG excretion in KO led to increased DCF-AG plasma in KO
relative to WT, and this trend was observed at two subtoxic doses of DCF (Figure 2.1
and Figure 2.2). Overall the data conclusively indicate that both DCF and DCF-AG are
Bcrp substrates with perhaps OH-DCF also being a Bcrp substrate based on the results
from the 10 mg/kg DCF dose. The results from the Mrp3 study were more profound.
Mrp3 KO mice had reduced DCF-AG plasma concentrations compared to WT mice, yet
there were no differences in the DCF-AG biliary excretions between WT and KO (Figure
2.4 and Figure 2.5). Neither DCF nor OH-DCF had any differences between WT and
KO in plasma concentrations or biliary excretion signifying that neither are Mrp3
substrates. Analysis of terminal liver concentrations did not reveal any accumulation of
DCF-AG in WT, Bcrp KO, or Mrp3 KO mice (Figure 2.6).

Whereas loss of the

canalicular efflux transporter Bcrp affected both biliary and plasma disposition of DCFAG, the deletion of the basolateral efflux transporter Mrp3 impacted only plasma DCFAG concentrations.

Taken together, our results were consistent with the published
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findings of Bcrp- and Mrp3-mediated transport of DCF-AG (Lagas et al., 2009; Lagas et
al., 2010).
That Bcrp and Mrp3 were carriers of DCF-AG was not surprising given their roles in
mediating the efflux of glucuronide conjugates derived from other compounds
(Kawabata et al., 2001; Nakatomi et al., 2001; Manautou et al., 2005; ZamekGliszczynski et al., 2009).

While loss of Mrp3 resulted in decreased plasma

concentrations of acetaminophen glucuronide and 4-methylumbelliferyl glucuronide
along with increased biliary excretion for those two respective glucuronides (Manautou
et al., 2005; Zamek-Gliszczynski et al., 2006b), there was no corresponding elevation in
KO biliary levels for DCF-AG despite WT mice having nearly 10-fold higher plasma
concentrations compared to KO.

Our data with Mrp3 implied that only basolateral

excretion of DCF-AG was affected by Mrp3 deletion, and that the function or expression
of Mrp3 did not affect biliary disposition of DCF-AG. Our finding is not an anomaly in
light of the evidence provided for the Mrp3 substrates fexofenadine and hydeoxycholate
glucuronide for which only basolateral excretion was significantly decreased in Mrp3 KO
animals while biliary efflux was comparable between WT and KO for both fexofenadine
and hydeoxycholate glucuronide (Zelcer et al., 2006; Tian et al., 2008).
As our studies provided evidence that Mrp3 can modulate DCF-AG disposition in vivo
with mouse knockout models, we next sought to determine the affinity of DCF-AG for
human MRP3. For these studies, we used commercially available MRP3 inside-out
vesicles where substrate affinity was measured by quantifying the transport of probe
into the vesicles and subsequently compared to the transport activity of human MRP2
vesicles.

The comparison to MRP2 was important as MRP2 has been shown to
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modulate DCF-induced toxicity as well as DCF-AG disposition in humans and rodents.
For instance, human subjects with reduced MRP2 expression were associated with
greater hepatotoxicity during DCF treatment while rats lacking hepatic Mrp2 were
refractory to intestinal injury following treatment with DCF (Seitz and Boelsterli, 1998;
Daly et al., 2007). We observed that MRP3 has an apparent high affinity and low
affinity binding site for DCF-AG (Figure 2.11). The low affinity site exhibited comparable
transporter kinetics as calculated for the MRP2-mediated transport of DCF-AG. The
high affinity MRP3 site implies that at low DCF-AG concentrations, transport of DCF-AG
is likely to be dominated by MRP3 relative to MRP2. To summarize this part of our work,
the mouse in vivo studies and human in vitro experiments indicated that MRP3/Mrp3
has a major role in the disposition of DCF-AG.
With Mrp3 transport of DCF-AG firmly established, our next aim was to find out whether
deletion of Mrp3 leads to increased hepatocellular or intestinal injury (Chapter 3). To
accomplish our goals, we used WT and Mrp3 KO mice and administered a single toxic
dose of 90 mg/kg DCF. The selected dose was the highest tolerated DCF dose that did
not result in morbidity. Clinical chemistry analysis using serum markers of liver injury
did not reveal any obvious damage to either WT or KO livers (Figure 3.3). In contrast to
our results, Lagas et al. (2010) reported elevated ALT levels suggestive of mild hepatic
injury after a 25 mg/kg DCF dose. The difference between our study and that of Lagas
is likely due to the triple knockout mouse model (Bcrp/Mrp2/Mrp3) they used, which is
expected to be more susceptible to injury due to a heavily compromised hepatobiliary
transport capacity (Kock and Brouwer, 2012).

Histopathological examination in our

studies showed no gross hepatic injury despite the presence of intense covalent DCF
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adducts (Figure 3.5). The lack of hepatocellular injury in our mouse in vivo studies may
be explained by less oxidative metabolism of DCF in mouse compared to human. Our
toxicokinetic experiment showed that hydroxylated metabolites accounted for a small
fraction of overall DCF metabolism (Figure 3.1), with DCF-AG and other conjugates
being the predominant metabolites identified in the bile (Figure 2.7 and Figure 2.8).
Hepatotoxicity in human hepatocytes following DCF exposure was revealed to be
dependent on CYP450-mediated generation of 5-OH-DCF and N,5-(OH)2-DCF (Bort et
al., 1999b).

In addition, repeated dosing may be necessary for immune-mediated

hepatic injury following DCF exposure. The rationale for this argument stems from the
work by Aithal et al. (2004) in which antibodies taken from human patients presenting
with hepatotoxicity as a result of DCF treatment recognized the hepatic covalent
adducts in rats that received daily dosing of 30 mg/kg DCF. However, the same human
antisera failed to recognize hepatic adducts in rats that were given a single 200 mg/kg
DCF dose.

We conclude therefore that Mrp3 deletion does not lead to increased

hepatotoxicity following acute exposure to DCF.
As Mrp3 is also expressed in the mouse gastrointestinal tract (Zelcer et al., 2006), we
examined the extent of GI injury after a toxic DCF dose. Compared to WT mice, the
intestines of KO mice exhibited profound damage in terms of ulcer count and overall
inflammation (Figure 3.4.). Interestingly, the level of covalent adduction in KO intestines
determined through immunohistochemistry was not commensurate with injury. In fact,
both WT and KO appeared to have the same level of intestinal covalent adducts despite
the finding that KO mice had more injury compared to WT (Figure 3.5). The apparent
disconnect between injury and adduct formation led us to the conclusion that covalent
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adducts of xenobiotics merely indicate the presence of reactive species, and that their
presence and intensity is not a direct indicator of the degree in tissue damage. In short,
covalent adduction is just a byproduct of metabolism and not an overt contributor to
injury on an acute basis. Disregarding the covalent adduct aspect for a moment, the
functional expression of Mrp3 served to protect the GI supported by the mild injury
observed in WT mice while the loss of Mrp3 was met by significant injury in KO animals.
Given the preponderance of data linking DCF-AG to Mrp3-mediated transport, we
believe that the increased intestinal injury in KO mice was due to altered DCF-AG
disposition and that DCF-AG was contributory toward intestinal enteropathy.

Since

MRP3 is known to be expressed along the human GI tract (Groer et al., 2013; Drozdzik
et al., 2014), the presumed protection afforded by Mrp3 in our mouse model may be
applicable to humans as well. Permutation to MRP3 function or expression due to
genetic polymorphisms, of which many are known to exist for MRP3 (Kobayashi et al.,
2008; Sasaki et al., 2011), may render certain patient populations more susceptible to
GI injury during the course of treatment with DCF.
The intense covalent adducts detected in mouse livers is understandable given that the
liver was the primary site of DCF-AG synthesis. Adduct formation in the GI tract was
more intriguing. Certainly brush border adduction would be likely to occur given that
DCF-AG would naturally come into contact with that part of the villi during transit in the
gut lumen.

The brush border staining we observed was consistent with what was

reported in rats that were administered DCF (Atchison et al., 2000b). We became
curious how adducts could form so deep in the villi. Endocytosis of adducted plasma
membrane protein was a possibility, though our investigation lead us to the belief that
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active uptake of DCF-AG was also an option. To examine if this could be the case, we
used stably transfected cells to characterize DCF-AG uptake by a major intestinal
transporter (Chapter 4).

Based on the expression of likely uptake transporter

candidates, we focused our efforts on OATP2B1 which is expressed both in the human
GI tract as well as mice intestines (Hagenbuch and Meier, 2004; Cheng et al., 2005).
To determine the extent of OATP2B1-mediated uptake of DCF-AG, a twocompartmental model was used. This same approach was also used to characterize
OATP-mediated uptake in transfected cells and primary hepatocytes (Poirier et al.,
2008; Menochet et al., 2012; Pfeifer et al., 2013). The advantage to using such a model
is that it allows for estimates of active and passive processes, and the models can be
adapted to utilize and fit data over a range of time rather than be limited to a single time
point as used in traditional transporter kinetic studies. Our studies indicated that DCFAG uptake by OATP2B1 was concentration-dependent and that uptake activity was
higher at pH 6.0 compared to pH 7.4 (Figure 4.2). The acidic nature of the intestinal
lumen would partially stabilize DCF-AG, which hydrolyzes more readily at pH 7.4
(Supplement 2), and potentially enhance its uptake by OATP2B1 at pH 6.0. With DCFAG uptake into enterocytes plausibly explained by OATP2B1 activity, we next
determined the potential for DCF-AG to directly induce injury.
Our cytotoxicity studies with DCF-AG demonstrated that not only could DCF-AG cause
cell death, but that it induced greater cell death compared to an equimolar concentration
of DCF (Figure 4.3). The cytotoxicity results were in line with the observations of Seitz
and Boelsterli (1998) who reported that DCF-AG elicited greater GI injury than DCF in
vivo. Furthermore, cell death was brought on fairly early and occurred within 3 hours of
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exposure to DCF-AG. To resolve the mechanism of the cytotoxicity, we examined the
potential for DCF-AG to induce reactive oxygen species and found that DCF-AG indeed
caused ROS to increase in a dose-dependent manner with onset occurring after 1 hour
(Figure 4.4). In comparison, DCF was reported to promote ROS generation at much
later time points (Lim et al., 2006). The presence of ROS was important as it indicated
that DCF-AG could create a state of oxidative stress. As suprofen acyl glucuronide was
purported to inhibit superoxide dismutase (Chiou et al., 1999), a key cellular defense
against oxidative stress, we examined if DCF-AG also inhibits SOD. We report that
DCF-AG exemplified a clear dose-dependent inhibition of SOD whereas DCF showed
either no effect or stimulation of SOD (Figure 4.5). Lastly, we examined if DCF-AG had
inherent pharmacology against cyclooxygenases as this has not been fully explored.
Our in vitro assays repeatedly demonstrated that DCF-AG possesses the ability to
inhibit both COX-1 and COX-2, and that the inhibition leads to decreased synthesis of
prostaglandin E2 from arachidonic acid. Considering the role PGE2 has in protecting the
GI tract and that inhibition of both COX enzymes is necessary for intestinal injury to
develop (Tanaka et al., 2001; Sigthorsson et al., 2002; Hoshino et al., 2003; Kotani et
al., 2006), DCF-AG modulation of COX activity may have exacerbated the GI injury
normally ascribed to DCF. Ostensibly, we believe our studies demonstrate that DCFAG directly contributed to enteropathy in our in vivo models via active uptake by mouse
Oatp2b1 resulting in enhanced cytotoxicity in Mrp3 KO animals, due to decreased
basolateral excretion (and greater enterocyte retention) from the combined effects of
ROS generation, SOD inhibition, and attenuation of the PGE2-derived protection of the
intestinal tract.
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The last aspect of our work focused on the upregulation of Mrp4 during oxidative stress
and the potential for inhibition of human MRP4 by analgesics and/or their metabolites
(Chapter 5). Induction of Mrp4 was shown to occur after toxic doses of APAP were
given to mice (Aleksunes et al., 2008b; Campion et al., 2008). Mrp4 transcriptional
regulation appeared to be causally linked to hepatic injury, as assessed by serum ALT
levels, after toxic APAP administration in mice (Figure 5.2).

MRP4 activity in the

presence of APAP, APAP metabolites, DCF, and DCF metabolites was characterized
using human MRP4 inside-out vesicles. Our study indicated that APAP-CYS and DCFAG were able to significantly inhibit MRP4 activity, with APAP-CYS having an IC50 of
125 µM and DCF-AG achieving 34% inhibition at 300 µM (Figure 5.4). The inhibition of
these two metabolites is physiologically relevant in that both metabolites are present,
following toxic doses of their respective parent compounds, at concentrations matching
their inhibitory potencies (Chen et al., 2003; Manautou et al., 2005; Scialis et al., 2015).
Since Mrp4 is upregulated in response to oxidative stress, which can occur following
toxic challenge by APAP or DCF (Moore et al., 1985; Lim et al., 2006), inhibition of
MRP4/Mrp4 may further promote injury by limiting the ability to excrete toxic agents.
In conclusion, our collective work offers conclusive evidence that the disposition of
DCF-AG is modulated not only by MRP2/Mrp2, but also by MRP3/Mrp3, Bcrp, and
OATP2B1.

Furthermore, we determined that Mrp3 serves a protective role against

injury by DCF-AG, and that loss of Mrp3 results in increased susceptibility to GI damage.
The enteropathy observed in our mouse studies was the result of the multi-factorial
mechanisms through which DCF-AG can induce harm, namely induction of oxidative
stress through generation of ROS, inhibition of SOD, cell death, and the combined
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effects of COX-1 and COX-2 inhibition resulting in the diminished protection by PGE2.
We also demonstrate that DCF-AG can inhibit MRP4, which is normally upregulated in
response to oxidative stress and is involved in PGE2 signaling. The results of our
studies represent novel findings and offer insight into the roles that DCF-AG has in
enteropathy. Subsequent studies should focus on identifying patient populations at risk
of GI injury from DCF-AG as a result of diminished MRP3 function so that alternative
treatment can be prescribed.
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Chapter 7 APPENDIX
Supplement 1 Stability of DCF-AG in mouse S9 fraction without co-factors at
37 °C
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The metabolic stability of 1 µM DCF-AG in the presence of 1 mg/mL mouse S9 fraction
at pH 7.4 is shown. Incubations were conducted at 37 °C using S9 without NADPH,
GSH, or UDPGA. Loss of DCF-AG is reflective by spontaneous hydrolysis as well as
the activity of endogenous hepatic esterases. The estimated t1/2 was 14.5 ± 0.6 min.
Dotted lines reflect the 95% confidence intervals of the fit (solid line).

Each point

reflects the mean ± standard error of the mean of n=4 measurements from two separate
experiments.
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Supplement 2 Stability of DCF-AG at various pH levels
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The aqueous stability of 1 µM DCF-AG at various pH levels and 37 °C is shown. The
pH values reflect the conditions utilized for several of the in vitro assays described
throughout the thesis. The pH value of 2.7 represents the acidity in 0.1% formic acid
that was used for sample preparation and LC/MS/MS analysis. The lines reflect the
best fit for the indicated pH. Each point reflects the mean ± standard error of the mean
from n=2 measurements from two separate studies.
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Supplement 3 Time-dependent uptake of DCF-AG by HEK-OATP cells
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The time-dependent uptake of 10 µM DCF-AG from media by stably-transfected HEK
cells is shown. The dashed line reflects the initial buffer DCF-AG concentration of 10
µM and demonstrates that OATPs can increase intracellular DCF-AG concentrations to
levels greater than initial buffer conditions. Each point reflects the mean ± standard
error of the mean of n=3 measurements.
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Supplement 4 Basal transporter expression in C57BL/6J male mouse liver
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The basal transporter expression in the livers of male C57BL/6J mice is shown.
Expression profiles were detected using a bDNA assay. Data are expressed as relative
light units (RLU) per 10 µg RNA. Each bar reflects the mean ± standard error of the
mean of n=4 subjects.
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